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Summary
An investigation into the occurrence of specific food antibodies in adults 
and infants has been carried out, and the levels of specific antibodies 
have been considered in relation to their significance in atopy and its 
development.
Enzyme-linked immunosorbent assays (ELISA) were developed to determined 
specific antibodies to ovalbumin, gliadin and B-lactoglobulin in a number 
of biological fluids. A novel method for the quantification of specific 
antibodies in serum was developed. ELISAs were also developed to determine 
food antigens, ovalbumin and gliadin, in serum.
A very wide range of specific circulatory IgG and salivary IgA antibodies 
to the three food proteins were observed in normal subjects. Specific 
anti-ovalbumin IgG levels were significantly higher than anti-gliadin 
(p<0.05) and anti-B-lactoglobulin IgG (p<0.01). Explanations are put 
forward for the observed differences in specific antibody titres to the 
food proteins investigated.
In atopic subjects, specific anti-ovalbumin IgG levels were significantly 
higher than in non-atopic subjects (p<0.02). It is proposed that this 
difference is due to the hyper-responsiveness of atopic individuals 
combined with the antigenicity of ovalbumin. IgG subclass antibodies to 
ovalbumin and gliadin were found predominantly in the IgG4 subclass, with 
anti-B-lactoglobulin IgG distributed between IgG2, IgG3 and IgG4. The 
proportion of antibodies to ovalbumin and gliadin in the IgG3 subclass was 
significantly greater in the atopic subjects than in the non-atopic group 
(p<0.05, p<0.02 respectively). The possibility of a pathogenic role for
specific IgG3 antibodies is discussed.
Feeding studies were carried out to determine the uptake of food antigens 
from the gut.The uptake of antigenically viable ovalbumin appeared greater 
than that of gliadin, and the presence of gliadin was found to 
significantly reduce the uptake of ovalbumin (p<0.05). The concentrations 
of antigen measured was related to the level of specific antibodies, and 
the influence specific antibodies exert on antigen uptake and its 
determination is considered.
A prospective study of 26 infants was carried out to investigate the 
effect the presence of maternal atopy and mode of feeding have on the 
production of specific antibodies in the infants, and the development of 
atopy. The presence of maternal atopy and whether the infant was bottle- 
or breast-fed had significant effects on the production of specific serum 
antibodies in the infant. Maternal specific antibody levels appear to 
influence production in the infant, and high maternal titres of anti-B- 
lactoglobulin IgG are related to the development of atopy in the infants. 
A model for the development of specific antibody titres in infants under 
the influence of maternal antibodies is put forward, and the importance of 
bottle and breast feeding, and maternal atopy discussed. The clinical 
implications of the findings of this project are discussed in relation to 
the prevention of atopy development in infants.
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Introduction
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1.1 Introduction.
The daily food comprises quantitatively the largest antigenic load on the 
immune system, and food antigens are a major stimulus of the local immune 
system of the gut. The systemic immune system may be activated by cellular 
migration from mucosal sites or through interactions with antigens 
crossing the mucosal membrane. Food antigens can induce a number of 
pathological reactions such as food allergy and Coeliac Disease.
1.2 The Immune System.
The special capacity of the immune system is that of pattern recognition. 
Antigenic determinants or epitopes are very small patterns on the surface 
of protein molecules, usually about 10 amino acids long (Roitt 1984). 
Antibodies recognise epitopes and attach, thereby marking the antigen for 
destruction or removal by other mechanisms available.
1.2.1 Immunoglobulins
Five structural types or classes of immunoglobulins are produced in man, 
IgG, IgM, IgA, IgD and IgE. The immunoglobulins have the same basic 
structure (Figure 1.1), which, when split with papain, produces three 
fragments. Two are identical and are able to combine with antigens to form 
soluble complexes (Fab - fragment antigen binding). The third fragment has 
no power to combine with the antigen (Fc - fragment crystalline) but 
directs the immunoglobulin's biological activity. Antibodies can also be 
broken down into their constituent peptide chains, giving 2 heavy and 2 
light chains per molecule. Five major types of heavy chain exist in 
humans, each of which gives rise to a distinct immunoglobulin class. The 
N-terminal portions of the heavy and light chains show considerable 
variations with the remaining parts of the chains showing little variation 
in structure. Variable regions on the light and heavy chains are 
responsible for the antibodies specificity.
18
Figure 1.1 The structure of immunoglobulin molecules.
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IgG is the major immunoglobulin synthesized during the secondary response 
to antigens and is a monomer of 150,000 molecular weight. Its main 
function is to neutralise bacterial toxins and bind antigens, enhancing 
their phagocytosis. Four subclasses of IgG antibodies exist (IgGl, IgG2, 
IgG3 and IgG4) which are physicochemically characterised by differences in 
their polypeptide heavy chain (Burton 1985) and differences in the number 
and/or distribution of interchain disulphide bonds (Stanworth 1983). IgGl 
represents 65% of the total IgG in serum, IgG2 23%, IgG3 8% and IgG4 
represents only 4% of total IgG antibodies (Roitt 1984).
IgA is the major immunoglobulin in mucous membrane secretions, where its 
function is in the defence of exposed external surfaces of the body 
(Tomasi 1968). It is present in fluids as a dimer, produced 
by combination with a cysteine rich J-chain and stabilized against 
proteolysis by secretory component. The IgM molecule is a pentamer, with 
polymerization of the units also dependant on J-chains. These antibodies 
are highly efficient aggulinating and cytolytic agents and appear early in 
response to infection. IgE is present at very low concentrations in serum, 
and its role is in the protection of external surfaces by triggering acute 
inflammatory reactions. IgE molecules are fixed to mast cells and contact 
with antigen leads to degranulation and release of vasoactive amines.
Antibodies can be produced to individual immunoglobulin molecules or the 
products of single clones of antibody producing cells (Steward 1986), as 
well as against foreign antigenic molecules. Each antigen-combining site 
on immunoglobulin molecules expresses its own set of idiotypic 
determinants in the hypervariable regions (McConnell et al 1981), and 
these idiotypic determinants are themselves potentially immunogenic. When 
the concentration of antibodies with such determinants reaches a critical 
level, they may induce the production of anti-idiotypic antibodies.
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1.2.2 Development of the immune system.
Immunological development occurs early in intrauterine life and at birth 
the infant has an immune system similar to that of adults. The lymphoid 
tissue appears in the thymus at 8 weeks gestation, and immunoglobulin 
secreting cells are formed in the spleen and lymph nodes by 20 weeks 
gestation. From this time both IgM and IgG can be synthesized by the 
fetus, with the synthesis of IgM predominating. The lymph nodes and spleen 
remain relatively underdeveloped until birth, except where intrauterine 
exposure to antigens has occurred as in congenital infection with rubella.
At birth the serum levels of IgG in the newborn infant are similar to 
those seen in the mother due to placental transfer of this immunoglobulin, 
and these fall in the first three months of life when catabolism is 
greater than synthesis (Allansmith et al 1968). By 3 months the rate of 
synthesis in the infant outstrips breakdown and the IgG titre rise (Figure 
1.2). The capacity for IgA synthesis develops slowly, with adult secretory 
levels not achieved until 2 - 4years of age and adult serum IgA levels not 
attained until 10 - 12 years of age (Allansmith et al 1968).
1.2.3 The systemic immune system.
The immune response to systemic antigens involves a delicately controlled 
response by various cells of the lymphoid and myeloid series and the end 
result of antigenic stimulation may involve the development of specific 
antibodies, development of cell mediated immunity (CMI), or both.
Macrophages will mop up excessive amounts of antigen, process the 
molecules and express the antigenic determinants at their surface. B- and 
T- cells with specific receptors then congregate around antigen-bearing 
macrophages. Co-operation is dependant on recognition by both B- and T- 
cells of the correct genetic marker on the surface of co-operating cells.
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Figure 1.2 Development of serum immunoglobulin levels.
Birth
% Adult level
IgG
188 -
IgM
50 —
IgA
1812
Age (months)
Infant
Maternal
(Roitt 1984)
2 2
Antigen recognising B and T-cells then proliferate, the B-cell clone 
differentiates to plasma and memory cells and the T-cell clone 
differentiates to cells with cytotoxic, helper, suppressor or lymphokine- 
producing functions (Figure 1.3). The response is continuously amplified 
and made more specific for the inducing antigen by the selection of higher 
affinity B-cell clones. This is the classical primary response initiated 
by the presence of large heterogenous antigens which stimulate B and T- 
cell co-operation. Interactions between T- and B-cells occur such that 
certain antibody responses are T-cell dependant.
Secondary responses involve the switching from IgM to IgG synthesis by B- 
cells. This requires T-cell assistance and the presence of large amounts 
of IgM. On the second antigenic challenge, IgM will increase as with the 
primary response, but if the antigen persists, the initial IgM response is 
superseded by a much larger IgG response. Amplification of the primary 
response is dependant on the diversification of B-cells to produce, not 
only plasma cells and antibodies, but also memory cells which increase the 
pool of antigen-sensitive lymphocytes (Roitt 1984).
The immune system has been described as a net-work of interacting 
antibodies and lymphocytes (Jerne et al 1982). Helper and suppressor T- 
cells help to regulate the immune response with helper cells amplifying 
the system and suppressor T-cells, which may be non-specific or antigen 
specific, apply a break to the system. Anti-idiotypic antibodies, which 
arise during the course of the immune response, can induce or suppress 
proliferation of specific clones of both B and T-lymphocytes (McConnell et 
al 1981).
23
Figure 1.3 T-dependant triggering of antibody production in B-cells.
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1.2.4 Mucosal immune system.
At the mucosal surfaces the immune system is represented by the mucosa- 
associated lymphoid tissue (MALT), which is composed of single follicles 
of lymphoid cells and more complex lymphoid structures such as the Peyer's 
patches, tonsils and appendix (Parrott 1987). Four key features of mucosal 
immunity distinguish it from the systemic immune system. First is its 
ability to survey antigens in fluids outside the body. Only antigens
adhering to epithelia are likely to be efficiently taken up into the
mucosal immune system. In the systemic immune system, all foreign 
macromolecules reaching the body fluids are likely to be filtered out. 
Effector cells of the secretory immune system are distributed throughout 
the lamina propria at sites distant from organized lymphoid structures in 
which proliferation and maturation of their percursors occurred. The main 
immunoglobulin of the secretory immune system is secretory IgA in contrast 
to IgG in the systemic immune system. Finally the effector cells of the 
secretory immune system and epithelium interact in producing effector 
molecules which can be delivered to external surfaces rather than to the 
circulation.
Two processes of lymphocyte migration are involved in the functioning of 
the mucosal immune system (Mestecky et al 1988). First is the afferent 
process by which B-lymphocytes from bone marrow and T-lymphocytes from the 
thymus enter lymphoid tissues from capillaries via the high endothelial 
venules. After proliferation and interaction with antigens and accessory 
cells resident in the Peyer's patches, B- and T-lymphocytes leave via the 
lymphatic system, and enter the thoracic duct. Secondly, these cells 
populate various mucosa-associated tissues, such as the salivary and 
mammary glands (Jackson et al 1981, Tseng 1987), where terminal
differentiation into IgA producing plasma cells occurs.
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Induction and expression of mucosal immune responses requires access of 
antigen to the tissues. Specialized epithelium (M cells), overlaying the 
Peyer's patches and lymphoid nodes, is necessary for presentation of 
antigen to the gut-associated lymphoid tissue (GALT), and for induction of 
an orderly gastrointestinal immune response (Walker 1987). Peyer's patches 
provide optimum conditions for T-cell antigen binding, containing 
precursors of lamina propria IgA cells and antigen, which is presented to 
T-cells by macrophages within the lymphoid tissues of the gut. 
Presentation of antigen leads to induction of antigen-specific T-helper 
cells and activation of T-suppressor cells. Activation of antigen-specific 
T-helper cells leads to the stimulation of B-lymphocytes with the 
production of a mucosal IgA response. Simultaneously, specific activation 
of T-suppressor cells for IgG/IgM production occurs, leading to systemic 
tolerance. In addition induction of T-suppressor cells, which suppress CMI 
responses, will protect the gut from deleterious mucosal CMI reactions.
1.2.5 Oral tolerance.
Tolerance is a condition in which the capacity to react to a normally 
effective antigenic stimulus has been specifically diminished or abolished 
by prior administration of that particular, or a related, antigen (Nossal 
& Ada 1971). Tolerance can also be considered as a manifestation of 
regulatory processes which modulate the magnitude of antibody responses to 
antigens (Hanson et al 1977a). Two types of tolerance have been described 
(Tomasi 1980): high zone tolerance, which is achieved with very high doses 
of antigen and reaches a profound degree of hyporesponsiveness quickly, 
and low zone tolerance, induced by sub-immunogenic antigen doses. High 
zone tolerance tends to be more complete and longer lasting than low 
zone tolerance.
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The net effect of antigen presence is dependant on the ratio of immunity 
and tolerance in the lymphocyte population, tolerance induction may occur 
in the majority of lymphoid cells, with a minority immunized. Thus the 
presence of antibody is not incompatible with a substantial degree of 
tolerance.
Tolerance induced by oral immunization has been well established 
a
(Challcombe & Tomasi 1980). Prior feeding with antigen leads not only to 
the suppression of induction of serum antibodies but also to a reduction 
in subsequent uptake of antigen from the gut. Thus feeding can give rise 
to the paradoxical state of systemic tolerance and local mucosal IgA 
production (Swarbrick et al 1979). The occurrence of a secretory response 
after mucosal contact with antigens is a useful mechanism for the 
exclusion of potentially harmful substances from the body where as the 
induction of systemic tolerance could act as a secondary defence to ensure
the immunological consequences of damaging reactions to antigens that
!a'
escape the exclusion mechanisms do not occur (Challcombe & Tomasi 1980).
Development of oral tolerance is associated with specific T-cells not B- 
cells (Hanson & Morimoto 1980), and affected by specifically activated T- 
suppressor cells (Bruce & Ferguson 1986a). Processing of antigens in the 
gut appears to be essential for the development of tolerance (Bruce & 
Ferguson 1986b) and may involve unfolding part of the antigen molecule to 
expose hydrophobic areas for T-cell recognition (Bruce & Ferguson 1986b) 
or the digestion of many antigen molecules into forms able to interact 
only with specific T-cells (Hanson & Morimoto 1980).
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1.3 Food hypersensitivity.
Hypersensitivity occurs when the secondary boosting of the immune response 
with an antigen is excessive and leads to gross tissue damage, if the 
antigen is present in relatively large amounts, or if the humoral and 
cellular immune responses are at a heightened level ■ (Roitt 1984). Under 
normal circumstances, T-cells are able to evaluate the threat posed by an 
antigen, able to distinguish between harmful and harmless foreign 
substances. If the regulation system fails, harmless substances are 
thought to be harmful, provoking an immune response and leading to atopy 
(Buisseret 1984). Five types of hypersensitivity reactions have been 
described and are summarised in Table 1.1. Food hypersensitivity reactions 
generally are either Type I, anaphylactic reactions or Type III, complex 
mediated reactions (Brostoff 1987).
Adverse immunological reactions to food affect between 0.3% (Collins- 
Williams 1956) and 27 % (Kajosaari 1982) of the population, with the 
incidence in most countries between 1-3% (Bender & Mattews 1981). 
Children less than 3 years old are more frequently affected than older 
children and adults, and many infants may be able to tolerate problem 
foods as they become older. Atopic dermatitis and immediate food reactions 
tend to predominate in infancy, with wheezing more prominent in later 
childhood (Van Aspern & Kemp 1989). Reactions to food can vary in severity 
from life threatening to a minor inconvenience and a very wide range of 
atopic conditions have been reported as being caused by food and include 
asthma, eczema, angioedema, urticaria, rhinorrhoea and gastrointestinal 
symptoms (Lessof et al 1980/ Atherton 1983a).
Table 1.1 Comparison of different types of hypersensitivity.
I II III IV
Anaphylactic Cytotoxic Complex-mediated Cell-mediated Stimulatory
Antibody
mediating
reaction.
Homocytotropic Ab Humoral Ab Humoral Ab
Hast cell binding + CF + C F
Receptor on T- 
lymphocyte
Humoral Ab 
Non-CF
Antigen Usually exogenous Cell surface Extracellular
(eg. pollen,food)
Associated with 
MHC antigens on 
macrophages or 
target cells
Cell surface
Response to 
intradermal 
antigen:
Max reaction 30mins
Appearance Wheal + flare
Histology Degranulated mast 
cells,'oedema; 
eosinophils
3-8hours 24-4Bhours
Erythema and Erythema and
oedema induration
Acute inflammatory Perivascular inflamm- 
reaction;polymorphs ationjpolymorphs 
predominant migrate,leaving mono­
nuclear cells
Transfer o f  < 
sensitivity
Serum antibody > Lymphoid cells Serum antibody
Examples Atopic allergy Haemolytic disease Farmer’s lung Contact sensitivity Thyrotoxicosis
of newborn (Rhl
CF = complement fixation
(Roitt 1984)
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1.3.1 Factors influencing development of atopy.
A number of risk factors have been identified in atopy development and 
include race, sex, maternal age, family structure, life style and certain 
environmental factors, in particular early feeding history and exposure to 
tobacco smoke (Wiitig et al 1978).
The strongest predisposing factor to the development of atopy however is 
family history, with the risk of developing allergy 15% if neither parent 
is atopic, 30% if one is atopic and 50% if both are atopic. The 
inheritance of an atopic predisposition seems to be linked to a given HLA 
haplotype within any one family, but no association with specific HLA 
types has been found as yet (Roitt 1984). The overall ability to 
synthesize IgE is an important marker in the prediction of atopic disease, 
with the higher the level of IgE in the blood, the greater the likelihood 
of developing atopy.
1.3.2 Mechanisms of sensitization.
Little is known regarding the complexity of the immunological response to 
the first eaten antigens in the vulnerable, relatively immunodeficient 
infant. Two main hypotheses have been developed to explain how certain 
predisposed individuals develop IgE antibodies and atopy.
The first hypothesis suggests that atopy is a consequence of antigenic 
overstimulation during early life due to a defect in another mechanism 
responsible for handling antigens or controlling the response (Taylor et 
al 1973). Atopy therefore depends on the ability to keep antigens out, 
rather than on the capacity to elicit a reaginic reaction once it gets in. 
A lack of IgA mediated exclusion of antigens in the gut has been proposed 
as the mechanism by which overstimulation occurs (Swarbrick et al 1979), 
with transient IgA deficiency seen early in life in those who subsequently 
develop atopy (Taylor et al 1973, Soothill et al 1976).
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It is postulated that the IgA deficiency is working at the mucosal level, 
as no differences in salivary IgA were noted between the control group and 
those developing atopy. Other studies however indicate that IgA deficiency 
does not play a crucial role in the pathogenesis of atopic disease 
(Plebani et al 1987).
Abnormal gut permeability to large molecules such as PEG 6000 (Jackson et 
al 1984) and CrEDTA (Schrander et al 1990) has been found in food allergic 
individuals and in sufferers from atopic eczema. High titres of serum 
antibodies to milk proteins in cow's milk allergic infants has been 
suggested to be due to leakage of the protein through the gut mucosa 
(Shiner et al 1975). These studies would indicated a link may be present 
between increased gut uptake of antigens and the development of atopic 
conditions. Robertson et al (1982) found that preterm infants, 
particularly those of less than 33 weeks gestation, had higher serum 
concentrations of B-lactoglobulin than did term infants, and concluded 
that the ability of the gastrointestinal tract to exclude antigenically 
intact food proteins increases with gestational age. Data from animal and 
human studies supports the concept that there is increased gut 
permeability of the intestine of human infants to macromolecules early in 
life (Walker 1986), at a time when the development of atopy is highest.
Despite Taylor et al (1973) hypothesis that atopy is due essentially to 
increased uptake of macromolecules, it is not clear whether the increased 
gut permeability seen in atopic individuals is the cause or a result of 
the atopic condition present. Local intestinal anaphylactic reactions can 
facilitate the uptake of macromolecules (Bloch & Walker 1981), indicating 
increased permeability may be a secondary consequence of atopy 
development.
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The second hypothesis for the development of atopy suggests that normal 
people avoid atopy by absorbing sufficiently large quantities of antigen 
to activate IgE immunoregulatory mechanisms particularly suppressor T- 
cells, causing inhibition rather than stimulation of the IgE responses 
(Jarrett et al 1977). In atopy, a defect is present in one or more of the 
components of the immunoregulatory mechanisms.
Slight and transient IgE antibody responses to food proteins are not rare 
even in healthy individuals, yet seldom give rise to clinical problems. 
The amounts of food antigens normally absorbed present a repeated 
stimulus, not only to effector cells for an IgE response, but also to a 
related suppressor mechanism which will eventually predominate (Jarrett & 
Hall 1981). IgG appears exempt from the suppressive influences generated 
by these very low levels of antigen, indicating a differentiated 
susceptibility of immunoglobulin classes to low-dose tolerance. In 
infants, the immune response to antigens is more readily suppressed than 
in adults, partly because of developmental immaturity of B-cells, which 
are more susceptible to negative signalling, and partially due to enhanced 
suppressive functions of T-cells in the perinatal period (Jarrett 1984). A 
role for transferred maternal IgG has been suggested, in compensating for 
the immaturity of the IgE regulatory system of the infant or at least 
sustaining it until the system has been adequately stimulated by antigen.
IgE responses in atopic individuals are more pronounced and reach higher 
concentrations, suggesting there is a reduced capacity to turn off an IgE 
response in atopy (Foucard 1984, 1985). Jarrett (1977) suggested that
atopy arises due to a deficiency or dysfunction of one or both types of 
IgE T-suppressor cells (T^-cells), or factors controlling their phenotypic 
expression.
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Reduced proportions of T-cells, which are known to regulate immunoglobulin
synthesis by suppressing T-cell dependant B-cell differentiation, are
found in the atopic population (Carionica et al 1979). No abnormalities
were seen in T-helper cell proportions. Other work has also suggested that
atopic individuals have a relative deficiency of a regulatory cell or
subjects!
function that in normal prevents excessive IgE production (Fiser & Buckley 
1979). The mean suppression by T-cells from infants who subsequently 
developed atopy was significantly lower than that in infants remaining 
disease-free (Chandra & Baker 1983), suggesting that a numerical and 
functional deficiency in Tg-cells is a primary abnormality and precedes 
the development of atopic disease.
Work by Firer et al (1981) indicated that low dose antigen stimulation was 
associated with the development of IgE hypersensitivity disorders, whereas 
ingestion of large amounts of antigen favours the development of IgA, IgM 
and possibly IgG , but not IgE antibodies. Small quantities of milk 
proteins in infants elicits the production of specific IgE, whereas large 
quantities are found to inhibit this response (Bjoksten & Saarinen 1978). 
The occurrence of what can be classed as two distinct types of cow's milk 
allergy fits well with the hypothesis of Jarrett (1977). Although the 
symptoms produced by cow's milk in breast-fed and formula-fed infants are 
very similar, the immunological mechanisms are very different (Gerrard & 
Shenassa 1983). In breast-fed infants the symptoms are triggered by traces 
of antigen found in the mother's milk.On contact with cow's milk, a severe 
IgE reaction results, and they are obviously highly atopic with skin prick 
tests and RAST usually strongly positive. In formula-fed infants, allergy 
is precipitated by large amounts of antigen, but the symptoms are never 
anaphylactic and small amounts of milk may be tolerated. This type of 
reaction is not IgE mediated and is not associated with positive skin 
prick tests or RAST.
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1.4 Food specific antibodies in disease.
a) Coeliac Disease
Elevated titres of serum antibodies to gliadin or gluten have been 
observed in Coeliac Disease (Kenrick & Walker-Smith 1970, Eterman et al 
1977) and characteristic patterns of anti-gliadin • immunoglobulins have 
been demonstrated (Friis et al 1986, Hed et al 1986). Serum IgA levels to 
gliadin show a greater correlation with villous atrophy than IgG 
antibodies (Juto et al 1985), and serum anti-gliadin IgA has been 
considered as a potential marker for Coeliac Disease (Savilahti et al 
1983). More recent studies indicate that alpha-gliadin IgA antibodies in 
serum are a more sensitive and specific indicator for Coeliac Disease (Al- 
Bayaty et al 1989).
Antibodies to dietary proteins other than gliadin also occur in raised 
titres in Coeliac Disease (Kenrick & Walker-Smith 1970, Ferguson & 
Carswell 1972). Husby et al (1985a) found anti-ovalbumin IgG levels to be 
raised in coeliac children, but anti-B-lactoglobulin IgG levels in these 
children were similar to the controls. Scott et al (1990) also found anti- 
B-lactoglobulin IgG levels, in addition to IgG antibodies to alpha-casein 
and alpha-lactalbumin, to be similar in adults with Coeliac Disease and in 
controls. The raised levels of food antibodies in this disease are thought 
to reflect alterations in gastrointestinal permeability.
b) Atopic disease.
Investigations into antibodies to food proteins have, apart from studies 
on Coeliac Disease, concentrated on food allergy in a hope of identifying 
pathogenic factors and producing diagnostic tools. The majority of studies 
on food allergy, and atopy more generally, have been carried out in 
children because of the greater prevalence in this group of the 
population.
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Elevated concentrations of IgG antibodies to ovalbumin and B-lactoglobulin 
have been found to persist in children with atopic disease in contrast to 
the fall in titres seen in non-atopic children (May et al 1977), 
indicating a difference exists between atopic and non-atopic subjects from 
a early age. This phenomena was also reported by Kettler et al (1971). 
Children with cow's milk protein intolerance have been observed to have 
significantly elevated IgG and IgE antibodies to casein, B-lactoglobulin, 
alpha-lactalbumin and bovine serum albumin compared to both adult and 
child controls (BUrgin-Wolff et al 1980). Other studies have also reported 
elevated IgG and IgE antibodies in children with cow's milk intolerance 
(Firer et al 1982, Taylor et al 1988). A recent study however found no 
differences in cow's milk protein specific IgG or IgE antibodies between 
cow's milk sensitive and normal children (Burks et al 1989).
Chidren with eczema without clinical food allergy were found to have 
increased IgG antibodies to milk proteins (Firer et al 1981, Taylor et al
1988) and it was proposed that this could be due to an underlying
undetected allergy to cow's milk. Antibodies to milk, ovalbumin and
gliadin are detected at increased frequencies in adults with chronic 
urticaria compared to controls (Lewis-Jones et al 1987). This increased 
frequency in IgG antibodies was not associated with raised total serum 
IgE. Danneaus et al (1977) found elevated food specific IgG titres to 
parallel elevations in IgE antibody titres to the same food. Finn et al 
(1985) found the frequency of detection of IgG antibodies to gliadin and 
B-lactoglobulin to be higher in atopic adults than was seen with non-
atopic adults. No difference, however, was seen in the rate of detection
of anti-ovalbumin IgG between the two groups.
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Other studies in adults have also found no differences in anti-ovalbumin 
IgG concentrations in atopic eczema suffers and controls (Husby et al 
1986a), although significant differences in anti-B-lactoglobulin IgG 
concentrations were found. The evidence for a pathogenic role for the 
elevated food IgG antibody titres seen in atopic subjects is limited, and 
it has been proposed that the elevated antibody titres in atopic subjects 
are due to these adults having a greater statistical chance than normal 
adults of maintaining or reinitiating antibody production following 
prolonged antigen intake (Barrick & Farr 1965).
The role of short-term sensitizing anaphylactic antibodies was attributed 
to the IgG4 subclass (Stanworth & Smith 1973), and stimulated the 
investigation of the role these antibodies play in the development of 
atopic conditions. There appears to be clinical allergy situations in 
which anaphylactic antibodies of the IgG4 subclass, as well as of the IgE 
class, are implicated (Stanworth 1986). Serum levels of total IgG4 have 
been observed to be elevated in adults with asthma and atopic eczema 
(Shakib et al 1977, Gwynn et al 1979). An increased prevalence of food 
protein IgG4 antibodies has been found in atopic eczema (Finn et al 
1985), chronic urticaria (Lewis-Jones et al 1987) and asthma (Barnes et al 
1988a). A relationship between specific IgG4 levels and the levels of the 
corresponding specific IgE antibodies has been reported (Merrett et al 
1984, Lilja et al 1990), although this relationship was observed in both 
atopic and non-atopic subjects (Lilja et al 1990).
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Despite the elevation of total and specific concentrations of IgG4 
antibodies in atopic conditions, no relationship between antibody levels 
and clinical symptoms has been reported (Bjorksten et al 1983, Shakib 
1986 a, de Martino et al 1988, Husby et al 1989 i), and it is proposed that 
the elevated levels of specific XgG4 encountered in atopic subjects result 
from an amplification of the normal immune reaction (Shakib et al 1984).
1.5 Antigens in food.
Antigenic determinants are defined as the discrete areas of protein 
structure that combine specifically with the complementary discrete areas 
of a specific antibody. Antigenic determinants can be sequential or 
conformational. Sequential determinants are organized from a number of 
amino acids, found directly in a linear sequence or in a randomly folded 
or unfolded form of the molecule. This type of antigenic determinant 
remains intact following dénaturation of the protein (Aas 1984). A 
conformation determinants results from the steric configuration or 
folding. Dénaturation of the protein usually destroys this type of 
determinant. All proteins can be considered complex antigenic mosaics as 
each molecule is made up of a number of different sets of potential 
antigenic determinants.
The foods most commonly reported to cause atopic conditions in the 
pediatric population are cow's milk, hen's eggs, legumes (peanuts and soya 
beans), wheat and fish (Bock et al 1978). Studies in adults are limited 
but indicate that shellfish, peanuts, nuts and grains frequently cause 
reactions ( Bernstein et al 1982, Adkins et al 1985). Many other foods 
have also been implicated as causes of allergic reactions. Three food 
proteins are studied in this project and are ovalbumin (hen's egg),gliadin 
(wheat) and B-lactoglobulin (cow's milk).
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1.5.1 Ovalbumin.
Proteins in hen's egg-white are common causes of hypersensitivity, but egg 
is ubiquitously used as a food, making it difficult to remove from the 
diet. Five major components, ovalbumin, ovomucoid, ovotransferrin, 
ovomucin and lysozyme, represent 80% of the total protein in egg white 
with the remaining 20% composed of at least 35 different minor proteins. 
Ovalbumin represents approximately 45% of the protein in egg white, and is 
a monomeric, almostspherical molecule of 45,000 molecular weight (Osuga & 
Feiney 1977), which is very susceptible to heat dénaturation, when a solid 
gel network forms. Because of the high percentage of ovalbumin in egg 
white, it is quantitatively the dominant allergen (Holen & Elsayed 1990), 
but ovomucoid, ovotransferrin and lysozyme are also highly allergenic.
1.5.2 Gliadin.
The endosperm of wheat contains 70-75% starch, 10-15% moisture, 6-8% 
proteins and 1-2% lipids. The flour proteins consist of gluten (90%), 
albumins and globulins, with gluten made up of glutenins and gliadin in 
equal quantities. Gliadin is soluble in alcohol and compromises of four 
different groups separated by their mobility on starch-gel 
electrophoresis. Alpha-, beta- and gamma-gliadin each contribute 30% to 
the total gliadin and omega-gliadin 10%. The molecular weights of alpha-, 
beta- and gamma-gliadin range from 31,000 to 44,000 and these are single 
polypeptide chains, with disulphide bonds. The amino acid profile of these 
proteins is unusual with approximately 40% glutamine and 15% proline. 
Omega-gliadin has a molecular weight of around 70,000. Antibodies to 
gliadin in man and rats are directed principally against alpha-gliadin 
(Coombs et al 1983), but in mice, antibodies were directed against omega- 
and possibly gamma-gliadin fractions (Johnson et al 1990). The reason for 
these differences in response to the gliadin fractions is not known.
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1.5.3 B-lactoglobulin.
Cow's milk contains 3% protein, made up of caseins, phosphoproteins 
precipitating at pH 7.4, and serum proteins which are soluble under these 
conditions. The serum proteins consist of 54% B-lactoglobulin, 21% alpha-
i,
lactalbumin and the remained includes serum albumin, immunoglobulins and
proteose-peptones. B-lactoglobulin, therefore, is the dominant whey
protein and is a dimer of molecular weight 37,700 (Gordon et al 1961). The
two subunits, A and B, are antigenically identical and in solution, near
pH 5.2, they are predominantly as the dimer, held together by noncovalant
forces. A further variation can be found in B-lactoglobulin structure in
that in the milk from Jersey cow's, only B-lactoglobulin C occurs (Hanson 
!a
& Johnsson 1970). B-lactoglobulin contains one free sulphydryl group which 
is important during dénaturation as it facilitates the SH/S-S interchange 
reaction. At 80®C, B-lactoglobulin becomes denatured, representing an
alteration in the molecules 3-dimensional structure and above 100®C B- 
lactoglobulin may become extensively bound to casein mycelles. The
influence of heat on the B-lactoglobulin is important to consider when
many infants are fed heat-treated milk, in which the antigenic 
determinants of B-lactoglobulin may have been masked or altered.
1.5.4 Determination of food protein antigens.
Food antigens have been determined in random samples of serum and breast 
milk (Jakobsson et al 1985) and at timed intervals after antigen feeding 
(Dannaeus et al 1979, Kilshaw & Cant 1984, Husby et al 1985b, 1986b). The 
purpose of the determination of food antigens in serum and breast milk has 
been to increase knowledge of the amounts of antigenically viable food 
antigens taken up from the gut and to investigate the importance of this 
uptake in the development of atopic conditions.
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Ovalbumin has been the most widely studied antigen, with ELISA (Husby et 
al 1985b, 1989b, Peng et al 1990) and both liquid (Kilshaw & Cant 1984)
and solid phase radioimmunoassays (Dannaeus et al 1979, Kageyama 1983) 
used to determine concentrations. The molecular weight of the absorbed 
antigen has also been determined used HPLC (Husby et al 1985b, 1986b),
FPLC (Peng et al 1990) and gel filtration on Sephadex G-lOO (Kilshaw & 
Cant 1984).
Gliadin has been determined in breast milk (Troncone et al 1987) using 
ELISA and an ELISA has been developed to determine the properties of 
monoclonal antibodies to gliadin (Mills et al 1989). This latter assay is 
much less sensitive than any other assay developed to determine antigens, 
with the limit of detection in the microgram rather than the nanogram 
range. The reason for the lack of sensitivity is proposed to be due to the 
use of monoclonal antibodies, which recognise far fewer epitopes on the 
captured antigen than do the more commonly used polyclonal antibodies.
B-lactoglobulin has been determined in both serum (Husby et al 1985b, 
1989b) and breast milk (Kilshaw & Cant 1984, Jakobsson et al 1985) using 
radioimmunoassay and ELISA. The molecular weight of the absorbed antigen 
has also been determined using similar methods to those employed to 
determine the molecular weight of ovalbumin. In addition, digestion 
studies have been carried out to study the uptake of B-lactoglobulin in 
the presence of proteolytic enzymes compared to the uptake of other milk 
proteins, such as alpha-lactalbumin and B-casein (Marcon-Gentry et al
1989).
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Chapter 2
Development of indirect ELISA to determine specific IgG 
antibodies to food proteins in serum and specific 
IgA antibodies in saliva and breast milk.
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2.1 Introduction.
The presence in the body of antibodies, specific to food proteins, is now 
considered normal (Husby 1988) and a number of methods can and have been 
employed to investigate their occurrence in normal and atopic individuals. 
The classical immunological techniques of precipitation, passive 
haemaggultination and complement fixation have been employed with no one 
technique showing a consistent advantage. However, methods such as enzyme- 
linked immunosorbent assays (ELISA), radioimmunoassays (RIA) and indirect 
fluorescent antibody tests have advantages over classical methods in terms 
of greater sensitivity and ability to allow antibodies of different 
classes and subclasses to be distinguished.
2.1.1 ELISA: The principles.
In ELISA, the coating antibody or antigen is immobilized onto the solid 
phase and then incubated with the standard or test antigen or antibody. 
After washing, the immobilized antigen-antibody complex is incubated with 
excess enzyme labelled antibody which will bind to another epitope on the 
antigen. Following further washing, the enzyme substrate solution is added 
and incubated. The enzyme reaction product concentration is directly 
proportional to the concentration of the standard or unknown 
antigen/antibody (Nakamura et al 1986). A flow diagram of an indirect 
ELISA for the assay of antibodies is shown in Figure 2.1.
When carrying out an ELISA, the solid phase is of prime importance and 
must have a high binding capacity. Polystyrene and polyvinyl chloride 
plates produced by different manufactures may have quite different 
intrinsic coating properties. 'Edge' effects and batch variation of the 
plates should be reduced to a minimum. High signal to background ratios 
are required for good sensitivity and high backgrounds are often 
attributable to poor enzyme-antibody conjugates (Catty 1989).
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Figure 2.1 Indirect immunosorbant assay.
Stage 1.
Coat the antigen to the 
plate.
Incubate
Wash. 
Stage 2.
Add samples and standards. 
Incubate.
I
Wash. 1
Stage 3.
Addition of enzyme labelled 
second antibody.
Incubate.
Wash. I
Stage 4.
Addition of enzyme substrate. 
Incubate.
Stage 5. Stop the reaction with acid and read 
the optical density of each well.
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The conjugated material should have all or most of the original antibody 
and enzyme activity, and should contain only limited amounts of unlabelled 
antibody or free enzy ;me. Polymerization of the enzyme must also be 
minimized during its production (Beyzavi et al 1987).
When developing an ELISA, the aim is to obtain the maximal difference 
between specific and non-specific binding. Optimum conditions need to be 
determined for each stage of the assay such as:
i) the optimum concentration of antigen or antibody for immobilization or 
coating to the solid phase. A high concentration of immobilized antigen or 
antibody will reduce specific binding and enhance non-specific binding. 
Also when the concentration is too low, the specific binding capacity is 
small and the sensitivity of the assay will be low (Nakamura et al 1986).
ii) optimum incubation times for each step in the assay.
iii) optimum type of substrate and time and temperature for the enzyme 
reaction to develop the product.
2.1.2 Quantification of antibodies.
The reporting of end results of quantitative ELISA for antigen 
concentration is simple, with the result expressed as the absolute 
concentration of the substance under assay. However, the quantification of 
antibody concentrations by ELISA is not so easy, with as many methodsof 
expressing results existing as there are groups in the field. The 
difficulty arises in quantifying specific antibodies for a number of 
reasons including the range of specific antibody concentrations 
encountered and differences in antibody affinity between individuals. One 
method used to express results is the titration method. The serum is 
diluted serially to the point (titre) at which the specific antibody 
activity can no longer be detected.
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One of the more commonly utilized method of communicating specific 
antibody concentrations is the absorbance method (Gallagher et al 1983), 
when the results are expressed in terms of absorbance values. The values 
produced however have to considered as raw laboratory data and may require 
some refinement before reporting ( de Savigny & Voiler 1980). The other 
commonly used method of expressing results is as a ratio of either a
negative or positive serum sample or patient pool (Firer et al 1981,
Falth-Magnusson et al 1988). When the sample under investigation is 
expressed as a ratio of a negative standard, ratios greater than 2 are 
usually considered positive.
One aim of this study is to develop a method by which concentrations of 
specific immunoglobulins in sera are determined in absolute terms,
combatting the problem of being unable to compare concentrations of 
different antibodies in any one individual and perhaps aiding comparison 
of results between groups.
2.1.3 Affinity purification.
Affinity chromatography includes a broad range of purification methods 
which involve the specific interactions of immunoglobulins with a binding 
molecule covalently attached to an insoluble support matrix (Hardy 1986), 
thus exploiting the unique biological specificity of the protein-ligand 
interaction. When the antibody containing solutions are applied to the
affinity columns, this interaction will deplete from the pass-through 
fluid only the proteins with appreciable affinity for the ligand. The 
specifically adsorbed protein can be eluted simply by altering the 
composition of the solvent to favour dissociation.
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The solid phase matrix support is a critical factor in affinity
chromatography, as it must possess chemical groups which can be activated 
or modified to permit covalent linkage of a variety of ligands. In 
addition it needs to possess a high degree of porosity since this allows 
good flow properties and does not hinder the penetration of macromolecules 
(Lowe & Dean 1974). Release of antibodies from the column matrix needs to 
occur under conditions innocuous to their specific activity. High affinity 
binding between antibody and antigen can cause problems with dissociation 
but this can normally be achieved by lowering the pH to less than 3.
Additionally, problems may arise in the immobilization of the antigen onto 
the inert matrix as this may alter the protein's 3-dimensional
conformation and may compromise the specificity of the reaction with
antibodies. Occlusion of antigen binding sites may also occur. Despite
these problems, affinity purification provides a rapid and easy separation 
method in essentially one single step, leading to the ready resolution of 
the antibody from whatever media in which it was present.
2.2 Aims of study.
The aim of the study was to develop indirect ELISAs to enable the 
determination of the levels of IgG antibodies against ovalbumin, gliadin 
and B-lactoglobulin in serum, and levels of IgA antibodies against the 
same antigens in saliva and breast milk.
With the assays developed, it was aimed to develop a method of purifying 
specific antibodies to ovalbumin, gliadin and B-lactoglobulin from serum 
to enable their concentrations to be quantified. Once the quantification 
method was developed, the validation of the indirect ELISAs to determine 
specific antibodies was required.
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2.3 Materials
Aldrich (Gillingham, Dorset, UK).
Dimethyl sulphoxide,
Amersham International (Amersham, UK.)
Biotin streptavidin peroxidase complex
British Drug House Ltd (Poole, Dorset, UK).
Acetic acid (IIM), ammonium sulphate, casein, citric acid. Commassie Blue, 
ethanol (96%), disodium hydrogen phosphate, gelatin :, hydrochloric acid, 
hydrogen peroxide (lOOvols, 30%), glycine, glutaraldehyde, methanal 
(formaldehyde) (40%), orthophosphoric acid, potassium chloride, potassium 
dihydrogen phosphate, sodium azide, sodium carbonate, sodium dihydrogen 
orthophosphate, sodium hydrogen carbonate, sulphuric acid (concentrated), 
thiomersal, urea.
Boehrinqer Mannheim (Mannheim, Germany).
3,3',5,5' Tetramethylbenzidine
Clifmar Associates (University of Surrey, Guildford, UK.)
1000Â aminopropyl porous glass beads
Dynatech Laboratories (Billinqshurst, UK).
Microtitration flat-bottomed polyvinylchloride plates, flat bottomed 
Immunol B polystrene plates.
Imperial Laboratories (Salisbury, Wiltshire, UK).
Normal horse serum
May and Baker Ltd (Daqenham, UK).
Sodium chloride
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Medical International Ltd (London, UK).
Viscing dialysis tubing
Sigma Chemical Company Ltd (Poole, Dorset, UK).
Biotinylated goat anti-human IgG, B-lactoglobulin B, bovine serum albumin 
(Fraction V), human serum albumin, human IgG preparation (lyophilyzed), 
gliadin (crude), ovalbumin (Grade V), 30mg 0-phenylenediamine 
dihydrochloride tablets, sodium cyanobromohydride. Tris (hydroxymethyl) 
aminomethane, polyoxyethylene sorbitan monolaurate (Tween 20).
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2.4. Methods.
A number of procedures remained constant through out the ELISAs described 
below. 200ul was added to each well at every stage with the exception of 
addition of substrate, when 15Oui was added, and acid stop, when 5Oui was 
added. When washing, each plate was washed three times and inverted onto 
absorbent paper to remove any remaining buffer. Washing was carried out on 
a Titertek S8/12 automatic washer (Flow Laboratories, Rickmansworth, 
Herts.) if 0.15M phosphate buffered saline plus 0.1% (w/v) gelatine and 
0.05% (v/v) Tween 20 (pH 7.4)(PBSGT) was the washing buffer, a Dynatech
Multiwash hand washer (Dynatech, Billingshurst) if 0.5% (w/v) casein
buffer (pH 7.6) was used and with wash bottles when other buffers were 
used. All incubations were carried out at 37®C in a moist chamber unless 
otherwise stated.
2.4.1 Development of an ELISA to determine anti-ovalbumin IgG in serum.
i)Optimization of washing and coating buffers. Half the wells of a soft 
plate were coated with lOug/ml ovalbumin in 0.15M phosphate buffered 
saline (pH 7.4)(PBS) or O.IM bicarbonate/carbonate buffer (pH 9.6), with 
the remaining wells containing buffer only. Following a 2hr incubation, 
the plates were washed with 0.5% (w/v) casein buffer (pH7.6) when coated 
with PBS and with PBSGT when coated with bicarbonate/ carbonate buffer. 
Three adult serum samples were double diluted from 1:50 to 1:200 in both 
buffers and duplicates of each dilution added to the plate. After 
incubation at 4°C overnight and washing, horseradish peroxidase sheep 
anti-human IgG conjugate (1:15000) in the appropriate buffer was added and 
incubated for 2hr. All plates underwent a final wash in PBSGT prior to 
addition of 0-phenylenediamine dihydrochloride substrate (OPD). The 
substrate consisted of 30mg OPD in 75mls of 0.025M citrate/phosphate 
buffer (pH 5.6) with 30ul 30% hydrogen peroxide (H2O2).
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The reaction was stopped with 2.5M sulphuric acid (HaSO4) after 30 mins 
and the optical density read at 492nm using a Titerteck plate reader 
linked to a plate reading program on an Amstrad 1430. The results were 
obtained by plotting the optical density values of the three dilution and 
comparing them to the plot for the same sample when added to wells 
containing only buffer.
ii)Antigen coating concentration. In order to determine the optimum 
coating concentration of ovalbumin, solutions of ovalbumin containing 10, 
20, 50 and lOOug/ml in PBS were coated onto soft plates and incubated for 
2hr. Negatives containing just PBS were also included. The plates were 
washed in casein buffer and the assay continued as detailed above.
Hi) Antigen incubation time. 50ug/ml ovalbumin in PBS was added to soft 
plates and the assay incubated for varying times before washing and the 
addition of sample. The timings used were 1, 2 and 4hr at 37®C and 24hr 
at 4®C. The plates were washed in casein buffer and continued as above.
iv)Sample incubation time. 50ug/ml ovalbumin in PBS was coated onto soft 
plates and incubated for 2hr. After washing, the samples, diluted 1:50 to 
1:200, were added in duplicate and incubated for either 1,2 or 4hr at 
37®C or overnight at 4®C. The assay was then continued as above.
2.4.2 Development of an ELISA to determine anti-gliadin IgG in serum.
This assay was adapted from that of Juto et al (1986). Gliadin is only 
soluble in 70% ethanol therefore this was the only coating buffer used.
i)Optimization of washing buffers. Gliadin in 70% ethanol (50ug/ml), was 
coated onto half the wells of soft plates and the remaining wells coated 
with 70% ethanol only. The plates were left in the open overnight for the 
ethanol to evaporate, then fixed with 10% methanal for lOmins before 
washing with casein buffer, PBS with 0.05% Tween 20 (PBSTj, or PBSGT.
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Three samples were double diluted 1:100 to 1:1600 in each of the three
buffers and added, in duplicate, to the appropriate plate. The samples
were incubated overnight at 4°C in a moist chamber, before further washing
with the appropriate buffer. Horseradish peroxidase sheep anti-human IgG
conjugate, diluted 1:15000 in casein, PBST and PBSGT, was added to the
plates. Following an incubation of 2hr, the plates were washed in the
appropriate buffer with the exception of the casein plate which was washed
was
in PBSGT. OPD substrate added and the reaction was stopped, after SOmins, 
with 2.5M H2SO4 and the plates read at 492nm. The results were obtained by 
plotting the optical density values at the five dilutions of each sample 
when added to the wells containing gliadin against the optical density 
values obtained when added to the the wells coated with only ethanol.
ii) Optimization of antigen coating concentration. To obtain the optimum 
gliadin coating concentration, gliadin was coated onto soft plates in 70% 
ethanol at concentrations of 100, 50, 20 and lOug/ml. Ethanol blanks were
included, and the plates allowed to stand in the open overnight. The assay 
was then continued as detailed above.
Hi) Optimization of sample incubation. Soft plates were coated with 
gliadin (50ug/ml) in 70% ethanol and blanks included. After leaving in the 
open overnight, the plates were fixed with 10% methanal and left at room 
temperature for lOmins before washing with casein buffer. Samples, double 
diluted 1:100 to 1:1600 in casein buffer, were added and incubated for 
either Ihr, 2hr or 4hr at 37°C or overnight at 4®C. The plates were washed 
in casein buffer and the assay continued as detailed above.
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2.4.3 Development of an ELISA for determination of anti-B-lactoglobulin 
IgG in serum.
Development of anti-B-lactoglobulin antibody assays was in collaboration 
with Julie Lovegrove, Dept. Biochemistry, University of Surrey (Hampton et 
al 1990).
i) Optimization of coating and washing buffers. B-lactoglobulin, at a 
concentration of lOOug/ml, was coated onto soft plates in bicarbonate 
/carbonate buffer, PBS and 70% ethanol. Blanks were included, comprising 
of wells coated with only the appropriate buffer. The bicarbonate 
/carbonate and PBS coated plates were incubated overnight at 4°C before 
washing with PBSGT and casein buffer respectively. The ethanol coated 
plate was left in the open overnight before fixing for lOmins with 10% 
methanal and washed with PBSGT. Subsequently, it was treated identically 
to the bicarbonate/carbonate plate.
Samples, double diluted 1:50 in the same buffer as used for washing, were 
added in duplicate. Plates were incubated for 2hr before washing in PBSGT 
for bicarbonate/carbonate and ethanol coated plates and casein buffer for 
the PBS coated plate. Horseradish peroxidase sheep anti-human IgG 
conjugate (1:15000) was added in the appropriate buffer and incubated for 
2hr. All plates underwent a final wash with PBSGT before addition of 
substrate. Results were obtained by plotting optical density values 
obtained for samples added to the wells coated with B-lactoglobulin 
against those obtained when samples were added to wells containing only 
buffer.
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ii) Optimization of antigen coating concentration. B-lactoglobulin was 
coated onto soft plates at concentrations of 100,50, 20 and lOug/ml in
bicarbonate/carbonate buffer and incubated overnight at 4°C before washing 
with PBSGT and the addition of samples. The assay was continued as above 
using PBSGT as the washing and diluting buffer.
Hi) Optimization of antigen coating time. B-lactoglobulin was coated onto 
soft plates at a concentration of 50ug/ml in bicarbonate/carbonate buffer. 
The plates were incubated for Ihr, 2hr or 4hr at 37®C or overnight at 4®C 
before washing with PBSGT. The samples were added, double diluted 1:50 to 
1:800, and the assay continued as detailed above.
iv) Optimization of sample incubation. B-lactoglobulin was coated onto 
soft plates (50ug/ml in bicarbonate/carbonate buffer) and incubated 
overnight at 4°C. The plates were then washed with PBSGT and the samples, 
double diluted 1:50 to 1:800, added in duplicate and incubated for either 
Ihr, 2hr or 4hr at 37®C or overnight at 4®C before further washing. 
Horseradish peroxidase sheep anti-human IgG conjugate (1:15000) was added 
and incubated for 2hr at 37®C before washing. Substrate was then added.
V) Use of an avidin-biotin amplification system. A soft plate was coated 
with B-lactoglobulin and incubated overnight at 4®C, then washed with 
PBSGT. The samples, diluted as above, were added and incubated for 2hr. 
After washing, biotinylated goat anti-human IgG (1:20000) was added and 
incubated for 2hr before washing. Streptavidin biotin peroxidase complex 
(1:1000), was added and the plate incubated for Ihr. After a final wash, 
with PBSGT, substrate was added.
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2.4.4 Development of an ELISA to determine anti-ovalbumin IgA in saliva 
and breast milk.
The ELISA to determine anti-ovalbumin IgA in saliva and breast milk was 
carried out in an identical manner to the fully optimized assay developed 
to determine anti-ovalbumin IgG in serum, with the exception that the 
samples were double diluted from 1:10 to 1:160.
2.4.5 Development of an ELISA for the determination of anti-gliadin IgA in 
saliva and breast milk.
The assay to determine anti-gliadin IgA in saliva and breast milk was 
carried out in an identical manner to the fully optimized assay to 
determine anti-gliadin IgG in serum with the exception that the samples 
were double diluted from 1:10 to 1:160..
2.4.6 Development of ELISA for the determination of anti-B-lactoglobulin 
IgA in saliva and breast milk.
The development of the ELISA for the determination of anti-B- 
lactoglobulin IgA in saliva and breast milk was carried out by 
J.Lovegrove, Department of Biochemistry, University of Surrey with advise 
from Professor Anne Ferguson, Western General Hospital, Edinburgh.
Soft plates were coated with lOug/ml B-lactoglobulin in 0.16M NaCl, in 
glass distilled water. The plates were incubated for 2hr before washing 
with 0.16M NaCl plus 0.5% (v/v) Tween 20 and the block of 0.16M NaCl plus 
0.5% Tween 20 and 3% normal horse serum was added. After incubating for 
30min, the block was emptied out and the plates inverted onto absorbent 
paper. Breast milk standards double diluted from 1:100 to 1:1600, and 
samples diluted 1:100 in 0.16M NaCl, 0.5% Tween 20 and 1% normal horse 
serum were added and incubated at 37®C for 3hr. Saliva samples were 
diluted 1:10 to 1:160 in the same buffer as breast milk before addition to 
the plate.
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Following washing with 0.16M NaCl and 0.5% Tween 20, horseradish 
peroxidase sheep anti-human IgA conjugate was added and the plates 
incubated for 2hr. A final wash was carried out before the addition of TMB 
substrate. The substrate was made up of 20ml 0.025M citrate/phosphate 
buffer (pH 5.6), 8ul 30% hydrogen peroxide and lOOul 20mg/ml 3, 3',5 ,5'
tetramethylbenzidine (TMB) in dimethyl sulphoxide.
2.4.7 Preparation of antigen affinity columns.
lOmg of each ligand ^ (B-lactoglobulin, ovalbumin, gliadin) was dissolved 
in 10ml PBS plus 0.02% (w/v) sodium azide. If the compounds had not 
dissolved completely, the solution was centrifuged to remove any large 
particals.
0.5g activated 1000Â aminopropyl porous glass beads were added to 10mls 
1.25% (v/v) gluteraldehyde in PBS and mixed on a roller for 2hr at room
temperature. The beads were then washed in 100ml PBS/0.02% sodium azide 
and the protein solution added and mixed for a further 2hr. The beads 
were allowed to settle out and the supernatant aspirated off. 0.15g 
glycine and 0.063g sodium cyanobromohydride in 10ml PBS were added to the 
beads and mixed overnight at room temperature. The beads were then poured 
into a 5ml column and washed with O.IM glycine/HCl (pH 2.2) The column was 
finally washed with PBS/0.02% sodium azide to return the pH of the beads 
to 7. PBS/ 0.02% sodium azide was left in the columns for storage at 4®C.
2.4.8 Affinity purification of antibodies.
The column was emptied, without allowing it to run dry, and 2ml of sample 
added. The column was mixed on a roller for 60 mins at room temperature 
and the sample drained out. 20ml PBS was passed through the column to wash 
off any non-specifically bound proteins and the desorbing buffer, 2ml O.IM 
glycine/HCl (pH 2.2), added. The column was rolled for a maximum of 10 
mins before the glycine/HCl and specific antibody were eluted.
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The column was washed again with PBS to return the pH to 7 and PBS/0.02% 
sodium azide added prior to storage. The eluted antibody was dialysed 
immediately against PBS overnight at 4®C. The protein content was 
determined by obtaining the optical density of the antibody solution at 
280nm using a LKB Biochem Ultrospec 4050 spectrophotometer.
2.4.9 Selection of specific human IgG source.
For the initial development of the method for quantifying specific IgG 
antibodies, anti-ovalbumin IgG was used as a model, and therefore the only 
specific IgG purified and analysed. Serum was obtained from 10 subjects 
and screened by indirect ELISA (Chapter 2) for the presence of anti­
ovalbumin IgG. The serum giving the highest optical density was selected 
for subsequent use. A human IgG preparation was also screened to ensure
that anti-ovalbumin IgG was present.
The serum and human IgG (dissolved in PBS) were both purified following
the method in section 2.4.8. 2mls of serum and a total of Img human IgG 
were added separately to the column and eluted with 2mls O.IM glycine/HCl 
(pH 2.2). The protein concentration of the eluted antibodies was 
determined after dialysis against PBS (pH7.6). The sample once passed
through the column and the eluted antibody were screened by ELISA for the 
presence of anti-ovalbumin IgG.
2.4.10 Quantification of specific antibodies in serum.
10 X 10ml serum samples were obtained from volunteers within the 
Biochemistry Department at the University of Surrey. The samples were 
screened for the presence of IgG antibodies to ovalbumin, gliadin and J3- 
lactoglobulin using indirect ELISA (Chapter 2). A 100ml blood sample was 
obtained from the subjects showing the highest optical density values for 
each of the antibodies under investigation. The serum was separated off 
and aliquoted before freezing at -20°C.
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A 2ml fraction of each serum was purified on the appropriate column 
following the method given in section 2.4.8. After dialysing overnight 
against PBS, the volume of purified antibody was measured and the protein 
content of the eluted anti-ovalbumin and anti-gliadin antibodies were 
determined by the method of Bradford (1976). Total specific IgG 
concentration was determined by laser nephelomeb ry at Department of 
Clinical Biochemistry, St.Luke's Hospital, Guildford, Surrey.
Purified anti-B-lactoglobulin human IgG was freeze dried, before being 
reconstituted in 2ml PBS just prior to the determination of IgG 
concentration by laser nephelomettry and protein determination by the 
method of Bradford (1976).
An aliquot of each purified specific human IgG was diluted to give a 
concentration equivalent to a 1:10 dilution of the original unpurified 
serum. The diluted purified antibodies were analysed for specific antibody 
content using the appropriate ELISA (Chapter 2). Also included on the 
ELISA plate was a 1:10 dilution of the original serum. The optical density 
values for the purified and unpurified specific human IgG were obtained, 
and the specific antibody concentration of the serum determined.
Calculation of specific antibody content.
BxC / E = specific antibody concentration (mg/ml)
A / D
Volume of serum purified (mis) = A
Volume of eluted antibody (mis) = B
Protein content of eluted antibody (mg/ml) = C
Optical density of original serum = D
Optical density of eluted antibody = E
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2.4.11 Validation of indirect ELISAs to determine specific IgG and IgA.
i) Determination of sensitivity.
For all assays, the standard curve was added to the plates in sixlicate. 
The mean optical density and standard deviation for each point on the 
curve was determined and the sensitivity or limit of detection defined as 
2 standard deviations above the zero value.
ii) Intra- and inter-assay variation.
Quality control samples were obtained for each assay and included in 
sixlicate on one plate to determine intra-assay variation, and in 
duplicate on six different plates to determine inter-assay variation.
Hi) Parallelism.
Samples containing high amounts of the specific antibody under 
investigation were double diluted from 1:100 - 1:800 for serum and anti-B- 
lactoglobulin IgA determination in breast milk, and 1:10 - 1:80 for anti- 
gliadin and anti-ovalbumin IgA determination in saliva and breast milk. 
The optical density of the diluted samples was then plotted with the 
standard curve to ensure the two ran parallel.
iv) Crossreactivity.
The crossreactivity of three anti-ovalbumin IgG and IgA with BSA, HSA and 
B-lactoglobulin was determined by the addition to the plate of lOOul of 3 
samples diluted 1:50 and 1:100 in the case of serum and 1:5 and 1:10 in 
the case of saliva and breast milk. To this was then added either lOOul of 
assay buffer or 200ug/ml and lOOug/ml solution of the crossreactants. The 
final dilution of sample was therefore the same as used in all other 
assays, with a final concentration of crossreactants of 0, 50 and
lOOug/ml. Optical density values with the addition of no crossreactant 
were compared with those obtained with crossreactant present.
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Crossreactivity with specific anti-gliadin antibodies in serum, saliva and 
breast milk was determined in the same way as above using BSA, HSA and 
ovalbumin as crossreactants.
Anti-B-lactoglobulin antibodies in serum were crossreacted with casein 
derived from sheep, goat and cow's milk, giving a final concentration of
these crossreactants of 0, 50 and lOOug/ml and 1:50 and 1:100 dilutions of
out
the samples used. Julie Lovegrove kindly carried the crossreactivity 
studies on anti-B-lactoglobulin IgA in breast milk.
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2.5 ResultsV' -------- '—
2.5.1 Development of ELISA to determine anti-ovalbumin IgG in serum.
i) Optimization of washing and coating buffers. The use of PBS to coat 
the plate and casein buffer for all subsequent dilutions and washes proved 
the best combination of buffers (Figure 2.2). These gave consistently low 
levels of non-specific binding for the three serums used.
ii) Optimization of antigen coating concentration. Little difference was 
seen in the results obtained with coating concentrations of 100 and 
50ug/ml ovalbumin. lOug/ml produced a curve only slightly above the level 
of non-specific binding. 50ug/ml ovalbumin was taken as the optimum 
coating concentration.
Hi) Optimization of antigen incubation time. The level of non-specific 
binding for the varying incubation times were very similar, with 
increasing incubation time decreasing specific binding. The minimum 
incubation time of Ihr therefore gave the best results.
iv) Optimization of sample incubation time, A 4hr incubation of samples 
produced the highest specific binding, but the non-specific binding was 
also high. The greatest difference between specific and non-specific 
binding was obtained with the overnight incubation of samples (Figure 
2.3).
When fully optimized, the anti-ovalbumin assay was carried out as detailed 
below: Soft plates were coated with 50ug/ml ovalbumin in PBS and incubated 
at 37*C for Ihr. After washing with casein buffer, samples, diluted 1:100, 
and standards, diluted 1:100 - 1:1600, were added and incubated at 4®C 
overnight before washing. Horseradish peroxidase sheep anti-human IgG 
conjugate was added and incubated at 37®C for 2hr, and the plates washed 
with PBSGT. OPD substrate was added and stopped after 30min.
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Figure 2.2 Optimization of coating and washing buffers used in the 
determination of anti-ovalbumin IgG.
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Figure 2.3 Optimization of sample incubation time in the determination of 
anti-ovalbumin IgG.
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Figure 2.4 Optimization of the washing buffers used in the determination 
of anti-gliadin IgG.
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Figure 2.5 Optimization of coating and washing buffers used in the 
determination of anti-B-lactoglobulin IgG.
w
C ^0) E 
~o c
_  CM rt cn
CLo
0.8-1
0.6 -
0.4- — A-
0.0
800400 6002000
Bicarb/PBSGT +ve 
Bicarb/PBSGT -ve 
PBS/Casein +ve 
PBS/Casein -ve 
EtOH/PBSGT +ve 
EtOH/PBSGT -ve
Dilution of sample 
(1/X)
62
2.5.2 Development of ELISA to determine anti-gliadin IgG in serum.
i) Optimization of washing buffers. The results obtained with the
different washing buffers are given in Figure 2.4. The use of PBSGT and 
casein buffers produced lower non-specific binding than with PBST, with 
the specific binding of both PBSGT and PBST being greater than seen with 
casein. The use of casein buffer, however, produced the most acceptable 
combination of specific and non-specific binding.
ii) Optimization of antigen coating concentration. 50ug/ml gliadin was
the optimum coating concentration for the assay. Higher concentrations
brought little increase in specific binding, with the binding decreasing 
with lower concentrations.
Hi) Optimization of sample incubation time. The four incubations times 
used showed little difference in the degree of non-specific binding, 
however, the 4hr incubation gave the highest specific binding and was 
therefore used in all subsequent assays.
With the optimizations complete, to determine anti-gliadin IgG antibodies, 
soft plates were coated with 50ug/ml gliadin in 70% ethanol and left 
uncovered overnight. 10% methanal was added and left for lOmins before the 
plates were washed with casein buffer. The samples, diluted 1:100 and 
standards, diluted 1:100 -1:1600, were added and incubated at 37®C for 
4hr. Following washing, the horseradish peroxidase sheep anti-human IgG 
conjugate was added, incubated at 37®C for 2hr and the plates then washed 
with PBSGT. Substrate was added and incubated at 37®C for 30mins before 
stopping.
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2.5.3 Development of ELISA to determine anti-B-lactoglobulin IgG in serum.
i) Optimization of coating and washing buffers. Bicarbonate/carbonate 
buffer with PBSGT was the only combination to produce any appreciable 
difference between the specific and non-specific binding (Figure 2.5).
ii) Optimization of antigen coating concentration. Two samples were 
added to the assay to determine optimum B-lactoglobulin coating 
concentration, and each gave slightly different optimum values. However, a 
coating concentration of 50ug/ml produced acceptable results for both 
samples.
Hi) Optimization of antigen coating time. Differences in antigen 
coating time appear to have limited influence on the assay as shown in 
Figure 2.6. In all cases, the non-specific binding was close to the 
specific binding, with the exception of the 2hr, where the greatest 
difference between the two was seen.
iv) Optimization of sample incubation time. Although a 4hr incubation 
produced the greatest difference between specific and non-specific 
binding, the 2 hr incubation time was chosen to prevent the assay being 
over long for one day.
V) Use of an avidin-biotin amplification system. The inclusion of the 
avidin-biotin system into the assay brought about a large amplification of 
the specific binding with only a small increase in the level of non­
specific binding (Table 2.1). Samples with low concentrations of antibody 
were able to be distinguished more clearly from those containing none as 
the sensitivity of the assay was improved.
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Figure 2.6 Optimization of B-lactoglobulin coating time,
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Table 2.1 Use of a avidin-biotin amplification system.
Label used
Sample Horseradish peroxidase Avidin-biotin system
+ - + -
1 0.148 0.103 0.247 0.197
2 0.427 0.081 0.833 0.123
3 0.320 0.093 0.673 0.163
4 0.089 0.087 0.150 0.119
+ = specific binding 
- = non-specific binding
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After the assay was fully optimized, anti-B-lactoglobulin IgG was 
determined as detailed below. Soft plates were coated with 50ug/ml B- 
lactoglobulin in bicarbonate/carbonate buffer, incubated at 4®C overnight, 
then washed with PBSGT. The samples, diluted 1:50, and standards, diluted 
1:50 - 1:800 were added and incubated at 37°C for 2hr before washing and
the addition of the biotinylated goat anti-human IgG. The plates were then 
incubated at 37®C for 2hr, washed and streptavidin-biotin peroxidase 
complex added. Following a Ihr incubation at 37®C, plates were washed 
with PBSGT and OPD substrate added. The reaction was stopped after 30min.
2.5.4 Development of ELISA to determine anti-ovalbumin IgA in saliva and 
breast milk.
Figure 2.7 shows the dilution profiles of samples of breast milk and 
saliva. The use of 1:10 dilutions of both samples produces adequate 
binding, and no further development of the assay was required as the non­
specific binding in the saliva and breast milk was sufficiently low.
2.5.5. Development of ELISA to determine anti-gliadin IgA in saliva and 
breast milk.
As with the anti-ovalbumin IgA assay, no further development was required 
as the levels of non-specific binding were sufficiently low. The 1:10 
dilution of both saliva and breast milk was suitable, giving an adequate 
degree of binding (Figure 2.8).
2.5.6 Development of ELISA to determine anti-B-lactoglobulin IgA in 
saliva and breast milk.
The assay was able to determine anti-B-lactoglobulin IgA in breast milk 
with a large difference existing between the levels of specific and non­
specific binding (Figure 2.9). As can be seen from Figure 2.9, it was 
not possible to determine the specific IgA levels in saliva as the non­
specific binding was elevated, combined with very low specific binding.
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Figure 2.7 The specific and non-specific binding in an ELISA to determine 
anti-ovalbumin IgA in saliva and breast milk.
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Figure 2.8 The specific and non-specific binding in an ELISA to determine 
anti-gliadin IgA in saliva and breast milk.
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Figure 2.9 The specific and non-specific binding in an ELISA to determine 
anti-B-lactoglobulin IgA in saliva and breast milk.
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2.5.7 Selection of specific IgG source.
The serum from 10 volunteers and a human IgG preparation were screened 
for specific IgG antibodies to ovalbumin. The IgG preparation was shown to 
contain specific anti-ovalbumin IgG, giving an optical density value of 
0.949 at a concentration of Img/ml.
The protein content and ELISA optical density reading for the specific 
anti-ovalbumin IgG content were obtained for the purified serum and human 
IgG preparation. The results of these determinations are shown in Table 
2.2. The purification of anti-ovalbumin IgG from serum yielded a greater 
amount of active specific IgG than the human IgG preparation. Serum proved 
to be more successful as a source of specific antibodies for purification 
than the human IgG preparation. In both cases however, a high proportion 
of the specific antibody remained in the sample.
2.5.8 Quantification of specific antibodies.
Three subjects were selected, from the 10 screened, as high producers of 
one of the IgG antibodies under investigation. Each serum was purified and 
protein content determined by two methods. The specific antibody content 
of each serum was calculated using the equation in section 2.4.8 using the 
results of both protein determinations (Table 2.3). The specific antibody 
content was higher with the total protein content of the eluted antibody 
determined compared with selectively measuring the IgG content.
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Table 2.2 Protein content and ELISA activity of purified anti-ovalbumin 
IgG from two sources.
Source Sample Protein Optical density
(mg/ml) (492nm)
Serum Eluted IgG 0.40 0.269
Stripped serum - 0.320
Unpurified serum - 0.836
Human IgG Eluted IgG 0.00 0.000
Stripped serum - 0.168
Unpurified 0.206
Table 2.3 Specific IgG antibody content of serum as determined by two 
methods and calculated using the equation in section 2.4.8.
Antibody Protein determination method
C.Blue* Nephelomatory 
(mg/ml)
Ovalbumin 2.07 1.034
Gliadin 1.30 0.586
B-lactoglobulin 0.78 0.169
C.Blue = Commassie Blue method of protein determination (Bradford 1976)
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2.5.9 Validation of indirect ELISAs to determine specific IgG and IgA 
antibodies.
i) Sensitivity,
The limit of detection of specific IgG antibodies in serum was found to be 
between 1.8 - 5ug/ml. Specific IgA antibodies in both saliva and breast 
milk were detectable above 1% standard. Illustrations of the standard 
curves produced are found in Figure 2.10 (serum), 2.11 (breast milk) and 
2.12 (saliva).
ii) Intra- and inter-assay variation.
The inter- and intra-assay variation for specific IgG antibodies in serum 
and IgA in saliva and breast milk are shown in Table 2.4.
Hi) Parallelism
Samples containing high amounts of antibody, when diluted, down were found 
to run parallel to the serum standards used for the specific IgG 
determinations. This is illustrated in Figure 2.13, with all three 
standard curves included. The breast milk samples studied also ran 
parallel to the curve as shown in Figure 2.14. Figure 2.15 shows the 
parallelism of the saliva samples with the standards.
iv) Crossreactivity
The specific antibodies studied showed no crossreactivity with the 
concentrations of crossreactants used, that is no reduction in optical 
density values was seen in the serum to which the crossreactant had been 
added when compared to serum containing no additions.
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Figure 2.10 Examples of the standard curves used in the determination of 
specific IgG concentrations in serum (mean + SEM, n=6).
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Figure 2.11 Examples of the standard curves used in the determination of 
specific IgA antibodies in breast milk (mean + SEM, n=6).
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Figure 2.12 Examples of the standard curves used in the determination of 
specific IgA in saliva (mean + SEM, n=6).
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Table 2.4 Intra- and inter-assay variation of indirect ELISAs to 
determine specific antibodies in serum, saliva and breast milk.
Serum
Biological fluid 
Saliva Breast milk
Antigen Cone. CV% Cone. CV% Cone. CV%
(ug/ml) a b (% snd) a b (% snd) a b
Ovalbumin 1 271 4 16 61 9 16 53 8 15
2 126 3 18 30 3 16 27 5 17
3 85 4 12 6 5 19 15 3 15
Gliadin 1 195 3 12 90 8 11 7 4 10
2 73 8 16 47 6 13 3 9 13
3 35 6 10 29 2 15 1 7 10
B-lacto. 1 121 4 13 44 4 16
2 40 7 22 NOT DETERMINED 28 5 17
3 16 3 14 11 5 19
% snd = % standard 
a = intra-assay variation 
b = inter-assay variation
1,2,3 = high, medium and low quality control samples
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Figure 2.13 Determination of parallelism between standards and samples 
in the measurement of specific antibodies in serum.
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Figure 2.14 Determination of parallelism between standards and samples 
in the measurement of specific antibodies in breast milk.
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Figure 2.15 Determination of parallelism between standards and samples 
in the measurement of specific antibodies in, saliva.
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2.6 Discussion
2.6.1 Development of ELISAs to determine specific antibodies in serum, 
saliva and breast milk.
It was possible to produce indirect ELISA assays to measure anti-ovalbumin 
and anti-gliadin IgG in serum and cord blood, and these assays were
readily able to determine specific IgA antibodies to these two proteins in 
saliva and breast milk without further optimization. The use of casein 
buffer in both assays was very successful at blocking all remaining 
binding sites,so reducing non-specific binding to a minimum.
The development of an indirect ELISA assay to measure anti-B-lactoglobulin 
IgG was not as simple, with problems of low specific antibody levels and 
high non-specific binding. However, the use of an avidin-biotin
amplification system enabled both these problems to be overcome. The
avidin-biotin system exploits, firstly, the very high affinity of avidin 
for biotin (dissociation constant: 10“^^ M: Guesdon et al 1979) and
secondly, the presence of four binding sites for biotin on each avidin 
molecule. The biotin is covalently linked to the required second antibody 
and so through this becomes bound to the solid phase. Avidin is then 
added in which three of the biotin binding sites are occupied by a biotin 
enzyme conjugate. A bridge is therefore formed between the antibody-bound 
biotin and the enzyme labelled biotin via the avidin molecule. The signal 
amplification arises as three enzyme molecules now able to bind to each 
antibody immobilized on the solid phase, as opposed to one with enzyme 
labelled antibodies.
In order to measure anti-B-lactoglobulin IgA in breast milk, a new ELISA 
system needed to be developed. The concentration of anti-B-lactoglobulin 
IgA in breast milk was sufficient for an amplification system not to be 
required.
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It has not proved possible to determine the specific IgA in saliva due to
the high degree of non-specific binding encountered with this fluid.
J.Lovegrove tried a number of different approaches to overcome this
problem, not detailed, which included the use of blocking agents such as
casein, 1% gelatine and polypep, the inclusion of an avidin-biotin
c
amplification system and chemiluminesence. None of these were successful, 
with little change in the degree of non-specific binding. The assay 
developed was thought therefore to be insufficiently sensitive to 
distinguish the small amounts of anti-B-lactoglobulin IgA present from the 
background binding.
2.6.2 Quantification of specific antibodies.
The use of the glass bead affinity columns produced has shown that this
method is very suitable for the purification of specific anti-ovalbumin,
IgG
gliadin and B-lactoglobu.lin from serum. The purification method is simple 
and quick, giving acceptable yields of specific antibody.
Two sources of human IgG were investigated for the purification of 
specific IgG. The human IgG preparation contained anti-ovalbumin IgG but 
on purification the activity of the antibody was lost, with little 
antibody binding to the column and the majority remaining in solution. 
Elution with stronger desorbing buffers (4M, 7M urea) was also tried, 
although the data has not been presented, and this increased the recovery 
of the anti-ovalbumin IgG. However, the activity of the antibody was very 
low. Purification of anti-ovalbumin IgG from serum was more successful 
giving good recoveries from the column and showing a high proportion of 
the original antibody activity. It was therefore decided that the specific 
antibody content of serum would be determined using affinity purification 
rather than using purified antibodies as the standard curve.
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IgG antibodies to ovalbumin, gliadin and B-lactoglobulin were purified and 
the concentration of eluted antibody determined by two different 
methods. Total protein measurements of eluted antibodies gave appreciably 
higher specific antibody concentrations compared to results obtained with 
total IgG determinations. Non-specific binding of serum proteins to the 
columns occurs and is not washed off but eluted with the antibody. In 
addition, serum contains IgA, IgM and small amounts of IgE to food 
proteins, and these will bind to the column. Total protein determination 
is therefore not as accurate as determining IgG alone. Specific antibody 
concentrations calculated from nephelometury results were taken as the 
most representative of the actual situation in serum.
Purification of salivary anti-ovalbumin IgA was attempted, but was not as 
successful as the purification of IgG antibodies. Recoveries from the 
column were very low and this, combined with lower concentrations of 
immunoglobulin in saliva, made measurement of the eluted antibodies 
difficult. These factors combined were felt to prevent an accurate 
estimation of the specific antibody content of saliva being made. It was 
therefore decided not to quantify antibodies in saliva and to express 
titres as a percent high standard.
With the methods presently used to express levels of specific antibodies, 
it is very difficult, if not impossible, to compare results produced by 
different laboratories with exception of the titration method. In both the 
commonly used methods, absorbance and ratio methods, results are expressed 
in terms of a standard,which differs between laboratories. In addition, it 
is not possible to compare the concentrations of specific antibodies to 
different food proteins when the results are expressed in these ways. 
Antibodies to different proteins can not be expected to act in the same 
way, the affinities and dose response curves are unlikely to be identical.
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The method of specific IgG antibody quantification developed in this study 
can overcome both these common problems. The quantification of specific 
antibodies in absolute terms, rather than relative to an essentially 
arbitrary standard, enables the comparison of results between laboratories 
and the comparison of concentrations of different specific antibodies to 
be made with ease.
2.6.3 Validation of specific IgG and IgA antibody ELISAs.
The validations of the indirect ELISA assays to determine specific IgG in 
serum and specific IgA in breast milk and saliva have shown that the 
assays produced are sensitive, specific and reproducible. The sensitivity 
of all the assays ensured that the specific antibody levels could be 
determined in all samples despite very low levels being encountered in
some. The use of serum, saliva and breast milk samples as standards
ensured that matrix effects were not encountered and the samples behaved 
in a similar manner to the standards, as seen in the parallelism studies.
The crossreactivity studies carried out can not be classed as giving a 
true representation of specific antibody crossreactivity. However it is 
very difficult to determine this factor in any other way due to the 
likelihood of antibodies to the theoretical crossreactants being present 
in the sample as well. As no changes were noted in the binding of the 
specific antibody under investigation to its antigen bound to the plate in 
the presence of possible crossreactants, it can be assumed that the
antibodies are specific for the antigen. The crossreactivity studies were
carried out on only a limited number of antibodies, and it is possible 
that antibodies from others sources may show crossreactivity with the 
compounds used in these studies.
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The intra- and inter-assay variation on all the assays was within 
acceptable limits, although it is higher than that encountered with 
radioimmunoassay. The inter-assay coefficient of variation of several of 
the quality control samples was slightly higher than would be considered 
acceptable, for example that of the medium control in the anti-B- 
lactoglobulin IgG determination. The reason for the higher variation is 
not known but may be due to the position of the sample on the standard 
curve. The quality control samples showing the greatest variation are 
those which^^on the section of the standard curve where it begins to 
flatten out. Thus at this point small changes in optical density readings 
can cause large differences in the concentration measured.
This study has shown that ELISAs can be developed to determine specific 
food antibodies in a range of biological fluids, and that these assays are 
both sensitive and specific, and reproducible. A new method of quantifying 
specific antibodies in serum has been produced, which enables comparisons 
to be made between serum levels of various specific antibodies, and 
hopefully will aid in the comparison of results between laboratories.
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Chapter 3
Development of immunoassays to determine ovalbumin 
and gliadin in serum.
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3.1 Introduction
The term 'immunoassay' covers a number of different techniques including 
radioimmunoassay (RIA), immunoradiometric assays and enzyme-linked
I :
immunosorbent assays (ELISA). Immunoassays are characterised by the fact 
they use a labelled form of antibody or antigen for quantification and a 
non-precipitating antibody in the primary reaction (Morris 1985). Food
antigens have been determined by both RIA and ELISA in breast milk 
(Kulangara 1980, Kilshaw & Cant 1984, Axelsson et al 1986) and serum
(Husby et al 1985a).
RIA is an important technique, used in the clinical and biochemical 
fields for the quantification of hormones, steroids and drugs as well as 
determination of food antigens. It combines the specificity of the immune 
reaction with the sensitivity of radioisotope methods and the technique is 
based on the competition between unlabelled antigen and a finite amount of 
the corresponding radiolabelled antigen for a limited number of antibody 
binding sites in a fixed amount of antiserum.
The use of RIA has many advantages which include:
a) The ability to assay any compound that is immunogenic, available in a 
pure form and able to be radiolabelled.
b) High sensitivity of detection.
c) Many radiolabelling procedures are relatively simple to carry out.
However, RIA also has a number of disadvantages:
a) Relatively high cost of equipment and reagents.
b) Short shelf life of reagents: half life of ^^ I^ is 60 days, 
necessitating relatively frequent labelling which may result in batch to 
batch variation.
c) The majority of assays usually take days rather than hours.
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d) Radiological hazards of using radioisotopes, particularly during the 
labelling stage.
e) Requirement for careful disposal of all radioactive materials.
( Wilson & Goulding 1986).
An alternative to RIA is ELISA, and this technique, discussed more fully 
in chapter 2, combines the specificity of an immunological reactant with 
the sensitivity of simple spectrophotometric enzyme assays. ELISA does 
have a number of advantages over RIA which include:
a) Enzymes are less expensive than radioisotopes and can be obtained with 
high purity.
b) Enzymes can be conjugated easily to antibody or antigen to give a 
stable product with a long shelf life.
c) No radiation hazards occur during labelling or disposal of waste.
d) Equipment for enzyme assay can be inexpensive and is generally 
available.
3.2 Aims of study.
The aim of this section of the project was to develop sensitive and 
specific immunoassays to determine ovalbumin and gliadin in serum and 
cord blood. The levels of both these antigens in serum are thought to be 
on average below lOng/ml, therefore the sensitivity of the assay was of 
prime importance.
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3.3 Materials
Biozyme Laboratories Ltd (Gwent, UK).
Horseradish peroxidase
British Drug House,
Ethanolamine, sodium acetate, sodium periodate.
Pierce
N-hydroxy succinamide biotin
Sigma Chemical Company Ltd (Poole, Dorset, UK).
Conalbumin (type 1), trypsin inhibitor - partially purified ovomucoid.
The 1425 sheep and N1 and N2 rabbit anti-ovalbumin antiserum was a gift 
from Dr Shelagh Hampton. The A17 sheep anti-gliadin antiserum was a kind 
gift from Mr Brian Morris, Department of Biochemistry, University of 
Surrey.
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3.4 Methods
3.4.1 Preparation of reagents for the development of ELISA to determine 
antigens in biological fluids.
i) DEM ion exchange purification of anti serum,
A Zetaprep 15 disc (LKB-Bromma, Sweden) was prepared by passing through 
75ml IM acetic acid, followed by 75ml O.IM phosphate buffer (pH 6.8) and 
finally 75ml O.OIM phosphate buffer (pH 7.4). 2ml of antiserum diluted 
1:10 in O.OIM phosphate buffer was added to the disc, and collection of 10 
X 5ml fractions of the eluent commenced. The disc was then regenerated by 
passing through acetic acid and O.IM and O.OIM phosphate buffer. The 
fractions collected were screened for protein at 280nm against O.OIM 
phosphate buffer. The fractions with the highest protein concentrations 
were pooled and thiomersal added to^final concentration of 0.02% w/v.
ii) Affinity purification of antiserum.
Affinity purification of antiserum was carried out by the method detailed 
in chapter 2, with the exception that 4ml of antiserum were loaded onto 
the column and eluted off with 4ml O.IM glycine/HCl (pH 2.2).
Hi) Conjugation of antibodies to horseradish peroxidase.
Specific antibodies were conjugated to horseradish peroxidase using the 
method of Beyzavi et al (1987). Affinity purified antibodies were dialysed 
at 4°C overnight against O.IM bicarbonate/carbonate buffer (pH 9.6) and 
protein content determined. Horseradish peroxidase, in a 1:1 w/w ratio of 
enzyme to antibody, was dissolved in 3ml water and 1.5ml O.OIM sodium 
periodate and mixed at room temperature for 30mins. Following dialysis at 
4*C overnight against ImM sodium acetate (pH 4.4), the enzyme was added to 
the antibody and mixed at room temperature for 2hr before the addition of 
0.5ml ethanolamine buffer (pH 7.6). After mixing for 2hr, the conjugate 
was dialysed against 0.15M PBS (pH 7.6).
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iv) Biotinylation of purified antibodies.
Affinity purified antibodies were dialysed at 4°C overnight against O.IM 
sodium hydrogen phosphate and the protein content determined. N- 
hydroxysuccinamide biotin was brought up to room temperature before 
dissolving in dimethyl sulphoxide at a concentration of Img/ml. 20ul N- 
hydroxysuccinamide solution was added to the purified antibodies per mg 
protein. The solutions were mixed immediately and allowed to stand at room 
temperature for 2hr. The label was then dialysed overnight against PBS.
3.4.2 Development of ELISA to determine ovalbumin in serum.
The initial work of determining the coating and washing buffers required 
was carried out by Miss Sara Pickling, Dept. Biochemistry, University of 
Surrey. All incubations are at 37°C in a moist chamber unless otherwise 
stated and 200ul was added to each well at every stage with the exception 
of addition of substrate when 15Oui was added and stopping when 5Oui was 
added. All washing was carried with 0.5% (w/v) casein buffer (pH 7.6) 
unless otherwise stated.
i)Optimization of antibody coating concentration and enzyme label 
dilution.
Hard plates were coated with 40, 20, 10, 5 and Oug/ml DEAE purified sheep 
anti-ovalbumin in PBS and incubated for 2hr before washing. lOng/ml 
ovalbumin in casein buffer was added and the plates incubated at 4®C 
overnight. After washing, the sheep anti-ovalbumin horseradish peroxidase 
conjugate was added, diluted 1:500, 1:1000 and 1:2000. The plates were
incubated for 2hr before washing with PBSGT and OPD substrate added.
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a )Optimization of ovalbumin standard curve with inclusion of a human 
plasma substitute.
Hard plates were coated with 2Oug/ml DEAE sheep anti-ovalbumin in PBS and 
incubated for 2hr. After washing, standard curves containing lOng/ml - 
0.04ng/ml ovalbumin in 1:100, 1:50, 1:20, 1:10, 1:4, and neat normal horse 
serum were added and incubated at 4°C overnight. After washing, sheep 
anti-ovalbumin horseradish peroxidase conjugate (1:500) added. After 2hr 
incubation the plates were washed with PBSGT and substrate was added.
With the addition of normal horse serum, the antibody coating 
concentration and enzyme label dilution were reoptimized. The assay was 
carried out as detailed in section i. 1000, 500, 250, 125 and Oug/ml DEAE 
sheep anti-ovalbumin were coated onto the plate and sheep anti-ovalbumin 
horseradish peroxidase conjugate was diluted 1:800, 1:400 and 1:200.
Ovalbumin was dissolved in 1:4 normal horse serum:casein buffer.
Hi) Comparison of two peroxidase substrates.
A hard plate was coated with lOOug/ml DEAE sheep anti-ovalbumin in PBS and 
incubated for 2hr. After washing, ovalbumin standards from lOng/ml to 
0.04ng/ml in 1:4 normal horse serum were added in quadruplicate. After an 
overnight incubation at 4®C and washing, sheep anti-ovalbumin horseradish 
peroxidase conjugate (1:200) was added and incubated for 2hr. OPD 
substrate was added in duplicate and TMB substrate added to the remaining 
wells. The plate was stopped and read at 492nm for OPD and 450nm for TMB.
iv) Use of biotinylated sheep anti-ovalbumin.
A sheep anti-ovalbumin biotin label was produced by the method described 
in section 3.4.1. Hard plates were coated with lOOug/ml DEAE sheep anti­
ovalbumin in PBS and incubated for 2hr. After washing 5, 2.5, 1.25, 0.625 
and Ong/ml ovalbumin were added and incubated at 4®C overnight.
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Following washing, biotinylated sheep anti-ovalbumin added, double diluted 
1:500 - 1:8000. Following a further 2hr incubation and washing, biotin
streptavidin peroxidase complex (1:1000) was added and incubated for Ihr. 
Plates were then washed with PBSGT and TMB substrate added.
V) Inclusion of rabbit anti-ovalbumin antiserum as the second antibody. 
Hard plates were coated with 10Oug/ml DEAE sheep anti-ovalbumin in PBS and 
incubated for 2hr before washing with casein buffer. 10, 5, 2.5, 1.25 and 
Ong/ml ovalbumin were added and incubated at 4°C overnight. After washing, 
unpurified rabbit anti-ovalbumin, double diluted 1:1000 - 1:16000, was
added and incubated for 2hr. Following washing, donkey anti-rabbit 
horseradish peroxidase conjugate was added and incubated for 2hr. The 
plates were washed with PBSGT and TMB substrate added.
vi) Use of biotinylated donkey anti-rabbit.
Hard plates were coated with 10Oug/ml DEAE sheep anti-ovalbumin and 
incubated 2hr. After washing, ovalbumin standards from 5ng/ml to 0.65ng/ml 
in 1:4 normal horse serum were added and incubated overnight at 4°C. 
Following washing, rabbit anti-ovalbumin was added and incubated for 2hr. 
Biotinylated donkey anti-rabbit, double diluted 1:200, - 1:1600, was added 
after washing and following a 2hr incubation and washing, biotin 
streptavidin peroxidase complex (1:1000) added and incubated for Ihr. The 
final wash was in PBSGT and substrate was then added.
vii) Optimization of assay incubation times.
DEAE sheep anti-ovalbumin was coated onto hard plates and incubated for 1, 
2 or 4hr and overnight at 4®C. The assay was then continued as detailed in 
section vi. A second set of plates were set up and ovalbumin standards 
added, incubated at 4®C for 16, 20 and 24hr. The third optimization
carried out was of rabbit anti-ovalbumin incubation time. Rabbit anti­
ovalbumin was added and incubated for 1, 2 or 4hr and overnight at 4°C.
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3.4.3 Development of ELISA to determine gliadin in serum.
All incubations are carried out at 37°C in a moist chamber unless 
otherwise stated.
Hard plates were coated with 160, 80, 40, 20 and Oug/ml DEAE purified
sheep anti-gliadin in either PBS or bicarbonate/carbonate buffer. The 
plates were incubated for 2hr and washed with casein buffer where coated 
with PBS and with PBSGT where coated with bicarbonate/carbonate buffer. 
lOng/ml gliadin, predissolved in 70% ethanol, was added to the plate in 
either casein or PBSGT, as appropriate, and the plates incubated at 4°C 
overnight. After washing in the appropriate buffer, sheep anti-gliadin 
horseradish peroxidase conjugate was added, diluted 1:200, 1:400 and 1:800 
and incubated for 2hr. All plates were then washed with PBSGT before the 
addition of TMB substrate.
i) Inclusion of normal horse serum as a human serum substitute.
The assay was repeated as above, using 8Oug/ml DEAE sheep anti-gliadin in 
bicarbonate/carbonate buffer to coat the plates. Plates were washed in 
PBSGT before addition of the gliadin standards, from 1Ong/ml to 0.04ng/ml, 
in PBSGT and 1:10 and 1:4 normal horse serum. Sheep anti-gliadin 
horseradish peroxidase conjugate, was added at a dilution of 1:200.
With the addition of normal horse serum to the assay the coating 
concentration of the sheep anti-gliadin was reoptimized. The plates were 
coated with 1200, 600, 300, 150 and Oug/ml DEAE sheep anti-gliadin and
continued as above.
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ii) Use of biotinylated sheep anti-gliadin,
150ug/ml DEAE sheep anti-gliadin in bicarbonate/carbonate buffer was 
coated onto soft plates and incubated for 2hr. After washing, gliadin 
standards, 5 - 0.65ng/ml, were added in 1:4 normal horse serum and
incubated at 4®C overnight. Following washing biotinylated sheep anti- 
gliadin, double diluted 1:500 - 1:8000, was added, incubated for 2hr and 
washed. Biotin streptavidin peroxidase complex (1:1000) was then added and 
incubated for Ihr. Following a final wash, TMB substrate was added.
Hi) Comparison of DEAE and affinity purified sheep anti-gliadin as 
coating antibodies.
Hard plates were coated with 10, 5, 2.5, 1.25, 0.6 and Oug/ml affinity
purified sheep anti-gliadin in bicarbonate/carbonate buffer and incubated 
for 2hr. After washing with PBSGT, 5ng/ml gliadin was added and the plates 
incubated at 4®C overnight, then washed. Biotinylated sheep anti-gliadin 
was added, double diluted 1:200 - 1:3200. Following a 2hr incubation and
washing, biotin streptavidin peroxidase complex (1:1000) was added and 
incubated for Ihr before washing and addition of substrate.
The assay was repeated using 1Oug/ml affinity purified and 15Oug/ml DEAE 
purified sheep anti-gliadin to the plates. Gliadin standards from 1Ong/ml 
to 0.04ng/ml in 1:4 normal horse serum were added to each plate and the 
biotinylated sheep anti-gliadin added to the plate with the DEAE coat at 
1:2000 and to the plate with the affinity purified coat at 1:16000.
iv) Optimization of incubation times.
Hard plates were coated with lOug/ml affinity purified sheep anti-gliadin 
and incubated for 1, 2, or 4hr and overnight at 4®C. After washing,
gliadin standards were added and incubated at 4®C overnight and continued 
as detailed above in section iii.
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Hard plates were coated with 1Oug/ml affinity purified sheep anti-gliadin 
and incubated for 2hr. Following washing, gliadin standards were added as 
above and incubated for 1, 2 or 4hr and overnight at 4®C. The assay was
then continued as detailed above.
3.4.4 Validation of antigen ELISA assays.
i) Determination of sensitivity.
Ovalbumin and gliadin antigen ELISAs were set up and the standards added 
in sixes for each assay. The mean optical density and standard deviation 
for each standard were calculated and the standard curves plotted from the 
mean values. The assay sensitivity or limit of detection was determined as 
2 standard deviations above the zero value.
ii) Intra- and inter-iassay variation.
Intra-assay variation was determined by the inclusion of 3 quality control 
serum samples with the standard curve. The quality controls were selected 
as giving a high, medium and low value when assayed. Ovalbumin and gliadin 
assays were set up with the standards added in duplicate and the quality 
controls added, diluted 1:4, in sixes. The intra-assay variation was 
determined by calculating the mean concentration and standard deviation of 
each quality control.
Inter-assay variation was determined by inclusion of duplicates of three 
quality controls on 6 different plates run over a period of two weeks. The 
mean concentration and standard deviation for each quality control was 
calculated from the six plates and coefficient of variation obtained.
iii) Recovery of antigen.
20, 10, 8, 4, 2 and Ong/ml ovalbumin and gliadin were added to a human
serum pool. The spiked samples were diluted 1:4 with the appropriate 
buffer and included in the ELISAs for each antigen.
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iv) Parallelism,
Samples containing high concentrations of each antigen were double diluted 
four times to ensure serum samples ran parallel to the standard curve.
V) Crossreactivity.
Ovalbumin assays were set up and in place of ovalbumin in the standard 
curve were added BSA, gliadin, B-lactoglobulin, ovomucoid and conalbumin 
from lOOOng/ml to 4ng/ml. HSA was added from lOOOug/ml to 4ug/ml. Gliadin 
assays were set up and BSA, HSA, ovalbumin and B-lactoglobulin added to 
the standard curves at concentrations of lOOOng/ml to 4ng/ml.
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3.5 Results.
3.5.1 Development of ELISA to determine ovalbumin in serum.
i) Optimization of antibody coating concentration and enzyme label 
dilution.
A checkerboard was setup to determine the optimum antibody coating and 
enzyme label concentrations. The combination of 20ug/ml DEAE sheep anti­
ovalbumin and a 1:500 dilution of the enzyme label gave an acceptable 
optical density at lOng/ml ovalbumin with lower non-specific binding than 
was seen with the other coating concentrations. The horseradish 
peroxidase sheep anti-ovalbumin conjugate did not bind to the plate, 
indicated by the very low optical density values obtained when no coating 
antibody was present.
ii) Optimization of ovalbumin standard curves with the inclusion of normal 
horse serum as a human serum substitute.
The inclusion of normal horse serum into the standard curve brought about 
a progressive flattening of the curve with increasing serum content 
(Figure 3.1). The standard curves containing decreasing concentrations of 
normal horse serum were run in parallel and all stopped once the curve 
containing buffer had reached its maximum optical density. Greater 
sensitivities could therefore be obtained with all the curves containing 
normal horse serum, with the exception of neat serum, if the reaction were 
allowed to proceed'. for a longer period of time. The use of neat normal 
horse serum is not possible as no curve was produced. 1:4 normal horse 
serum was chosen as the human serum substitute as it allows minimal 
dilution of the samples whilst producing a curve with reasonable 
sensitivity.
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Figure 3.1 Use of normal horse serum in the standard curve of the ELISA to 
determine ovalbumin.
Concentration
(ng/ml)
2.5-1
2.0 -
Q.
0.5-
0.0
1 088420
Buffer 
1:100 NHS 
1:50 NHS 
1:25 NHS 
1:4 NHS 
Neat NHS
Figure 3.2 Optimization of DEAE ion exchanged sheep anti-ovalbumin 
coating incubation time.
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The reoptimization of the antibody coating and enzyme label concentrations 
with the inclusion of 1:4 normal horse serum gave a DEAE sheep anti­
ovalbumin concentration of lOOug/ml and the enzyme label dilution was 
reduced to 1:200. Very little difference was seen between the optical 
density values obtained from the four concentrations of coating antibody, 
therefore the lowest concentration was chosen
iii) Comparison of two peroxidase substrates.
TMB gave greater sensitivity than OPD with the assay limit of detection 
approximately 0.1ng/ml with OPD and 0.06ng/ml with TMB.
iv) Use of biotinylated sheep anti-ovalbumin.
A checkerboard was carried out of the biotinylated sheep anti-ovalbumin 
against ovalbumin concentration. A dilution of 1:500 biotinylated sheep 
anti-ovalbumin produced the best curve with acceptable optical density 
values and degree of non-specific binding. The sensitivity of O.lng/ml 
however was not increased over that obtained with the horseradish 
peroxidase label (0.07ng/ml).
V) Inclusion of rabbit anti-ovalbumin as the second antibody.
Unpurified rabbit anti-ovalbumin was added at 1:1000, 1:2000, 1:4000,
1:8000 and 1:16000. Optical density declined with decreasing concentration 
of rabbit antibody. The 1:1000 dilution of antiserum gave the most 
acceptable results and was therefore used in all subsequent assays. Two 
rabbit antisera available were compared, with both diluted 1:500. N1 
rabbit anti-ovalbumin gave a higher degree of binding, therefore a higher 
optical density, and was therefore used in all subsequent assays.
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vi) Use of biotinylated donkey anti-rabbit.
A checkerboard was setup to compare the use of biotinylated donkey anti­
rabbit at different concentrations. A 1:12000 dilution was chosen as the 
optimum concentration, as the use of a lower dilution of label would have 
meant the label was present far in excess of requirements. Despite the 
amplification the biotinylated donkey anti-rabbit brought about with the 
top standards of the curve, the degree of amplification at the lower end
of the standard curve was much less. Overall, although the use of a
biotinylated donkey anti-rabbit made the upper sections (10 - 0.65ng/ml)
of the standard curve much steeper, no significant increase in sensitivity 
was obtained.
vii) Optimization of assay incubation times.
The incubation times of the coating antibody were varied and the standard 
curves produced by the different incubation times plotted (Figure 3.2). 
The non-specific binding with the overnight and 2hr incubations was very 
high, making these timings unacceptable. 4hr incubation time was chosen, 
although the non-specific binding was slightly higher than the Ihr
incubation time, the curve produced was not as steep and did not flatten 
as early.
twt
Very little difference was seen b^n the curves produced after incubating 
the standards for either 16 or 20hr. The 24hr incubation, however, 
produced no curve at all. An incubation time not longer than 20hr was
therefore used in all subsequent assays.
The Ihr incubation time of unpurified rabbit anti-ovalbumin was seen to 
give an acceptable curve with reasonably low non-specific binding (Figure 
3.3). 2hr, 4hr and overnight incubation produced unacceptably high levels 
of non-specific binding, thus no curve.
98
Figure 3.3 Optimization of rabbit anti-ovalbumin incubation time for 
determination of ovalbumin.
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With the optimizations complete, the assay to determine ovalbumin in serum 
was carried out as detailed below: Hard plates were coated with lOOug/ml
DEAE purified sheep anti-ovalbumin in PBS and incubated for 4hr. After 
washing with casein buffer, the standards from 10 - 0.04ng/ml were added 
in 1:4 normal horse serum: casein buffer and incubated at 4®C overnight.
Rabbit anti-ovalbumin (1:1000) was added after further washing and 
incubated for Ihr. After washing, horseradish peroxidase donkey anti­
rabbit conjugate was added and incubated for 2hr. Following a final wash 
with PBSGT, TMB substrate was added and incubated for 30mins before 
stopping.
3.5.2 Development of ELISA to determine gliadin in serum.
Two checkerboards were set up between antibody coating concentrations and 
enzyme label dilution. The optical density values obtained from both
plates at 10 and Ong/ml gliadin are shown in Table 3.1. It can be seen
that PBS and casein buffer are not suitable for this assay, giving low 
specific and high non-specific binding. Therefore bicarbonate/carbonate 
buffer and PBSGT were used in all subsequent assays.
Little difference in binding is seen between the differing concentrations 
of coating antibody. The non-specific binding with 2Oug/ml DEAE sheep 
anti-gliadin was, however, higher than obtained with the other 
concentrations. A combination of 4Oug/ml DEAE sheep anti-gliadin and 1:200
enzyme label was taken as giving the greatest difference between specific
and non-specific binding.
i) Inclusion of normal horse serum as a human serum substitute.
As with the ovalbumin ELISA, the inclusion of normal horse serum reduced 
the binding of the assay. The use of a 1:4 dilution of normal horse serum 
produced an acceptable curve. The concentration of the coating DEAE sheep 
anti-gliadin was reoptimized to 150ug/ml.
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Table 3.1 Determination of optimum coating and label concentrations and 
buffers to be used in an ELISA for gliadin.
Buffers used
Bicarb / PBSGT PBS / casein
Coating Label. dilution Label dilution Antigen
(ug/ml) (ng/mj
1:200 1:400 1:800 1:200 1:400 1:800
160 1.614 1.119 0.672 0.343 0.258 0.128 10
0.174 0.161 0.159 0.286 0.123 0.100 0
80 1.770 1.109 0.681 0.330 0.268 0.206 10
0.164 0.159 0.116 0.116 0.114 0.099 0
40 1.703 1.066 0.656 0.192 0.472 0.169 10
0.130 0.140 0.117 0.336 0.350 0.200 0
20 1.613 0.993 0.618 0.234 0.547 0.285 10
0.292 0.228 0.121 0.859 0.411 0.177 0
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Figure 3.4 Comparison of DEAE ion exchanged vs affinity purified sheep 
anti-gliadin as the coating antibody in the determination of gliadin.
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Figure 3.5 Optimization of sheep anti-gliadin coating incubation time.
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ii) The use of biotinylated sheep anti-gliadin,
A checkerboard was set up of gliadin concentration against biotinylated 
sheep anti-gliadin dilution. The non-specific binding for each dilution of 
the biotin label used was high, increasing with decreasing dilution. 
1:1000 dilution of label was used in all subsequent assays and although 
this did not give ideal results, it was a compromise between lower non­
specific binding and economic use of the label.
Hi) Comparison of DEAE ion exchanged and affinity purified sheep anti- 
gliadin,
A checkerboard was first set up of affinity purified sheep anti-gliadin 
concentration against label dilution. The combination of lOug/ml sheep 
anti-gliadin and 1:16000 dilution of biotinylated sheep anti-gliadin gave 
high specific binding and low non-specific binding. Figure 3.4 shows 
standard curves produced with DEAE and affinity purified sheep anti- 
gliadin as the coating antibody. The use of affinity purified coating 
antibody was able to significantly improve the sensitivity of the assay.
iv) Optimization of assay incubation times.
The incubation time of the coating antibody was varied between 1, 2 and
4hr and overnight at 4°C. The overnight incubation gave no curve with the 
optical density the same along the length of the curve. Of the other three 
times the 2hr incubation produced the most acceptable curve (Figure 3.5). 
Short incubation times of the standards ( 1, 2hr) gave very high levels of 
non-specific binding. Although some reduction in non-specific binding was 
seen with 4hr incubation of standards, the overnight incubation was the 
most successful.
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When all the optimization stages were complete, the assay to determine 
gliadin in serum was carried out as detailed below: Hard plates were
coated with lOug/ml affinity purified sheep anti-gliadin in 
bicarbonate/carbonate buffer and incubated for 2hr. After washing with 
PBSGT, gliadin standards for 10 - 0.04ng/ml in 1:4 normal horse serum: 
PBSGT were added and incubated at 4®C overnight before washing.
Biotinylated sheep anti-gliadin (1:12000) was then added and incubated for
2hr. Following washing, biotin streptavidin peroxidase complex was added
and incubated for Ihr. The final wash was then carried out and TMB
substrate added, incubated and stopped after 30mins.
3.5.6 Validation of antigen ELISA assays.
i) Sensitivity.
When fully optimized, the limit of detection (2 standard deviations above 
zero) of the assay to measure ovalbumin in serum was 0.04ng/ml and of the 
assay to determine gliadin 0.14ng/ml.
ii) Intra- and inter-assay variation.
Concentrations of the three quality controls used in each assay and the 
intra- and inter-assay variations are shown in Table 3.2. The intra-assay 
variation for both assays was acceptable with the aim to achieve a 
coefficient of variation below 10% intra-assay and 15% inter-assay. 
Although the variation of the low quality control in the gliadin assay was 
high than is normally acceptable, the concentration was very near the 
limit of detection of the assay accounting for the greater variability.
Hi) Recoveries.
Ovalbumin and gliadin concentrations in samples spiked with known amounts 
of the appropriate protein were measured and the recovery calculated 
(Table 3.3). All recoveries were within + 20%, with mean percentage 
recovery for the ovalbumin assay 110%, and for the gliadin assay of 103%.
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iv) Parallelism,
Samples containing high concentrations of ovalbumin or gliadin were 
double diluted and the curve plotted against the standard curves (Figure 
3.6). The samples when diluted down followed the standard curve, therefore 
the inclusion of normal horse serum in the assays had minimized any matrix 
effects.
V) Crossreactivity.
A range of standard curves were set up of proteins that may crossreact 
with the antiserum used in the two assays. Conalbumin crossreacted 0.2% 
with ovalbumin and ovomucoid showed a very high degree of crossreactivity 
(58%) in the ovalbumin assay (Figure 3.7). The assay showed no 
crossreactivity with BSA, HSA , gliadin or B-lactoglobulin.
Ovalbumin, HSA, BSA and B-lactoglobulin did not crossreact at all (Figure 
3.9). No other wheat proteins were available to include in the 
crossreactivity studies.
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Table 3.2 Intra- and inter-assay variation of ovalbumin and gliadin ELISA.
Q.C.
Cone
(ng/ml)
Gliadin
C.V% 
Intra Inter
Ovalbumin 
Cone C.V% 
(ng/ml) Intra Inter
High 3.04 4 13 2.95 5 12
Medium 0.68 8 18 1.73 4 12
Low 0.21 19 24 0.61 5 25
C.V% = coefficient of variation
Q.C = quality control
Table 3.3 Recovery of antigen in ELISAs for ovalbumin and gliadin.
Ovalbumin Gliadin
Antigen added 
(ng/ml)
Measured
(ng/ml)
Recovery
(%)
Measured
(ng/ml)
Recovery
(%)
20 17.08 86 22.80 114
10 12.04 120 9.20 92
8 8.80 110 8.44 106
4 4.80 120 4.24 106
2 2.24 112 1.88 94
0 0.0 0.0
106
Figure 3.6 Determination of parallelism between standards and samples in 
ELISAs to determine ovalbumin and gliadin.
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Figure 3.7 Crossreactivity of the ELISA to determine ovalbumin.
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Figure 3.9 Crossreactivity of the ELISA to determine gliadin,
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3.6 Discussion.
This study aimed to develop an assay to determine ovalbumin and gliadin 
levels in biological fluids. Radioimmunoassay was the initial system of 
choice as generally they are more sensitive than ELISA and show less 
inter- and intra-assay variation. However, the development of 
radioimmunoassays to both ovalbumin or gliadin was unsuccessful although 
the details have not been presented here. Radioimmunoassays were not able 
to be developed because the antiserum available showed no displacement of 
labelled antigen by the unlabelled antigen.
The use of ELISA to determine ovalbumin and gliadin proved successful with 
sensitive, specific and reproducible assays developed. The aim was for the 
assays to measure these antigens in the 0.5 -lOng/ml range. Initially both 
assays had a limit of detection of 0.5ng/ml and as the samples were to be 
diluted 1:4 to ensure similar serum component concentrations as were 
present in the standard curve, the assays were only able measure 
concentrations of antigen above 2ng/ml. A number of different approaches 
were tried to increase the sensitivity of the assay including the use of 
biotinylated antibodies, blocking agents and chemiluminesence. Although 
some of these methods brought about improvements in the upper sections of 
the standard curve (10-0.65ng/ml), they were unable to produce significant 
increases in the sensitivity of the assays.
The methods which brought about the required increase in sensitivity were 
not the same for both assays, although the use of hard rather than soft 
microtitre plates and TMB rather than OPD as the substrate were important 
factors common to both assays. The inclusion of an additional stage in the 
assay to determine ovalbumin by the addition of rabbit anti-ovalbumin was 
able to bring about the required improvement in sensitivity, which the 
direct enzyme labelling of the rabbit antibody was unable to achieve.
109
The use of biotinylated antibodies in the gliadin assay caused a number of 
problems due the short shelf life of the label and the very high non­
specific binding seen with a high proportion of the biotinylated 
antibodies produced. Purification of the label made little difference to 
the non-specific binding, and it was found that fresh N-hydroxysuccinamide 
biotin was required to produce an acceptable biotinylated antibody label.
The final sensitivity of 0.04ng/ml for the determination of ovalbumin was 
better than achieved in published methods using a five stage ELISA 
(0.5ng/ml: Edevag et al 1986) very similar to that used in this study, and 
those using a biotinylated system (0.3ng/ml: Husby et al 1985a). The
sensitivity of the ELISA to determine gliadin was much greater than that 
obtained in the few assays published to determine this antigen, with a 
sensitivity of 0.17ng/ml compared to 5ng/ml (Troncone et al 1987).
The inter- and intra-assay variation obtained for the two assays was
within acceptable limits, although the inter-assay variation of the low
er
quality control samples were high than those obtained for the medium and
high samples. The low quality control samples in both assays contained
antigen at concentrations near to the limit of detection of the assays, so
accounting for the greater variability. Despite the variation shown by 
lit
these two assays^  was comparable with other published assays, with the 
inter-assay variation of these given at between 9-24% and intra-assay at 
between 14-16% (Husby et al 1985a).
The inclusion of normal horse serum in the standard curves proved to be an 
acceptable alternative to human serum, as seen by the parallelism studies. 
The human serum samples, when diluted, ran parallel to the standard curve, 
indicating that horse and human serum have similar effects in the assay.
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The major crossreactant with ovalbumin was ovomucoid (58%). This protein 
is found alongside ovalbumin in the white of eggs. Ovalbumin constitute 
between 65 - 70% of the protein in egg white with an array of other
protein including ovomucoid, conalbumin, and lysozyme making up the 
remaining 30 - 35%. The likelihood is low that ovomucoid is present in 
the blood at sufficiently high concentrations to influence the levels of 
ovalbumin detected. Additional, although the purest form possible of 
conalbumin and ovomucoid were obtained, neither were 100% pure and 
ovalbumin is likely to form a very large proportion of the contaminants.
No cereal protein fractions were able to be obtained to check for 
crossreactivity with gliadin. However gliadin represents 40 - 45% of the 
protein in wheat, and wheat is the major cereal consumed in the UK. If 
there are any major crossreactants to gliadin, as with ovalbumin, it is 
unlikely that they would be present in sufficient quantities to influence 
the concentrations of gliadin measured.
I l l
Chapter 4
Specific food antibodies in normal and atopic adults.
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4.1 Introduction.
4.1.1 Circulating food antibodies.
The major circulatory antibody is IgG, comprising 80% of the total 
immunoglobulins found in serum. Of the remaining immunoglobulins, IgA 
contributes 13% and IgM 6%, with IgD and IgE being present in very small 
amounts (Roitt 1984). For this reason, IgG antibodies in serum are those 
most commonly studied.
Circulating antibodies to dietary antigens have been demonstrated in a 
considerable proportion of the normal population, indicating that
immunization to proteins ingested as food is a frequent and natural 
occurrence. Rothberg and Farr (1965) detected antibodies to BSA in 75% of
children studied, in 25% of young adults and in only 8% of adults over 40
years of age. Antibodies to alpha-lactalbumin showed the same distribution 
but were found at only half the frequency. May et al (1977) also found a 
decrease in mean serum concentrations of milk protein antibodies with age.
The majority of normal infants develop antibodies to milk after weaning,
with titres increasing from 1 month of age. A peak was reached at 3
1
months, and the titres then gradually decline (Kett-r^ er et al 1971). This 
decline in milk specific antibodies was not seen in food allergic 
children, in whom antibody titres remained elevated (May et al 1977). The 
decline in antibody concentrations during childhood may be due to a 
decreasing gut permeability for immunologically intact proteins, in 
changes in the antigenic form of the absorbed proteins due to increased 
acidity of the gastric fluids and increased enzymatic activity or changes 
in antigen-specific suppression of the immune response (Husby 1988).
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IgG antibodies to individual proteins such as B-lactoglobulin, alpha- 
casein and ovalbumin have been measured in a large percentage of healthy 
adults (Husby et al 1985c). 90% had detectable IgG antibodies to
ovalbumin, and only 24% had detectable anti-alpha-lactalbumin antibodies. 
Barnes et al (1983) showed antibodies to gliadin and milk in only 10% of 
blood donors studied. The antibodies were predominantly IgG but also 
included some IgA and occasionally IgM. In further studies, this group 
showed that in adults that IgG antibodies to milk proteins were reactive 
predominantly with casein, rather than alpha-lactalbumin, B- 
lactoglobulin or albumin. The IgG antibodies raised against ovalbumin, 
gliadin and milk proteins were highly specific for each of the respective 
dietary protein antigens (Barnes et al 1988b).
The IgG subclass antibodies to food protein antigens have been determined, 
and show that IgG4 antibodies to milk, egg and cod are common in the
general population (Merrett et al 1983). IgG4 antibodies to ovalbumin, B-
lactoglobulin and gliadin were measurable in the majority of 40 healthy
subjects (Layton & Stanworth 1984). Husby et al (1985a) showed IgG
antibodies to ovalbumin to be in the IgGl, 2 and 4 subclasses whereas 
those to B-lactoglobulin were mainly in the IgG4 subclass. IgG4 appears to 
be the major antibody produced to food antigens, which is particularly 
striking considering the low total serum concentrations of IgG4.
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4.1.2. Secretory antibodies.
IgA is the major secretory antibody, with a structure that affords 
relative resistance to acid and pepsin digestion, thus enabling it to 
function better in the external secretions in which it is found 
(Brandtzaeg et al 1970). IgA is found in secretions produced at mucosal 
surfaces such as in the lung, urogenital tract and in the gastrointestinal 
tract. The most easily obtained of these IgA containing fluids is saliva.
Secretory IgA is the major antibody in saliva, at a concentration of 
140mg/l (Gronblad-Saksela 1986), and IgG and IgM are present in much 
smaller amounts (16 and 4.1mg/l respectively). IgA shows an inverse 
relationship to salivary flow rate, suggesting it is handled differently 
to other intrinsic salivary components such as amylase (Mandel & Khurana 
1969). 98% of salivary IgA is produced locally (Gronblad-Saksela 1986),
and this local production is unable to keep up with rapid increases in 
salivary volume. A number of studies have investigated specific IgA 
antibodies in serum and saliva (Claman et al 1967, Cernelc & Zalokar 1982, 
Allansmith et al 1983). No relationship has been found between IgA levels 
in serum and saliva, suggesting that IgA production in these two pools is 
under separate regulatory systems.
The IgA antibodies in saliva reflect the antigens to which the gut is 
exposed (Gleeson et al 1982). Low levels of anti-gliadin IgA have been 
recorded in the saliva of 54% of normal subjects (Al-Bayaty et al 1989). 
Anti-gliadin IgA was only detectable in the serum of 11% of these 
subjects. The presence of low levels of anti-gliadin IgA in normal adults 
has also been reported by Russel et al (1984, 1986).
As can been seen from the evidence above, food specific antibodies are 
commonly found in both serum and saliva, but the mechanisms and factors 
controlling their production are not clearly understood.
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4.2 Aims of study.
This study aims to first investigate the levels of circulatory and 
secretory antibodies to ovalbumin, gliadin and B-lactoglobulin in healthy 
adults. The importance of habitual dietary intake of these proteins in 
determining specific antibody levels in serum and saliva will be studied. 
The relationship between specific serum IgG antibodies and specific 
salivary IgA antibodies is also to be investigated, with the view to using 
saliva as a non-invasive method of determining food antibody titres.
Secondly, this study aims to investigate total specific IgG and IgG 
subclass antibodies to the three food proteins in a group of atopic 
subjects, age and sex matched to non-atopic controls.
4.3 Materials 
Serotec (Oxford, UK).
Polyclonal sheep anti-human IgGl (AHP-001), polyclonal sheep anti-human 
IgG2 (AHP-012), polyclonal sheep anti-human IgG3 (AHP-013), polyclonal 
sheep anti-human IgG4 (AHP-014).
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4.4 Methods.
4.4.1 Circulating and secretory food antibodies in healthy adults.
a) Subjects and sample collection.
Twenty adults (16 female, 4 male) aged between 20 and 64 years (37 + 12
years) were recruited into the study. A 7-day weighed food record was 
undertaken by each subject. Subjects were provided with digital scales, 
accurate to 2g (Soehnel, CMS Ltd, London), a diary and full instructions, 
both written and oral, as to how to carry out the weighed food record.
On the first day of measurement of food intake, a fasted blood sample was 
collected. The blood was allowed to clot at room temperature before 
centrifugation for lOmins at 3000rpm, aliquoted and frozen at -20*C until 
required for analysis. An unstimulated saliva sample was collected from 
each subject at the same time, and was centrifuged for ISmins at 3000rpm 
to remove any particulate matter before aliquoting and freezing at -20®C 
until required. The subjects completed a questionnaire regarding their 
history of food intolerance and family history of hypersensitivity.
b) Analysis of samples.
The 7-day food intake records were analysed with the aid of the COMPEAT 
nutritional analysis program (Lifeline Nutritional Services Ltd, London) 
based on the food composition tables (Paul and Southgate 1978). From the 
program, a breakdown of sources of protein was obtained for each subject 
and the amount of egg, wheat and milk protein consumed each day estimated.
Total serum IgG was measured by a nepholometric technique at the 
Department of Clinical Biochemistry, St.Luke's Hospital, Guildford, 
Surrey. Specific IgG antibodies to ovalbumin, gliadin and B-lactoglobulin, 
and specific IgA antibodies to ovalbumin and gliadin were determined by 
ELISA (see chapter 2).
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c) Statistical analysis
The data obtained from the antibody determinations underwent logarithmic 
transformation before analysis using paired Student's t-tests and 
Spearman's correlations. Statistical analysis was carried out using 
Statworks on an Apple Macintosh.
4.4.2 Specific IgG antibodies in atopic and non-atopic adults.
a) Subjects and collection of samples.
18 atopic subjects (15 female, 3 male), aged between 21 and 56 years ( 29 
+ 4 years) were recruited into the study. Age and sex matched non-atopic 
controls were included. Every subject completed a questionnaire on atopic 
disease, suspected cause and treatments received. The atopic subjects were
a
asked whether their condition had been dignosed by a member of the medical 
profession. If this were not the case, the subject was excluded from the 
study.
A fasted blood sample was collected from each atopic subject and control 
in October and November 1988. The samples were allowed to clot at room 
temperature, centrifuged as before, aliquoted and frozen at -20®C until 
required. From 10 subjects (5 atopic, 5 non-atopic), additional serum 
samples were obtained at approximately 6 week intervals for a period of 
12 months. All samples were stored until the study was complete and 
analysed together.
b) Analysis of samples.
Specific IgG to ovalbumin, gliadin and B-lactoglobulin were determined by 
ELISA (see chapter 2). IgG subclass antibodies to each of the food 
proteins were determined by modification to the specific antibody ELISAs.
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Anti-ovalbumin IgG subclass ELISA: Soft plates were coated with 50ug/ml
ovalbumin in 0.15M PBS (pH 7.6) and incubated at 37®C for Ihr. After
washing with 0.5% casein buffer (pH 7.4), samples diluted 1:100 and a
normal horse serum standard diluted 1:100 were added across the whole
plate, that is added to 8 wells. Three quality control samples were also 
included on each plate. After incubating at 4°C overnight and following 
washing, each polyclonal sheep anti-subclass antibody (lOug/ml) was added 
to each sample in duplicate. All four subclasses per samples were 
determined on the same plate. The plates were incubated at 37°C for 2hrs, 
and donkey anti-sheep horseradish peroxidase conjugate (1:5000) added 
following a final wash with casein buffer. The plates were incubated at 
37®C for a further 2hrs before washing with 0.15M PBS plus 0.1% gelatine 
and 0.05% Tween 20 (PBSGT) and the addition of TMB substrate.
Anti-gliadin IgG subclass ELISA: Soft plates were coated with 50ug/ml
gliadin in 70% ethanol and left in the open overnight. The plates were 
then fixed for lOmins with 10% methanal and washed with casein buffer. The 
samples, standards and quality controls, all diluted 1:100, were added in 
the same manner as above and incubated at 37*C for 4hr. Polyclonal sheep 
anti-subclass antibodies were added and the assay continued in an 
identical manner to that detailed above.
Anti-B-lactoglobulin IgG subclass ELISA: Soft plates were coated with
50ug/ml B-lactoglobulin in O.IM bicarbonate/carbonate buffer (pH9.6) and 
incubated at 4°C overnight. After washing with PBSGT, the samples, quality 
controls and standards, all diluted 1:50, were added to the plate and 
incubated at 37®C for 2hr. Following washing with PBSGT, the polyclonal 
sheep anti-human subclass antibodies (lOug/ml) were added and incubated at 
37°C for 2hr. Donkey anti-sheep horseradish preoxidase was then added and 
the plates incubated at 37°C for 2hr prior to the addition of substrate.
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c) Calculation of results.
Specific IgG subclass content of all samples was initially calculated for 
each subclass as a percentage above the zero value given by the normal
horse serum for that subclass. The results for all 4 subclasses in each
sample were then summed, and the percentage contribution of each subclass 
to the total calculated.
The specific antibody levels for the serial samples collected from 10 
subjects were obtained and allocated into one of four seasons dependent on 
the time the sample was taken : Autumn (September, October, November),
Winter (December, January, February), Spring (March, April, May) and 
Summer (June, July, August). The mean value for each atopic and non-
atopic subject was obtained for each season. Statistical analysis was then
carried out on these mean seasonal values.
d) Statistical analysis.
Statistical analysis was carried out following logarithmic transformation 
of the data, using paired Student's t-test and Spearman's correlation.
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4.5 Results.
4.5.1 Circulatory and secretory food antibodies in healthy adults.
The mean daily contribution made to protein intake by wheat, egg and milk 
for the twenty subjects are summarized in Table 4.1. The intake of egg 
protein was significantly lower than the consumption of both milk 
(p<0.001) and wheat (p<0.001). The contribution wheat made to the mean 
protein intake was also significantly lower than that made by milk 
(p<0.05). In real terms, the consumption of wheat per day was equivalent 
to 5 slices of bread and showed less variability between individuals than 
the intake of egg and milk protein. The consumption per day of egg was 
equivalent to 1/2 egg and for milk equivalent to 1 pint milk.
The specific antibody concentrations to the three food proteins in serum 
and saliva are shown in Table 4.2. Eighteen subjects had detectable levels 
of anti-ovalbumin IgG and anti-B-lactoglobulin IgG in serum. Anti­
ovalbumin IgA was not detectable in 4 subjects, only one of whom also had 
no detectable serum anti-ovalbumin IgG. All twenty subjects had detectable 
levels of anti-gliadin IgG in serum and 19 had detectable levels of anti- 
gliadin IgA in saliva.
The concentrations of anti-ovalbumin IgG found in serum (mean + SEM: 637 + 
157ug/ml) were significantly higher than both anti-gliadin IgG 
concentrations (262 + 89ug/ml, p<0.05) and anti-B-lactoglobulin IgG (130 + 
29ug/ml, p<0.01). Although the concentrations of anti-gliadin IgG in serum 
were higher than those against B-lactoglobulin, this difference was not 
significant.
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Table 4.1 Mean daily dietary intakes of specific food proteins in healthy 
adults.
Mean
SEM
Range
Protein intake 
(g/d)
Wheat protein Egg protein
15*
1
8-20
3*+
1
1-18
Milk protein 
20+
2
8-42
"p<0.001
Table 4.2 Mean antibody concentrations to ovalbumin, gliadin and 13- 
lactoglobulin in healthy adults, in serum and saliva.
Food protein
Serum
(ug/ml)
Saliva 
(% stand)
Ovalbumin Mean 637* ** 56
SEM 157 27
Range ÜD-2200 UD-364
Gliadin Mean 262* 29
SEM 89 9
Range 4-1170 1-146
B-lactoglobulin- Mean 130**
SEM 29 N/D
Range ÜD-144
N/D = not determined. 
UD = undectable.
* p<0.05, ** p<0.01
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No correlation was found between specific serum and salivary antibodies, 
however it was found that in these subjects, serum anti-ovalbumin IgG and 
anti-gliadin IgG concentrations were significantly correlated (r=0.6, 
p<0.005). The concentrations of neither of these specific antibodies were 
found to correlate with anti-B-lactoglobulin IgG concentrations. Anti­
ovalbumin IgG concentrations were significantly correlated with daily 
dietary intake of egg protein (r=0.46, p<0.05) (Figure 4.1).
4.5.2 Specific IgG antibodies in atopic and non-atopic adults.
In the atopic group, 7 subjects reported suffering from eczema alone, 1 
asthma alone, 7 hayfever and 3 reported suffering from both asthma and 
eczema. A summary of the reported causes of the atopic conditions is given 
in Table 4.3. Most commonly however the subjects reported the cause to be 
unidentified.
The specific IgG concentrations to ovalbumin, gliadin and B-lactoglobulin 
in the atopic and non-atopic groups are summarized in Table 4.4. In the
atopic group, anti-ovalbumin IgG levels were significantly higher (369 +
68ug/ml) than concentrations of anti-gliadin IgG (88 + 23ug/ml, p<0.001) 
and anti-B-lactoglobulin IgG (41 + 9ug/ml, p<0.001). Additionally, levels 
of anti-gliadin IgG were significantly higher in the atopic group than 
anti-B-lactoglobulin IgG (p<0.05). In the non-atopic control group, anti­
ovalbumin IgG concentrations were significantly higher (169 + 32ug/ml)
than levels of anti-B-lactoglobulin IgG (61 + 17ug/ml, p<0.02). No other 
differences were seen within the non-atopic group.
Comparing the concentrations of specific antibodies between the atopic 
group and non-atopic group, anti-ovalbumin IgG concentrations were 
significantly higher in the atopic group compared to the non-atopic group 
(p<0.02). The concentrations of the other two specific antibodies studied 
showed no differences between the two groups.
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Figure 4.1 Correlation between mean daily egg protein intake and anti­
ovalbumin IgG levels in healthy adults.
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Table 4.3 Reported causes of atopic conditions in the atopic subjects.
Reported cause of atopy Number of subjects
Animals 3
Pollen 10
Dust 5
Food+ 3
Metals 3
+ see text for details.
Table 4.4 Specific IgG antibody levels in atopic and non-atopic adults.
Antibody concentration 
(ug/ml)
Atopic Non-atopic
Food protein Mean SEM Range Mean SEM Range
Ovalbumin 369*-* 93 16-1010 169*~ 31 8-411
Gliadin 88*+ 22 12-401 133 27 13-341
B-lactoglobulin 41-+ 9 UD-130 61~ 17 UD-258
UD = undetectable
p<0.02, + p<0.05, ~ p<0.001
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The percentage contribution to the total of each IgG subclasses in atopic 
and non-atopic subjects against ovalbumin are illustrated in Figure 4.2, 
against gliadin in Figure 4.3 and against B-lactoglobulin in Figure 4.4. 
The greatest proportion of anti-ovalbumin IgG antibodies in both the
atopic and non-atopic groups were found in subclass 4 (atopic : 68 + 6%,
non-atopic; 81 + 4%), with the other three subclasses making a minor
contribution to total anti-ovalbumin IgG. Anti-ovalbumin IgGS antibodies 
in the atopic group made up a significantly higher proportion of the 
specific IgG present (24 + 4%) than was seen in the non-atopic group (9 +
1%, p<0.005). The proportion of specific IgG4 was higher in the non-atopic 
(82 + 4%) than in the atopic group (68 + 6%) although this difference was 
not significant.
Anti-gliadin subclass antibodies were found predominantly in IgG 
subclasses 3 and 4, with little specific antibody seen as IgGl. The
proportion of anti-gliadin IgG3 was significantly higher in the atopic
group (40 + 4%) than in the non-atopic group (20 + 4%, p<0.001).
Although not significant, the proportion of anti-gliadin IgG2 was higher 
(22+4%) in the non-atopic group than in the atopic group (15 + 3%).
Anti-B-lactoglobulin IgG subclass antibodies showed a progressive 
increase in importance from 1 to 4, with the greatest proportion of 
specific anti-B-lactoglobulin IgG antibodies present in IgG4 subclass. No 
differences were seen in the specific IgG antibody distribution between 
the atopic subjects and the non-atopic subjects.
The mean seasonal concentrations of IgG antibodies to ovalbumin, gliadin 
and B-lactoglobulin in 5 atopic and 5 non-atopic individuals are 
illustrated in Figure 4.5. No differences were found in specific antibody 
concentrations between seasons in either the atopic group or the non- 
atopic group.
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Figure 4.2 Distribution of anti-ovalbumin IgG subclass antibodies in 
atopic and non-atopic adults.
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Figure 4.3 Distribution of anti-gliadin IgG subclass antibodies in atopic 
and non-atopic adults.
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Figure 4.4 Distribution of anti-3-lactoglobulin IgG subclass antibodies 
in atopic and non-atopic adults.
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Figure 4.5 Seasonal variation in specific IgG antibody levels in atopic 
and non-atopic adults.
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4.6 Discussion
4.6.1 Circulating and secretory food antibodies in healthy adults. 
Anti-ovalbumin IgG was detectable in 90% of the subjects. This is in 
agreement with the findings of Husby et al (1985c). Barnes et al (1983) 
reported anti-ovalbumin IgG to be detectable in only 10% of subjects 
studied. Anti-gliadin IgG and B-lactoglobulin IgG were also detectable in 
the majority of subjects, in contrast to findings of other studies. Anti- 
B-lactoglobulin antibodies have been reported in between 5% (BÜrgen-Wolff 
et al 1980) and 50% (Husby et al 1985c) of normal subjects. Anti-gliadin 
antibodies, although prevalent in subjects with coeliac disease, have been 
found in a minority of normal subjects (Volta et al 1986). The difference 
in findings is probably reflecting the greater sensitivity obtained with 
the indirect ELISA used in this study.
Wide ranges of specific antibodies against ovalbumin, gliadin and B- 
lactoglobulin were seen in the group studied, with the level of anti­
ovalbumin IgG significantly higher than anti-gliadin and B-lactoglobulin 
concentrations. The variation in specific antibody titres between 
individuals was great, however Gallagher et al (1983) reported 10-100 fold 
variation in concentrations of food specific antibodies occurring between 
subjects. Levels of anti-ovalbumin IgG encountered in some of the subjects 
were very high (2.2mg/ml). This level of specific antibodies was 
considerably higher than circulating levels of specific antibodies 
produced by the immunization of animals (Beyzavi, personal communication). 
Ovalbumin is frequently used as a carrier coupled to small molecular 
weight compounds in order to produce an immune response (Shibier et al
1988). Levels of anti-ovalbumin antibodies in an animal immunized with 
these complexes are ten to fifty times higher than levels of antibodies to 
small compounds, indicating the highly antigenic nature of ovalbumin.
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In addition to the highly antigenic nature of ovalbumin, the significantly 
higher antibody levels seen to this protein may also reflect a greater 
absorption of antigenically viable ovalbumin compared to gliadin and B- 
lactoglobulin. The uptake of ovalbumin following a test meal has been 
found to be greater than uptake of gliadin when equivalent amounts of the 
two proteins were given (Chapter 5). Ovalbumin is more resistant to 
proteolytic degradation in the gut (Kilshaw & Cant 1984, Husby et al 
1985b). B-lactoglobulin, although more resistant to proteolytic 
degradation than casein and alpha-lactalbumin (Marcon-Genty et al 1989), 
is largely degraded when incubated with proteolytic enzymes (Husby et al 
1985b). Only small amounts of undigested peptides remain when gliadin is 
incubated with normal human gut mucosa (Cornell 1990). Despite the 
significantly lower amount of egg protein compared to wheat and milk 
protein consumed habitually by the subjects in this study, it is possible 
that greater concentrations of ovalbumin are crossing the gut and entering 
the circulation where they elicit an immune response leading to the 
production of specific IgG antibodies.This may also be the explanation for 
the correlation between specific anti-ovalbumin IgG levels in serum and 
daily intake of egg protein.
No correlation was found between serum IgG and salivary IgA specific 
antibodies to ovalbumin and gliadin. A number of studies (Claman et al 
1967, Cernelc & Zalokar 1982, GrOnblad-Saksela 1986) have found no 
association between specific serum and salivary IgA levels. Mechanisms of 
control over serum IgG levels and production of IgA in saliva are very 
unlikely to be the same, so the lack of correlation between the two 
immunoglobulin sources is not surprising.
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Salivary levels of anti-gliadin IgA have been proposed as a more sensitive 
diagnostic procedure for coeliac disease than serum antibodies (Al-Bayaty 
et al 1989), however the usefulness of salivary antibody determinations 
against food proteins is not clear. The information provided by specific 
food protein antibody determinations in serum and saliva is different, 
with one reflecting systemic reactions and the other mucosal reactions. 
Neither measure should be considered as superior to the other; Antibodies 
present in the two fluids are reflecting different degrees and types of 
antigenic exposure. Serum and salivary antibody determinations should be 
regarded as complementary measures of immune response to specific antigens.
The levels of specific food antibodies in serum and saliva do not appear 
related to dietary intake of the antigen. Chronic increases in protein 
consumption for 3-6 weeks produced no changes in circulating antibody 
levels (Gallagher et al 1983). The low incidence of anti-BSA IgG in adults 
has been attributed not to low dietary intake but to a number of other 
factors including immunological capacity to respond, exposure of gut 
lymphoid tissue, presence/absence of concomitant symptomatic allergic 
states associated with antibodies to other antigens and the age of the 
individual (Korenblat et al 1968).Tolerance may occur following continuous 
minimal antigenic stimulation, leading to the hyporesponsiveness seen in 
the work of Gallagher at al (1983). The most significant factor 
influencing naturally occurring serum IgG antibodies is the genetic makeup 
of the individual (Husby et al 1987a), with the human antibody response to 
dietary proteins regulated either to produce antibodies or to maintain 
orally induced tolerance.
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A proportion of normal individuals may be genetically high responders to 
dietary antigens presented via the gut (Barnes et al 1983), possibly an 
explanation for the very high specific antibody titres encountered in 
normal, healthy adults in this study. The presence of specific antibodies 
appears to reflect a normal immune response, with abnormal states 
occurring if values fall above or below a threshold level (Firer et al 
1981).
4.6.2 Specific IgG antibodies in atopic and non-atopic subjects.
The specific antibody concentrations seen in the atopic and non-atopic 
subjects showed anti-ovalbumin IgG to be significantly higher than the 
levels of anti-B-lactoglobulin IgG observed in the non-atopic group, and 
than both anti-gliadin and anti-B-lactoglobulin IgG levels in the atopic 
group. These findings are in agreement with the first section of this
study. The very high anti-ovalbumin IgG concentrations seen in the first 
half of this study were not encountered in either the non-atopic or atopic 
group. This highlights the rarity with which such elevated levels are
encountered.
Anti-ovalbumin IgG concentrations were found to be significantly higher in 
the atopic group compared to the non-atopic group. The levels of anti- 
gliadin and anti-B-lactoglobulin IgG were found not to be different 
between the two groups. In contrast to these findings, Finn et al (1984) 
found anti-gliadin and anti-milk protein antibodies to be elevated in 
subjects with atopic eczema compared to controls, with no difference in 
the levels of anti-ovalbumin antibodies between the two groups. Milk 
protein antibodies have been found to be elevated in atopic subjects in a
number of other studies (May et al 1977, Dannaeus et al 1978, BÜrgen-Wolff
et al 1980).
132
Higher antibody concentrations in hypersensitive individuals indicate a 
fundamental difference, either in permeability, in immunological
reactivity of the gut or in the development of immunological
unresponsiveness (May et al 1977). The elevated food antibody 
concentrations in subjects with food allergy and atopic eczema have been 
proposed to be due to an increased permeability of the gut in these
subjects (Finn et al 1985), thus allowing greater amounts of food antigens 
to reach the circulation. Jackson et al (1984) have shown that the uptake 
of large molecules from the gut occurs to a greater extent in subjects 
with either atopic eczema or food allergy than is seen in the non-atopic 
controls.
Falth-Magnusson et al (1984, 1985) were unable to find any increased gut
permeability in the atopic subjects studied. Subjects with inhalant
allergies showed no greater amounts of serum anti-milk protein antibodies 
than normal children (May et al 1977), providing further indication that 
increased gut permeability may be only present in certain sections of the 
atopic population. If increased gut permeability were a general phenomena 
among the atopic population, it would be expected for all antibodies to 
food proteins to be elevated above control values, as the more permeable 
gut would not be expected to be selective in the molecules allowed 
through. Increases in all the food protein antibodies investigated have 
not been found in this study, and so have confirmed that increased gut 
permeability is not a general phenomena in the atopic population as a 
whole as both inhalant allergies and atopic eczema were studied.
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The significantly higher anti-ovalbumin IgG levels seen in the atopic 
group compared to the non-atopic group are unlikely to be due to an egg 
allergy, as only one subject reported an allergy to egg. This subject also 
exhibited the highest anti-ovalbumin IgG concentrations (lOlOug/ml). Thus, 
although very elevated concentrations of food antibodies may be related to 
a specific food allergy, the moderate elevations above control values 
observed in the atopic, non-food allergic subjects are unrelated to food 
hypersensitivity. It is proposed therefore that the elevated anti­
ovalbumin IgG concentrations in the atopic subjects are a consequence of a 
combination of the antigenicity of ovalbumin, the immune
hyperresponsiveness of the atopic subjects and continual exposure to the
antigens.
It would appear that increased concentrations of food antibodies in atopic 
individuals are a consequence of the presence of atopy rather than a 
direct cause. However, the presence of substantial amounts of antibody to 
food proteins in serum should not be considered as natural and without 
potentially pathogenic significance (May et al 1977). The amount of
specific antibody present, or other characteristics, may influence the 
pathogenic potential. The manner in which individuals maintain or
reinitiate production of antibodies against antigens in food may represent 
another variable important in determining whether or not a given adult 
will have allergic symptoms (Barrick & Farr 1965).
The distribution of the specific food antibodies in the four IgG 
subclasses was found not to be uniform for the three proteins studied. 
Anti-ovalbumin IgG antibodies in the atopic and non-atopic groups were 
found predominantly in the IgG4 isotype. Anti-gliadin IgG antibodies were 
also found mainly in the IgG4 isotype, with an appreciable proportion also 
in the IgG3 isotype.
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Anti-B-lactoglobulin IgG antibodies were found in increasing amounts from 
IgG2 to IgG4. Little IgGl was detected to all three food antigens. The 
results of this study agree in part with previous studies. Anti-ovalbumin 
and gliadin IgG has been found to be restricted predominantly to the IgG4 
isotype (Lewis-Jones et al 1987, Barnes et al 1988b), although IgGl has 
also been detected in significant amounts to ovalbumin (Husby et al 1985a,
1989). Anti-B-lactoglobulin IgG has also been detected predominantly in 
the IgG4 isotype (Husby et al 1985a), and also in IgGl (Husby et al 1989) 
and IgG2 (Lewis-Jones et al 1987) isotypes. Shakib et al (1984) reported a 
similar distribution of anti-B-lactoglobulin IgG antibodies as seen in 
this study.
The differences in the distribution of specific IgG subclass antibodies 
may in part be due to differences in the methodology used for their 
measurement. The subclass assays developed for this study were sensitive 
and reproducible. Polyclonal anti-subclass antibodies were used in this 
study, with monoclonal antibodies used in the majority of other studies 
into IgG subclasses to food antigens. Polyclonal antibodies were chosen in 
preference to monoclonal antibodies because a monoclonal antibody is 
specific for only one epitope, and this may or may not be present on each 
IgG molecule. The use of monoclonal antibodies may therefore lead to an 
underestimation of the levels of specific subclass antibodies present, 
unless a bank of monoclonal antibodies were used together (Jefferis et al 
1985). This problem does not arise with the use of polyclonal antiserum as 
it contains antibodies to a wide number of different epitopes. It has been 
assumed, from the information provided by the manufacturers, that the 
polyclonal anti-subclass antibodies showed no crossreactivity between 
subclasses. It has not been possible to confirm this, as no subclass 
myeloma lines were available to us.
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Generally the results of specific IgG subclass determination are expressed 
in terms of a negative control which is a pool of normal human serum. The 
use of this presupposes that no antibodies are present in the serum and 
that any activity is due to non-specific binding (Layton & Stanworth 
1984). The negative pool used in this study was known to contain no human 
IgG subclass molecules and therefore any activity was due to non-specific 
binding and not very low levels of specific antibody. It can be considered 
that the results obtained were a true reflection of the distribution of 
IgG subclass antibodies in the samples measured.
IgG4 has been thought to be involved in allergic responses, and although a 
number of studies have been carried out to investigate this, the evidence 
does not support a role for IgG4 in atopic disease (Bjôkstén et al 1983, 
Layton & Stanworth 1984, Shakib et al 1984, Rowntree et al 198 5). IgG4 
antibodies to food proteins have been observed in greater concentrations 
in atopic subjects compared to non-atopic subjects (Shakib et al 1984, 
Merrett et al 1984, Rowntree et al 1987, de Martino et al 1988) and high 
concentrations of anti-alpha-casein IgG4 appear to be diagnostic of milk 
intolerance (Shakib 1988). A combination of specific IgE and specific IgG4
antibodies gives a better correlation to a positive food challenge than
does skin testing alone (El Rafei et al 1989). Despite this, it is
generally accepted that the restriction of food antibodies to the IgG4
isotype is part of the normal immune response to envir(5nental allergens,
A
with IgG4 becoming prominent upon chronic antigenic stimulation (Aalberse 
et al 1983). A preferential switch, with prolonged antigenic stimulation, 
occurs from the production of high affinity IgGl antibodies to the 
production of high affinity IgG4 antibodies (Devey et al 1990), with the 
isotype switching thought to occur predominantly within the germinal 
centres.
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Increased concentrations of specific IgG4 in atopic subjects represents an 
amplification of the normal response because of associated increases in 
antigen uptake and decreased clearance rates of ingested protein (Shakib 
et al 1984). In addition it is possible that an IgG4 restricted response 
in atopic subjects is a natural defence mechanism to reduce the effects of 
complement dependent antibodies (Merrett et al 1984). IgG2 and IgG4 are 
unable to fix complement so have the advantage of being able to react with 
antigen without forming potentially damaging immune complexes. IgGl and 
IgG3 are efficient complement- fixing antibodies and complexes containing 
these subclasses may initiate tissue damage (Shakib 1986b, Hamilton 1987). 
The proportion of IgG3 antibodies to ovalbumin and gliadin was 
significantly higher in the atopic group than the non-atopic group in this 
study. The production of greater amounts of IgG3 antibodies in the atopic 
subjects may be an indicator of the underlying breakdown in the normal 
immune response to antigens, which presents itself as allergy. The 
relation to the presence of specific IgG3 antibodies and allergy symptoms 
and severity has not been able to be investigated in this study. This type 
of study may be of use in determining the role specific IgG3 antibodies 
have to play in atopic disease.
The concentration of anti-gliadin IgG was not significantly higher in the 
atopic group compared to the non-atopic group, however significant 
differences were seen in the IgG subclass distribution between the two 
groups. The total concentrations of specific antibodies may therefore not 
provide as much information on the differences in immune response to 
commonly encountered antigens in atopic and non-atopic subjects as can be 
obtained from studies of the distribution of the IgG subclass antibodies 
to a particular antigen.
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No significant seasonal differences were seen in the levels of IgG 
antibodies to ovalbumin, gliadin and B-lactoglobulin in the small number 
of atopic and non-atopic subjects studied. The small differences seen over 
the year in concentrations of anti-ovalbumin and B-lactoglobulin IgG are 
difficult to interpret because of the low number of subjects. Further 
work is required in this area before any conclusive statement about 
seasonal variations of specific antibody levels can be made.
138
Chapter 5
Studies on the uptake of intact ovalbumin and gliadin 
from the gut of healthy adults.
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5.1 Introduction
5.1.1 Uptake of antigens by the gut.
The main function of the gastrointestinal tract is to digest and absorb 
nutrients. The very large proportion of macromolecules in food ingested 
are degraded in the gut lumen to mono- or dimeric subunits before 
absorption. However it is now generally accepted that part of the 
macromolecules derived from food can escape enzymatic breakdown and a 
small proportion of these are absorbed intact through the intestinal 
mucosa. It has been estimated that a maximum of 0.1% of an antigenic load 
will be absorbed intact into the circulation of normal individuals 
(Paganelli & Levinsky 1980).
The transport of macromolecules across the gut may in principal occur by 
intra-cellular or inter-cellular pathways. The transcellular transport may 
take place by receptor-mediated endocytosis, non-selective pinocytosis in 
the plasma membrane or leakage through the intercellular junctions 
(Walker & Isselbacher 1974). The non-selective pinocytosis of antigens 
occurs in specialized epithelial cells (M-cells), which exist in the gut 
to facilitate the transfer of antigens to the intestinal lymphoid tissue 
(Klienman & Walker 1984). The antigens are first taken up by these 
specialized cells by endocytosis and then extruded into the extracellular 
space. This specialized transport process appears to represent an 
important access route whereby antigens reach the lymphoid tissue and 
thereby stimulate the local and systemic immune system (Walker 1986). At 
physiological levels of antigen, this specialized uptake pathway is 
preferred, but at increased antigen levels a more generalized uptake of 
antigen takes place.
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A number of studies have been carried out to investigate the absorption of 
food antigens from the gut. Up to 3ng/ml B-lactoglobulin was detected in 
the serum of healthy volunteers after consuming 1.2 litres cow's milk 
(Paganelli & Levinsky 1980). Kilshaw and Cant (1984) were able to 
demonstrate the uptake of ovalbumin into the circulation of lactating 
mothers but found no detectable B-lactoglobulin. Both proteins, however,
were detected in the breast milk of these women. Husby et al (1985c) also
were able to detect ovalbumin in serum of healthy adults after a test meal
but no B-lactoglobulin. No fragments of ovalbumin were found after uptake 
and this raises the possibility that the ovalbumin molecule is absorbed 
essentially intact (Husby et al 1986).
5.1.2 The consequences of antigen uptake.
The simultaneous presence of serum antibodies and of antigens crossing the 
gut leads to the formation of immune complexes. The formation of immune 
complexes represents, essentially, a normal event in the course of immune 
responses, leading to antigen neutralization and elimination. The type and 
amount of complexes formed will differ according to both gut permeability 
and antibody classes present (Pagenelli et al 1986). Low levels of 
immune complexes are therefore present in all normal individuals, and are 
subjected to rapid clearance by the liver and spleen (Mannik 1982). An 
increase in immune complexes after a meal has been reported by some
workers (Gallagher et al 1983) but not by others (Husby et al 1985c).
There is a great deal of evidence to suggest that increased levels of 
circulating immune complexes are associated with a variety of diseases in 
which the complexes, once deposited in the tissues, cause damage by 
activating complement and other effector mechanisms ( WHO 1977).
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The formation of B-lactoglobulin containing immune complexes has been 
found to be greater in atopic individuals compared to non-atopic 
individuals (Paganelli et al 1981). Further work suggests that in healthy 
individuals, serum IgA is concerned in handling antigens which enter via 
the gastrointestinal tract (Paganelli et al 1983). IgA complexes are 
cleared by the liver (Delacroix et al 1981) and this would provide a safe 
way of handling enterically-absorbed antigens, since complexed IgA is not 
thought to activate complement or elicit damaging reactions. Atopic 
subjects, however, incorporate antigens into immune complexes of different 
immunoglobulin classes, with most producing IgG- and IgE- containing 
complexes (Pagenelli et al 1983). These complexes are capable of 
activating the classical complement pathway, and so can cause tissue 
damage. Circulating immune complexes may have a transport function, 
carrying antigenically viable food proteins to distant target tissues 
where they may trigger delayed clinical symptoms.
5.2 Aims of study.
The aim of the study were to investigate the uptake of two food proteins, 
ovalbumin and gliadin, from the gut of healthy, non-food allergic adults. 
In addition, the influence the presence of one food protein has on the 
uptake of a second in man was also to be investigated.
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5.3 Methods
5.3.1 Subjects.
11 healthy adult volunteers aged between 19 and 28, with no reported 
atopic eczema or food allergy were involved in the two studies carried 
out. 5 (3 female, 2 male) took part in stage 1 and the remainder ( 4
female, 2 male) in stage 2.
5.3.2 Study protocol.
The studies were carried out at the Investigation Unit, St. Luke's 
Hospital, Guildford. For both sections of the study, the subjects fasted 
from 9pm the evening before the study, and were allowed only water or 
black tea or coffee, in addition to the test meal, until the study was 
completed.
Each study consisted of two test meals taken at least 1 week and a maximum 
of 4 weeks apart. The composition of the meals in the two studies is given 
in Figure 5.1. The subjects were allowed 15mins in which the test meals 
were to be consumed.
Venous blood samples were collected via an indwelling canula, situated at 
the elbow joint, before (-15 and Omin) and 30, 60, 90, 120, 150, 180, 210, 
240, 300 and 360mins after the test meal was consumed. The samples were
allowed to clot at room temperature, centrifuged and the sera aliquoted 
and frozen, and stored at -20°C until required.
5.3.3 Analysis of samples.
Samples were analysed using the ELISA methods detailed in chapters 2 and 
3. Ovalbumin and gliadin concentrations and the specific antibody levels 
to these two antigens were determined.
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Figure 5.1 Composition of the test meals given in the antigen uptake 
studies.
Study 1
Part 1 2 raw eggs (size 2)
200ml orange juice
Study 2
2 raw eggs (size 2) 
200ml orange juice
Part 2 132g wholemeal rolls
lOg sunflower margarine 
200)^ 1 orange juice
2 raw eggs (size 2)
132g wholemeal rolls 
lOg sunflower margarine 
200ml orange juice
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5.4 Results
5.4.1 Study 1: The uptake of antigens after a single protein meal.
5g of ovalbumin was contained in the eggs given and 5g gliadin was present 
in 132g bread. It can be seen from Table 5.1 that the protein and fat 
content of the two test meals were similar. The carbohydrate and energy 
contents, however, were different, with the energy content of part 1 being 
approximately half that of part 2.
After the single protein meal, ovalbumin was detectable in all five 
subjects. In two subjects (2 and 5), in whom very high concentrations of 
ovalbumin were detected, an uptake peak was not reached during the 6hrs of 
the study. One subject (1) showed a delayed appearance of ovalbumin in the 
serum following the test meal when compared to the other 4 subjects 
(Figure 5.2). The maximum concentration of ovalbumin measured during the 
study ranged from 0.52ng/ml - 31.80ng/ml.
Gliadin was detected in only 4 of the 5 subjects after feeding bread 
alone. The peak levels were reached at between 180 - 30Omin (Figure 5.3), 
with a maximum concentration of 1.12 - 12.2ng/ml. One subject showing 
high gliadin uptake also showed high ovalbumin uptake (Subject 2).
The mean concentrations of the antigens at each time point are shown in 
Figure 5.4. Although the uptake of ovalbumin can be seen to be much 
greater than that of gliadin, the difference was not found to be 
significant at any time point.
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Table 5.1 Nutritional content of the test meals given in the study of 
antigen uptake from the gut.
Test meal 
Ovalbumin Gliadin
Energy (Kcal.) 1070 2200
Protein (g) 16 16
Fat (g) 14 17
Carbohydrate (g) 12 76
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Figure 5.2 Ovalbumin uptake into the circulation over 6hr following a 5g 
ovalbumin load in five healthy adults..
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Figure 5.3 Gliadin uptake into the circulation over 6hr following a 5g 
gliadin load in five healthy adults.
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Figure 5.4 Mean ovalbumin and gliadin concentrations following the test 
meals containing ovalbumin and gliadin.
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Figure 5.5 Mean ovalbumin uptake when 5g ovalbumin was given with and 
without the presence of gliadin in the test meal.
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The specific IgG antibody concentrations to ovalbumin and gliadin were 
determined on the -15min sample, giving a mean concentration of anti­
ovalbumin IgG of 11lug/ml (SEM + 25ug/ml, range 20-158ug/ml) and of anti- 
gliadin IgG of 336ug/ml (SEM + 128ug/ml, range 65-1200ug/ml). The specific 
antibody concentrations correlated well with area under the uptake curve. 
Ovalbumin uptake showed a negative correlation (r = -0.8) with specific 
antibody concentration, with gliadin uptake positively correlated with 
specific antibody concentration (r = +0.8). Neither of these correlations, 
however, were found to be significant.
5.4.2 Study 2: The influence on the uptake of one protein by the
presence of a second protein.
5g ovalbumin was provided in both test meals consumed, with the addition 
of 132g bread to the second test meal as the second protein source. The 
nutrient intake was therefore much greater in the second test meal than 
the first and the bulk of the meal was also greater.
After the single protein meal, ovalbumin was detectable in the serum of 4 
of the 6 subjects involved. The peak serum levels were obtained at between 
180 - 300 mins following the test meal, with maximum serum concentrations 
of ovalbumin between 0.64 - 1.28ng/ml.
Following the test meal containing both proteins, ovalbumin was detected 
in 3 of the 6 subjects. Peak serum levels were obtained at between 150 -
210 mins, with maximal concentrations of 0.72 - 1.08ng/ml. Gliadin was 
only detectable in 1 of the 6 subjects, with peak serum concentrations 
reached at SOmins and with a maximal serum concentration of 14.16ng/ml.
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The mean concentrations of ovalbumin at each time point after both test 
meals are shown in Figure 5.5. The results for both curves were calculated 
from the results obtained from the 4 subjects with detectable ovalbumin 
after the first, single protein test meal. The basal levels of ovalbumin 
were not significantly different between the two experiments. The 
concentration of ovalbumin in serum was, however, significantly higher at 
SOOmins (p < 0.05) after the consumption of egg alone than after the
consumption of egg and wheat together. This was the only point at which 
the difference in ovalbumin concentration was significant.
Specific IgG antibodies to ovalbumin were determined in the -15min 
samples, giving a mean concentration of llOug/ml (SEM: 46ug/ml, range 19 - 
223ug/ml). Ovalbumin was not detectable after either test meal in the 
subjects with the highest anti-ovalbumin IgG concentrations (196, 
223ug/ml). The subject with 152ug/ml anti-ovalbumin IgG had detectable 
levels of ovalbumin following the meal containing just egg, but not when 
egg and wheat were fed together. Anti-gliadin IgG was also determined, 
giving a mean concentration of 270ug/ml (SEM: 179ug/ml, range 47-990ug/ml). 
In this group of subjects, anti-ovalbumin IgG antibody concentration was 
also found to be negatively correlated with ovalbumin uptake (r=-0.8), but . 
no correlated was found between anti-gliadin IgG antibody concentration 
and gliadin uptake.
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5.5 Discussion.
5.5.1 The uptake of antigens after a single protein meal.
In both sections of this study the majority of subjects (9/11) had 
detectable levels of ovalbumin after the consumption of 5g ovalbumin. The 
number with detectable gliadin in serum was lower (4/11), but it must be 
taken into account only half these subjects received wheat on its own.
The nutrient composition of the two single protein test meals was similar 
with the exception of the carbohydrate content. Composition of the meals 
was important as the fat, carbohydrate, and protein content of foods are 
known to influence the rate of gastric emptying. A delay in gastric 
emptying would, therefore, lead to a delay in the exposure of the small 
intestine to the antigens under investigation, the major site of antigen 
uptake (Udall & Walker 1982).
The uptake of ovalbumin and gliadin from the gut into circulation was 
monophasic, in agreement with the findings of Kageyama (1983), Husby et al 
(1985c) and Troncone et al (1987). Paganelli et al (1980, 1981) found a
diphasic uptake of B-lactoglobulin and of the appearance of B- 
lactoglobulin containing immune complexes into the blood of healthy and 
atopic subjects following the consumption of 1.2 litre fresh cow's milk. 
This may reflect differences in mucosal handling of milk derived proteins 
compared to other food protein antigens.
Peak levels of ovalbumin were seen between 240 - 360 mins, with maximum 
serum concentrations of 0.52 - 31.08ng/ml. A wide range of absorption 
times has been reported by a number of other groups, Husby et al (1985c) 
found peak concentrations were obtained between 120 - 300mins with the 
longest time to peak 420mins, with ovalbumin reported to be detectable in 
serum upto 8hrs post-consumption (Danneaus et al 1979, Kageyama 1983).
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The maximum concentrations achieved in this study show a wider range than 
seen in some other studies. Husby et al (1985c) reported a maximum 
concentration range of 1.7 - 10.5ng/ml, Kilshaw and Cant (1984) 0.44 -
2.88ng/ml. The amount of antigen absorbed into the circulation appears to 
be a very individual phenomena and it is possible that the subjects 
selected for this study were high absorbers relative to the population as 
a whole. However, the subjects in this study were given 2 raw eggs to 
consume, with only one egg given in the studies quoted above. Where 
equivalent amounts of ovalbumin to this study were given, high 
concentrations of ovalbumin were also seen (Danneaus et al 1979; 1.6 -
64.1ng/ml, Kageyama 1983: 1 - 24ng/ml). The amount of ovalbumin detected
in serum following egg consumption is therefore, as would be expected, 
determined in part by the amount consumed.
The peak gliadin concentrations were seen between 180 - 300mins, with
maximum concentrations of 1.12 - 12.2ng/ml. Very little work has been 
carried out on the uptake of gliadin into the circulation. Troncone et al 
(1987) detected gliadin in the breast milk of lactating mothers given a 
gluten load, but none was detectable in the serum of these women. The 
gliadin peak concentrations in breast milk were seen between 2 - 4hrs,
with the maximum concentration of approximately 80 - lOOng/ml. Kulangara 
(1980) also detected gliadin in breast milk.
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The mean concentration of ovalbumin was higher, although not
significantly, than the mean concentration of gliadin following the single 
the ^
protein meals. As amount of the two proteins consumed was identical, it 
would appear that the uptake of antigenically viable ovalbumin occurs to a 
greater extent than the uptake of antigenically viable gliadin. This 
difference in uptake may due to a number of factors. The gliadin 
containing meal was much bulkier, with the consumption of starches and 
fibre with the gliadin, so it was not as concentrated as the ovalbumin in 
the eggs. Additionally, the starches and fibres may physically reduce the 
amount of gliadin coming into contact with the gut mucosa.
The amount of antigen reaching the gut mucosa intact is also determined by 
its resistance to the proteolytic enzymes in the lumen. Ovalbumin is known 
to be more resistant to proteolytic degradation than other food proteins 
(Husby et al 1985c), and this may account for its greater uptake compared 
to gliadin. Kilshaw and Cant (1984) found the absorbed antigenically 
viable ovalbumin was of normal molecular weight, thus intact native 
molecules rather than degradation products. This finding was confirmed by 
the work of Husby et al (1985c) and Peng et al (1990). It is possible that 
the antiserum used in the ELISA assay was not able to detect all the 
antigencally viable gliadin passing into circulation. In cooking the 
gliadin molecules become complexed to glutenin molecules via di-sulphide 
bridges. The degradation of these large complexes may give rise to 
products with antigenic determinants not recognizable by antiserum raised 
to crude gliadin.
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the
The uptake of antigens into circulation was correlated with the 
concentration of specific IgG in serum. The uptake of ovalbumin was 
negatively correlated with anti-ovalbumin IgG concentrations, confirming 
previous reports (Danneaus et al 1979, Kageyama 1983, Husby et al 1985c). 
The inability to determine ovalbumin in the serum of subjects with high 
specific antibody titres may be a result of the formation of immune 
complexes, which could not be determined in this study. Husby et al 
(1985c) found that subjects with substantial amounts of serum anti­
ovalbumin antibodies, particularly in the IgG class, preferentially showed 
high molecular weight material corresponding to immune complexes 
containing ovalbumin.
Animal studies have shown that prior feeding of protein antigens may 
reduce the subsequent absorption of that antigen without altering the rate 
of its elimination (Swarbrick et al 1979, Lim & Rowely 1982). This 
inhibitory affect is due to antibodies functioning by complexing and 
trapping the antigen in the mucosal layer. The presence of secretory 
antibodies to ovalbumin was not determined in the subjects involved in 
this study, but high levels of secretory antibodies, particularly at the 
mucosal surface as implied above, would limit the quantity of antigen able 
to penetrate the mucosa and enter circulation (Walker et al 1972). Serum 
derived antibodies may also retard the penetration of antigens, as shown 
in rabbits (Tolo et al 1977), although it is not known if this is due to 
immune exclusion at the mucosal surface or local elimination in the 
lamina propria. In this study, it is not possible to state whether the 
lack of detectable ovalbumin in subject with high serum anti-ovalbumin IgG 
titres is due to the formation of complexes or exclusion of the antigen at 
the gut surface. Further investigation into the occurrence of ovalbumin- 
containing immune complexes is required to clarify this point.
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The positive correlation between gliadin uptake and anti-gliadin IgG titre 
is in contrast to the findings with ovalbumin. It is much more difficult 
to see how a positive correlation between antibody and antigen
concentrations can arise, but this may be a reflection of the slightly
different assay methods used in determining gliadin and ovalbumin.
An affinity purified antibody was used as the coating antibody for the 
determination of gliadin, with an ion exchanged antibody used in the
ovalbumin assay, thus a much purer antibody preparation was used in
measurement of gliadin. Sheep anti-gliadin antibodies may have a higher 
affinity for gliadin than human anti-gliadin IgG, thus gliadin would bind 
more strongly to the plate bound antibody than to the human antibody in 
solution. If the difference in affinity were sufficiently great, the 
reaction equilibrium would favour the binding of gliadin to the sheep 
antibody rather than the human causing a reduction in the amount of 
gliadin complexed in solution. The assumption is made that in . subjects 
with high specific antibody titres, the majority of the antigen is in 
immune complexes.
An increased uptake of gliadin would occur if a deficiency of anti-gliadin 
IgA existed at the mucosal surface. A role of IgA in the gut is to complex 
with antigens in the lumen, or that have crossed the mucosa, to prevent 
their entry into general circulation. If the antigens do enter the 
circulation, they will trigger a systemic immune response, which in turn 
gives rise to elevated IgG antibody levels. It can not be stated that this 
is the reason for the positive correlation between anti-gliadin IgG and 
gliadin uptake as no information is available on the specific secretory 
IgA levels in the subjects involved in this study.
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5.5.2 The influence on the uptake of one protein by the presence of a 
second protein.
The consumption of a single foodstuff at a time, followed by a long fasted 
period was a very atypical situation, therefore the results obtained from 
such experiments give only an indication of the extent of antigen uptake. 
The presence of other proteins, as demonstrated in the second section of 
this study, may reduce the uptake of a single antigen.
The peak uptake of ovalbumin was reached earlier (mean - 150min) after
the consumption of two proteins than when egg was consumed alone ( mean; 
300min). The mean maximum concentration was also lower after the two 
protein meal ( 0.63ng/ml) than after the single protein meal (0.95ng/ml). 
The difference between the uptake after the two meals only reached a 
significant level (p < 0.05) at 300min. The presence of wheat therefore 
would appear to reduce the time over which ovalbumin was absorbed and also 
the amount of ovalbumin absorbed.
The apparent difference in ovalbumin uptake following the two meals may be 
due to the greater bulk of the two protein meal, preventing ovalbumin 
reaching the mucosal surface in the concentration achieved with the single 
protein meal. However, if this were the case, a much slower absorption of 
ovalbumin would be expected with the peak concentration reached later 
than observed following the single protein meal. The maximum concentration 
may not be as high in this situation as the time available for ovalbumin 
to undergo proteolytic degradation would be greater.
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Studies in mice, unimmunized to ovalbumin, resulted with the uptake of 
ovalbumin being significantly reduced by the presence of B-lactoglobulin. 
Conversely the uptake of B-lactoglobulin was reduced, but not 
significantly, by the presence of ovalbumin, suggesting competition for 
antigen absorption in the gut (Roberts et al 1981). The reduction in 
ovalbumin uptake following the two protein meal may be a result of
competition between the two proteins for absorption across the gut.
It is not known whether the absorption of gliadin was influenced by the 
presence of ovalbumin, the detection of gliadin in only 1/6 subjects is 
suggestive of its uptake being limited. The range of anti-gliadin 
antibodies found in the subjects fed both wheat and egg together was very 
similar to that seen in the subjects given wheat alone. The lack of
detectable gliadin in the former group is therefore unlikely to be due to
the formation of immune complexes, locking gliadin in a form unable to be 
detected by the assays used in this study. If this were the case, the 
detection of gliadin in the group fed wheat alone would be expected to be 
as low, however gliadin was detectable in the serum of 4/5 of these 
subjects. It is possible therefore that whilst the presence of gliadin 
reduces the uptake of ovalbumin, concurrently the presence of ovalbumin is 
reducing the uptake of gliadin. *
These two studies have provided a small amount of information on the 
uptake food antigens from the gut into the circulation, quantifying the 
uptake of two dietary antigens. Exclusion or elimination of antigens is by 
no mean complete and a number of factors are working together to 
determined the concentrations of any one antigen actually reaching the
systemic circulation and include specific IgG antibody titres, secretory 
IgA levels and the presence of other food protein.
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Chapter 6
An observational study on the transfer of specific food 
antibodies and antigens from mother to infant.
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6.1 Introduction
6.1.1 Placental transfer of IgG antibodies.
In man, transmission of IgG from the mother to infant occurs entirely 
before birth (Brambell 1966). This provides the infant with a major line 
of defence against infection in its first few weeks of life, enabling it 
to deal with pathogens to which it has had no previous exposure (Roitt 
1984). Placental transfer of IgG occurs throughout pregnancy, but this 
transfer increases significantly after 32 weeks gestation (Akin et al 
1990). At birth, the overwhelming majority of IgG present in the infant's 
circulation has been derived from its mother. The half life of maternally 
derived antibodies in newborn infants has been estimated at between 24 - 
30 days, however, antibodies thought to be maternal in origin have been 
detected in infants at 12 months of age (Albrecht et al 1977).
The mechanism of transplacental IgG transfer is both complex and 
selective. Immunoglobulins are incorporated into vesicles within the
syncytiotrophoblasts by endocytosis. The vesicles migrate through the
cytoplasm and fuse with the basement membrane, releasing their contents 
into the extracellular space. The immunoglobulins travel through the
interstitium by direct diffusion and enter the fetal circulation through 
interendothelial gaps (Lin 1980). The transfer of immunoglobulins is very 
selective. The binding sites on the syncytiotrophoblastic membrane are
specific for the Fc portion of the IgG molecule and, additionally, these 
receptors will only recognise momomeric IgG, therefore not bind aggregated 
IgG or IgG-antigen complexes (Wood et al 1982).
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6.1.2 Transfer of IgA antibodies in breast milk.
A wide variety of soluble and cellular components such as lactoferrin, 
lysozyme, lactoperoxidase and bifidus factor, have been identified in 
human milk and colostrum. The role these factors play in the mechanisms of 
protection in the new-born infant remains to be determined. However human 
milk and colostrum also contain immunoglobulins, with IgA being the 
dominating immunoglobulin (Mickleson & Moriarty 1982).
IgA in breast milk is the secretory form, present as a dimer complexed to 
the J chain and associated with secretory component. It is generally 
assumed that the IgA present in breast milk is produced locally and thus 
the mammary gland is the site of a local immune response (Hanson et al 
1979). There is some evidence to indicate that in the very early stages 
of lactation that this may not be the case, with the majority of the IgA 
in milk derived from distant sites and transferred via the blood to the 
mammary gland. In the later stages of lactation however the IgA is 
predominantly derived from the mammary gland itself (Halsey et al 1982).
A relation exists between gut antigen exposure and mammary gland IgA 
production. This involves the migration of lymphocytes originally 
sensitized in the gut to the mammary gland, then differentiating into 
plasma cells and producing the IgA which enters the milk (Hanson et al 
1979). Direct evidence of B-lymphocyte traffic between the gut and 
mammary gland (the enteromammary axis) has been provided by studies in 
mice. Gut derived lymphocytes, when administered intravenously, showed a 
much greater tendency to reach the mammary gland than lymphocytes derived 
from peripheral tissues (Roux et al 1977). The gut derived cells reaching 
the lactating mammary gland were overwhelmingly IgA producers.
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When antigen was fed to mice before and during pregnancy, and during 
lactation, an intestinal immune response was stimulated, but in addition 
lactating mammary glands contained numerous antigen-specific IgA plasma 
cells (Weisz-Carrington et al 1979). The sIgA found in breast milk, thus 
transferred to the new born infant, is therefore reflecting the mother's 
intestinal antigenic load (Cruz et al 1981).
6.1.3 Influence of maternal antibodies in the newborn infant.
As a consequence of the transfer of maternal IgA, the infant receives 
antibodies against the microbes and food proteins to which its mother has 
been exposed, and to which the infant will also be exposed. The sIgA 
antibodies can only bind to the antigen, whether it be a bacterial, viral 
or food component. This complex does not activate complement, enhance 
phagocytosis or induce inflammation. Thus the milk derived sIgA is able to 
prevent contact between the gut mucosa and potentially pathogenic 
microorganisms or allergenic foods. Should any pathogens or food proteins 
enter the systemic circulation, maternally derived IgG antibodies will be 
present to aid in the removal of the foreign material from the blood.
6.2 Aims of study.
The aims of this study are firstly to investigate the amount of food 
specific antibodies to ovalbumin, gliadin and B-lactoglobulin, transferred 
from mother to infant via the placenta and breast milk. The incidence of 
transfer of antigenically viable food protein across the placenta will 
also be investigated. Transfer of these components will be compared to the 
mother's normal dietary intake of egg, milk and wheat.
Salivary levels of IgA antibodies to ovalbumin and gliadin are to be 
determined in the infant's first month of life to assess the 'feasibility 
of the use of this fluid for following changes in its immune response.
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6.3 Methods.
6.3.1. Subjects.
Women at 32 -34 weeks gestation, planning to breast feed their infant, 
were recruited from antenatal clinics held at St.Luke's Hospital, 
Guildford and Louise Margaret Maternity Wing, Cambridge Military Hospital, 
Aldershot. A full explanation of the study was given to each mother before 
consent was obtained. Written permission from the Consultant Obstetrician 
at both hospitals for the inclusion in the study of women under their care 
had been obtained. The women were given a questionnaire to complete, 
giving details of personal and family history of allergy.
6.3.2 Samples.
At 35 - 36 weeks gestation, the mothers were asked to complete a 7 day
weighed food record, and were asked to make particular note of foods 
containing egg, wheat or milk. At the beginning of the 7-day period, a 
venous blood sample and unstimulated saliva sample was obtained from 
each mother. At delivery, a cord blood sample was collected into non- 
heparinized glass blood tubes by the midwives at the two hospitals 
involved and centrifuged at 2000g for 15mins and frozen within 6hrs.
Breast milk samples were collected from each mother for the first 10 days 
postpartum and then at days 14, 21 and 28. The mothers were asked to 
collect their samples at approximately the same time each day and before 
feeding the baby. The samples were frozen at -20°C in glass tubes 
immediately after collection and were stored at this temperature until 
required.
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Saliva samples were obtained from the infants over the first four weeks of 
life. Samples were collected on preweighed pairs of cotton buds and then 
stored in pairs at -20°C in sealed LP4 tubes. The mothers were asked to 
collect the samples just before feeding the baby to minimize the risk of 
contamination with breast milk.
6.3.3 Preparation of samples.
The maternal and cord blood samples were allowed to clot at room 
temperature before centrifuging at 2000g for ISmins, to separate the serum 
from the blood cells. The samples were aliquoted and frozen at -20®C 
until required for analysis. The maternal saliva sample was centrifuged 
at 2000g for 20min to remove any particulate matter, aliquoted and frozen 
until required.
The breast milk samples were centrifuged at 2000g for ISmins and the
resultant fat layer removed as completely as possible. The samples were
then aliquoted into plastic storage vials and refrozen at -20°C until
required for analysis. The samples were recentrifuged for Smins using an 
P
Ependorph microcentrifuge just prior to analysis and the aqueous, non- 
cellular fraction was used in the assays.
Pairs of cotton buds containing the infants' saliva samples were reweighed
and the saliva content determined. The cotton wool from each pair was
removed and placed into Spin-X centrifuge filter units (Costar, Cambridge,
Massachusetts, USA). Casein buffer was added to produce a 1:20 dilution of
Pthe saliva samples. The filters were then centrifuged in an Ependorph 
microcentrifuge for 5min to separate the saliva and buffer from the cotton 
wool. The diluted saliva was returned to the storage LP4 tube and then 
used in the ELISA assays. Any remaining saliva was frozen at -20°C.
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6.3.4 Analysis of samples.
a) Analysis of questionnaire.
Personal details such as age and occupation, were obtained from the 
questionnaire and collated for the group. The incidence of allergy in the 
mothers, their children and in first degree relatives was noted.
b) Analysis of weighed intake data.
The 7-day weighed food records were analysed using the COMPEAT dietary 
analysis package (Lifeline Nutrition Services Ltd, London). An estimate of 
the intake of wheat, egg and milk protein was made from the protein source 
breakdown of each diet obtained from this program.
c) Analysis of samples.
IgG antibodies to ovalbumin, gliadin and B-lactoglobulin were determined 
by ELISA (see chapter 2) in the maternal serum and cord serum samples. 
Ovalbumin and gliadin were also measured by ELISA (see Chapter 3) in these 
same samples. IgA antibodies to ovalbumin and gliadin were determined in 
the maternal and infant saliva samples. IgA antibodies to all three 
proteins were measured in the breast milk samples obtained.
In the analysis of the infant saliva samples, additional quality control 
saliva samples were added to cotton buds and treated in an identical 
manner to the infant saliva samples. These eluted samples were then 
included in the routine analysis of the infant samples, to ensure the 
elution method was consistent from day to day.
6.3.5 Statistical analysis.
The data underwent logarithmic transformation before analysis was carried 
out using the Statworks package on a Apple Mackintosh computer.
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6.4 Results.
6.4.1 Subjects.
20 mothers were recruited into the study and completed the collection of 
samples. Their mean age was 31.0 years ( range 27 - 35), with a mean 
parity, excluding the present child, of 1 (range 0-3). The mothers were 
evenly distributed between socio-economic classes I - III based on the 
mother's occupation where it was given, otherwise on the husband's 
occupation. No subject fell into socio-economic classes IV or V.
Three women reported suffering from allergy, 1 eczema, 1 asthma and 1 
hayfever and three reported having a child suffering from eczema. No other 
reports were made of first degree relatives suffering from any form of 
atopic disease.
6.4.2. Analysis of samples.
a) Food intake data.
The average daily energy and protein intakes were calculated from the 7- 
day weighed food diaries (Table 6.1). The average daily intakes of milk 
and wheat protein were very similar and were significantly higher (wheat 
p<0.001, milk p<0.001) than the daily intake of egg protein (Table 6.1). 
The women were receiving, on average, 27% of their daily protein intake 
from wheat, 4% from eggs and 28% from milk.
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Table 6.1 Summary of the 7-day weighed food intake records from 20 
pregnant women.
Mean SEM Range
Energy (kcal) 2149 97 1650 - 3219
Protein (g) 79 3 59 - 108
Wheat protein (g) 21 2 5- 3 5
Egg protein (g) 3 1 1 - 7
Milk protein (g) 22 2 8 - 39
Table 6.2 Specific antibody concentrations in maternal serum and saliva, 
and fetal cord serum (n=20).
Serum (ug/ml) Mean
SEM
Range
Specific antibody 
Ovalbumin Gliadin
196*+ 
54 
1 - 925
79*
25
12 - 523
B-lactoglobulin
56+
19
ud - 336
Cord (ug/ml) 
Serum
Mean
SEM
Range
316*~
98
1 - 1590
74#
20 
4 - 404
48~
7
2 - 216
Saliva (% stand)Mean 23 24
SEM 7 4
Range UD - 109 UD - 67
N/D
N/D = anti-B-lactoglobulin IgA in saliva was not able to be determined. 
UD = undetectable 
* ^ p<0.05, + ~ p<0.02
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h) Analysis of serum and cord serum.
Specific IgG antibodies to ovalbumin, gliadin and B-lactoglobulin were 
determined in the maternal serum and cord serum samples (Table 6.2). A 
wide range of concentration of antibodies was seen to all three antigens. 
IgG antibodies to these food proteins were detectable in the majority of 
subjects. The concentrations of anti-ovalbumin IgG were significantly 
higher in maternal serum (196 + 54ug/ml) and cord serum (316 + 98ug/ml)
than levels of anti-gliadin IgG (serum: 79 + 2Bug/ml, cord serum: 74 +
20ug/ml :p<0.05) and anti-B-lactoglobulin IgG (serum: 56 + 19ug/ml, cord
serum: 48 + 7ug/ml :p<0.02). Anti-gliadin IgG concentrations were higher
than anti-B-lactoglobulin IgG concentrations but did not reach a 
significant level.
Fetal cord serum concentrations of anti-ovalbumin IgG were higher than 
those seen in maternal serum (Figure 6.1). This difference however was not 
significant because of the wide variations in concentration encountered. 
In contrast, cord blood and serum concentrations of anti-gliadin and anti- 
B-lactoglobulin IgG were similar.
Specific IgA levels to ovalbumin and gliadin in the maternal saliva showed 
a wide range of concentration, similar to that seen in serum. No 
correlation was seen between specific IgA antibodies in saliva and 
specific IgG antibodies in serum.
Concentrations of antigenically viable ovalbumin and gliadin were 
measured in the maternal serum samples and in the fetal cord serum samples 
(Figure 6.2). Concentrations of ovalbumin in serum and cord serum were 
lower, although not significantly, than levels of gliadin present. Serum 
and cord serum levels of ovalbumin and gliadin were similar, showing a 
wide range of concentrations across the group.
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Figure 6.1 Serum and cord serum concentrations of specific food 
antibodies (n=20).
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Figure 6.2 Maternal serum and cord serum concentrations of ovalbumin and 
gliadin (n=20).
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Ovalbumin was detectable in 75% (15/20) of mothers and in 85% (17/20) of 
cord serum samples. Gliadin was detectable in all mothers, but one, in 
both serum and cord serum samples. No correlation was found between 
specific antibody concentrations and the observed antigen levels in 
either maternal serum or cord serum. In addition maternal serum and cord 
serum concentrations of ovalbumin and gliadin were found not to correlate 
with specific salivary IgA levels or food protein intake.
c) Analysis of breast milk and infant saliva samples.
The concentrations of specific IgA antibodies in breast milk showed a 
rapid decline in the first 5 days postpartum (Figure 6.3). Anti-B- 
lactoglobulin IgA levels do not appear to have undergone as rapid a 
decline in this period as occurred with anti-ovalbumin and anti-gliadin 
IgA. The variation seen between mothers was very large, accounting for the 
large standard errors encountered. Anti-ovalbumin and anti-gliadin IgA 
were detectable in the breast milk of all 20 mothers throughout the 
sampling period. Anti-B-lactoglobulin IgA was detectable in the breast 
milk of all subjects, with the exception of two. One in whom the antibody 
was undetectable for the whole sampling period, and the second, where it 
was undetectable after day 10 postpartum.
Anti-ovalbumin and anti-gliadin IgA was determined in the saliva samples 
obtained from the infants (Figure 6.4). The levels of these two 
antibodies were very low at birth, detectable in only 50% (10/20) of the 
children studied. The concentrations of the specific antibodies rose in 
the first month of life, with anti-ovalbumin IgA detectable in 80% (16/20) 
of the children at one month of age and anti-gliadin IgA detectable in 90% 
(18/20). 2 infants had no detectable anti-ovalbumin IgA in the first month 
of life, and one child had no detectable anti-gliadin IgA over the study 
period.
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Figure 6.3 Specific antibody concentrations in breast milk.
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Figure 6.4 Specific food antibody levels in infants' saliva over the 
first month of life (n=20).
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Levels of anti-ovalbumin and anti-gliadin IgA in the saliva of the infants 
at 1 week of age were significantly lower than maternal levels (p<0.05, 
p<0.005 respectively). The differences in specific salivary antibody 
concentration compared to maternal concentrations were no longer apparent 
in the infants at 4 weeks of age.
Recovery of quality control samples of saliva from the cotton buds was 
determined. The mean recoveries for the high, medium and low quality 
control anti-ovalbumin IgA samples were 99%, 85% and 90% respectively. The 
mean recoveries for anti-gliadin IgA were 98% for the high quality 
control, 77% for the medium and 80% for the low. The coefficient of 
variation for all the recoveries was below 10%.
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6.5 Discussion.
6.5.1 Maternal serum and cord serum antibody and antigen concentrations.
IgG concentrations to ovalbumin and B-lactoglobulin observed in this group 
of pregnant women were very similar to those seen in non-atopic adults 
(chapter 4). The mean concentration of anti-gliadin IgG was approximately 
half that observed in non-atopic adults. The reason for this difference is 
not clear, but may be due to the high levels of anti-gliadin IgG seen in 
several of the non-atopic adults which elevated the mean value of the 
group. Serum anti-ovalbumin IgG concentrations were once again found to 
be significantly higher than the concentrations of anti-gliadin and 13- 
lactoglobulin IgG, which is in agreement with the studies carried out in 
normal adults (chapter 4).
Cord serum concentrations of specific antibodies mirrored the findings in 
maternal serum with anti-ovalbumin concentrations higher than 
concentrations of anti-gliadin and anti-B-lactoglobulin IgG. The 
concentrations of anti-ovalbumin IgG were higher in cord serum than 
maternal serum, with the concentrations of anti-gliadin and B- 
lactoglobulin IgG similar in cord serum and maternal serum. Total cord 
serum IgG levels have been found to be on average 1.5 times high than 
total maternal IgG concentrations (Allansmith et al 1968). The IgG is 
transferred selectively across the placenta by an active transport 
mechanism (Kohler & Farr 1966), with IgA, IgM and IgD excluded. The 
increased concentrations of IgG in the fetal circulation are unlikely to 
be due to fetal synthesis, although the fetus is able to synthesize IgG by 
20 weeks gestation (Van Furth et al 1965). Specific antibodies to 
Escherichia Cali 0 antigen have also found to be higher in cord serum than 
maternal serum (Carlsson et al 1976).
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From the results obtained in this study, it would appear that the transfer 
of specific IgG across the placenta does not occur in a uniform manner. 
Anti-ovalbumin IgG concentrations were on average 1.6 times higher in cord 
serum than maternal serum, indicating that the transfer of this antibody 
follows the pattern seen with total IgG. The transfer of the other food 
antibodies studied did not show this enhanced transfer to the fetal 
circulation, with the similarity in concentrations in fetal and maternal 
circulation giving no indication of active transport of IgG molecules 
across the placenta. It would appear therefore that anti-ovalbumin 
antibodies are preferentially transferred across the placenta in 
comparison to IgG antibodies to other food proteins. Alternatively, some 
mechanism is in play to restrict the transfer of anti-gliadin and anti-B- 
lactoglobulin IgG transplacentally, which may involve the presence of 
immune complexes containing these antibodies.
The concentrations of antigenically viable ovalbumin and gliadin in the 
maternal serum were very similar, with no correlation seen with the
concentration of specific maternal IgG. The lack of correlation in these 
samples was unexpected, with the serum samples collected at random times 
during the day. The correlations obtained in chapter 5 were between total 
antigen absorption over a period of time and specific antibody 
concentrations, and no correlations were seen between antibody and antigen 
concentrations at single time points during the study. The similarity in 
ovalbumin and gliadin concentrations in the serum gives further
indications of increased absorption of ovalbumin over gliadin. The
consumption of egg protein was significantly lower than the consumption of 
wheat protein, thus a higher proportion of ingested ovalbumin must be
absorbed intact to give similar serum concentration to gliadin.
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No differences were seen between antigen levels in cord serum and maternal 
serum. It would appear therefore that food proteins present in the 
maternal serum are able to cross the placenta in quantities that may have 
important immunological consequences. The mechanism of this transfer is 
unclear, and the similarity of concentrations in serum and cord serum give 
no indication that active or selective transfer is involved.
Intra-uterine sensitization to food proteins has been proposed (Matsumura 
et al 1975), with evidence available to indicate that the sensitization 
may be passive, that is, produced by antibodies transmitted from maternal 
circulation via the placenta, or active, that is, induced by antibodies 
actively produced by the fetus (Matsumura et al 1973). Determination of 
IgE antibodies in cord blood has also provided indirect evidence for 
intra-uterine sensitization (Michel et al 1980, Gordon et al 1982, 
Furukawa et al 1990), as IgE is unable to cross the placenta thus must be 
of fetal origin. Intra-uterine sensitization occurs in only a small 
percentage of 'at risk' children (Michel et al 1980, Kjellman & Croner 
1984), however this study has found that antigenically viable food 
proteins are transferred across the placenta in a large percentage of 
mothers. In the majority of infants, the intra-uterine transfer of food 
proteins appears to have no detrimental effect. The presence of antigen- 
antibody complexes in the fetus may be involved in the development of 
tolerance (Auerbach & Clarke 1975) and the transplacental transfer of 
tolerogenic influences are considered to be of major importance in the 
development of human immunological unresponsiveness.
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6.5.2 Breast milk and infant salivary antibody levels.
Antibodies to ovalbumin, gliadin and B-lactoglobulin were highest in 
colostrum, with concentrations declining rapidly to 6-8 days postpartum 
after which the concentrations remained reasonably constant. The 
concentration of total IgA in breast milk has been found to be 28% of the 
ineital colostral value by 3 days postpartum, 4% at 6 days and 2% from day 
14 to 70 (Mickelson & Moriarty 1982). The decline in antibody 
concentrations during the first week of lactation appears to be 
compensated for by increases in milk volume (Carlsson et al 1976). The 
decline in antibody concentrations in the first week is due to a dilution 
effect (Ammann & Steihm 1966), with an inverted relation existing between 
antibody content and milk volume.
Although it can not be stated conclusively due to the method of 
quantification used, the concentrations of anti-B-lactoglobulin IgA 
antibodies appeared to be higher in breast milk than the concentrations of 
anti-ovalbumin and anti-gliadin IgA. Considerable amounts of milk protein 
antibodies have been reported previously to be present in human breast 
milk (Hanson et al 1977bj. The presence of specific food antibodies in 
breast milk is indicative of the close relation between lymphoid tissues 
of the mammary gland and intestinal mucosa (Hanson et al 1977b) with the 
antibodies in breast milk reflecting the current and earlier immunological 
experience of the mother (Carlsson et al 1976) with breast milk antibody 
titres to ovalbumin, gliadin and B-lactoglobulin unaffected by avoidance 
of these proteins (Falth-Magnusson 1989). The great variability in 
antibodies levels encountered is due to differences in antigenic exposure 
at the intestinal level (Cruz et al 1981).
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IgA in breast milk is considered to act as an antigen exclusion mechanism 
(Walker et al 1973), so limiting the exposure of the intestinal mucosa to 
potential allergens. This would be of particular importance with mixed 
feeding as it offers protection until the infant's own intestinal antibody 
response has fully developed (Hanson et al 1977b). In rats from the onset 
of suckling to sometime between 15 - 21 days of life, IgA and secretory 
component have been found localized on the luminal surface of the villi in 
the proximal third of the small intestine (Nagura et al 1978). The IgA was 
associated with specific binding sites on the plasma membrane which were 
lost 3 weeks after birth.
The role of IgA in breast milk is not confined to functioning at the 
mucosal surface. Small amounts of colostral IgA are absorbed from the 
neonatal intestine in the first 18-24 hrs after birth (Ogra et al 1977). 
Uptake is transient and does not occur 24-36 hrs after birth, although 
other reports indicate uptake of IgA up to three days after birth (Vukavic
1983). During this period, 10-15% of ingested IgA reaches the serum, 60% 
is excreated in the faeces and 25-30% is lost either due to proteolytic 
degradation or retention on the intestinal mucosal surfaces.
The collection of saliva from infants as young as 1 week has proved 
possible, using a very simple and quick method, with salivary anti­
ovalbumin and anti-gliadin IgA detectable in 50% of infants at 1 week of 
age and seen in the majority by 1 month. Detection of sIgA in the saliva 
of newborn infants is not uncommon (Ben-Aryeh et al 1984) and the findings 
of this study are in agreement with those of Seiner et al (1968).
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Total salivary IgA was not detectable in the first week postpartum, but 
appeared subsequently until by 28 days 92% of normal infants had 'adult' 
levels of IgA. Development of specific IgA antibodies follows this 
pattern, with anti-ovalbumin and anti-gliadin IgA levels significantly 
lower than adult levels at 1 week of age, by 4 weeks no differences in 
adult and infant levels were present.
Serum IgA levels increase gradually over the first few months of life, not 
reaching adult levels until approximately 12 years of age (Allansmith et 
al 1968). In comparison, the immunological maturation of the mucosal IgA 
is very rapid (Seiner et al 1968) and this is of importance during the 
neonatal period since IgA is the prime immunoglobulin of mucosal surfaces 
and thus antibodies at these surfaces may be crucial in defence against 
infection and sensitization. Other findings however have suggested that 
complete maturation of salivary IgA does not occur until after the age of 
6 years (Ben-Aryeh et al 1984, D'Amelio et al 1986).
The IgA antibodies in the saliva of newborn infants is of fetal not 
maternal origin (Archibald et al 1990). Salivary antibodies can be 
stimulated by maternal anti-idiotypic antibodies, however Archibald et al 
(1990) found that anti-HIV gpl60 antibodies were not present in the saliva 
of uninfected infants born to seropositive mothers. Serum IgA production 
in the fetus results from strong antigenic stimuli (Allansmith et al 
1968). The placental transfer of antigens may therefore be responsible 
for the stimulation of the production of specific salivary IgA antibodies 
very early in postnatal life.
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Chapter 7
The influence of maternal atopy and mode of feeding on the 
transfer of food specific antibodies and antigens 
from mother to infant: a prospective study.
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7.1 Introduction.
Breast milk from a mother in good health and nutritional status provides a 
complete food, unique to the species (DHSS 1988), with no better nutrition 
available for healthy infants, both at term and during the early months of 
life. Breast feeding is considered to provide more satisfactory growth 
and freedom from disease than if an artificial substitute is given (DHSS
1980). No change in the incidence of breast feeding has occurred in the UK 
since 1980, with 65% of mothers initially breast feeding their infants. A 
number of factors are associated with the incidence of breast feeding and 
these include parity of the mother, social class, education beyond 18 
years of age and smoking (Martin & White 1985). Despite the recommendation 
made in 1980 (DHSS 1980) that "mothers should breast feed their babies, 
preferably for 4 to 6 months, but at least for the first few weeks of 
life", only 51% of women breast-fed for as long as two weeks, and only 26% 
breast-fed for 4months or more (Martin & White 1985).
The alternative to breast feeding is the use of infant formulas, which, 
whether based on cow's milk or soya protein isolates, are designed to have 
a composition as close to and as biologically adequate as human milk. 35% 
of infants receive infant formulas from birth, with 62% of infants 
receiving formula by the age of 6 weeks (Martin & White 1985). 33% of
women decided to bottle feed their infants before the birth, with previous 
experiences having a strong influence on the mode of feeding chosen. The 
incidence of combining bottle and breast feeding has increased since 1980, 
thus few babies are exclusively breast-fed.
Breast milk is believed to afford protection against infection and the 
development of atopic disease, however the protection against atopic 
disease is by no means complete, with infants showing sensitivity to the 
first known encounter with foods.
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7.1.1 Protective effect of breast feeding.
A number of studies have been carried out to investigate the protective
effects of breast feeding on development of atopic conditions since Grulee
and Sanford (1936) first reported that breast feeding protects against
'infantile eczema'. The results of these studies have been somewhat
contradictory, and problems in comparison arise from differences in study
design and classification of allergy and type of feeding (Burr 1983,
Kramer 1988). Hide and Guyer (1985) observed breast feeding, whether
to
sustained or just initiated, appeared give protection against the
development of asthma but not eczema. Other studies have shown beneficial 
effects of breast feeding on development of atopic eczema (Mattews et al 
1977, Chandra 1979, Saarinen et al 1979, Hide & Guyer 1981) and Vandenplas 
& Sacre (1986) found a significantly lower incidence of atopy overall in 
breast-fed infants (3.7%) compared to bottle-fed infants (12.9%). However, 
an equal number of studies reported no effect of breast feeding on 
incidence of atopy (Kjellman & Johansson 1979, Kramer & Moroz 1981, Taylor 
et al 1984, Savilahti et al 1987'^ .
Despite disagreement in study results, a concensus of opinion exists that 
breast feeding is beneficial in the prevention of atopy and many reasons 
favour its use over cow's milk formula (Mattews et al 1977, Gerrard 1979), 
particularly in infants with a family history of atopy. The mechanisms of 
the protective effect of breast milk against the development of atopy, and 
conversely the provocative effect of cow's milk formula, are likely to be 
extremely complex (Atherton 1983b), but may include immunologically active 
components of breast milk, delayed introduction of foreign protein and 
maturation of the gut barrier function.
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Human milk contains sIgA as the dominant antibody, and the specific 
antibodies produced reflect the antigen exposure of the mother (Cruz et al
1981). These antibodies will complex with antigens within the gut of the 
infant and prevent their uptake across the mucosal gut barrier. Human milk 
also contains numerous host defence factors, in addition to these 
antibodies (Hanson et al 1985). Breast feeding has been strongly 
implicated in maintaining immunological homeostasis in the neonatal 
intestine during the period of functional immaturity of the secretory 
immune system (Ogra et al 1983), and has been proposed to favour the 
establishment of an environment for the growth of normal gut flora in the 
newborn infant.
Human milk contains factors which accelerate the production of sIgA by the 
neonate (Atherton 1983a), thus speeding the maturation of the mucosal 
immune system. Studies in rats have shown that breast-fed pups were 
protected from enhanced antigen penetration across the intestinal mucosal 
barrier in the immediate postpartum period compared to artificially fed 
animals (Udall et al 1981). This antigen exclusion in breast-fed animals 
was not mediated by immune exclusion mechanisms, and non-immunological 
factors in breast milk are thought to be important to the accelerated 
maturation of gut barrier function. The introduction of cow's milk or 
soya formula within the first three months of life does not allow 
sufficient time for gut barrier function to mature (Eastham et al 1978), 
thus greater amounts of antigenically intact foreign protein is able to 
enter the circulation and can lead to sensitization in susceptible infants.
181
Entry of large amounts of antigen into circulation is thought to induce 
tolerance rather than sensitization (Jarrett & Hall 1981)|. However in the 
neonatal period, antigen feeds lead to a net gain in T-helper cells, 
because of immunologic and digestive immaturity, which prevents the 
induction of tolerance due to T-suppressor cells (Strobel & Ferguson
1984). Breast feeding in early neonatal life allows time for maturation of 
immune and digestive systems before the introduction of large amounts of 
foreign protein and also aids in this maturation process.
7.1.2 Development of atopy in breast-fed infants.
Although in the majority of cases, breast milk is beneficial in 
preventing atopy, the protection is not complete and numerous reports of 
the development of atopy in wholly breast-fed infants exist. Gerrard 
(1979) reported food allergy in breast-fed children under 10 months of 
age. Food allergic asthma, eczema (Cant et al 1984, Cogswell et al 1987), 
urticaria, vomiting (Van Asper-n et al 1983) and colic (Jakobsson & 
Lindberg 1978) have been observed in exclusively breast-fed infants.
Development of food allergies in exclusively breast-fed infants would 
indicate they are receiving proteins from their mothers' diet via breast 
milk. Axelsson et al (1986) observed B-lactoglobulin in 40% of breast milk 
samples and significant correlations existed between high levels of 13- 
lactoglobulin in breast milk and presence of diarrohea, vomiting and colic 
in the infants. Elimination of cow's milk from the mothers' diet resulted 
in the disappearance of colic in 53% of infants, with 90% of these 
reacting to maternal challenge with whey proteins (Jakobsson & Lindberg 
1983). Ovalbumin has been demonstrated in the breast milk of 7% of women 
with atopic children (Cant et al 1985), and 50% of the children showed 
evidence of egg sensitivity. Wheat antigens have been demonstrated in 
breast milk (Kulangara 1980), with consequences for coeliac infants.
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The very low concentrations of food antigens are sufficient to sensitize 
infants. It has been shown that repeated exposure to low doses of antigen 
in breast milk increases the likelihood of developing an IgE response to 
food proteins (Jarrett & Hall 1979). The feeding of cow's milk formula in 
the first few days of life has been suggested as a means of reducing the 
incidence of atopy in infants with a positive family history (Lindfors & 
Enocksson 1988). The large dose of antigen is suggested to act by 
suppressing IgE production, as seen in mice when administered high doses 
of ovalbumin (Jarrett 1977). However, the development of atopic disease in 
infants does not just depend on the amount of antigen reaching the infant, 
but on the immune responsiveness of certain infants to minute amounts of 
antigen (Cant et al 1985).
7.1.3 Influence of family history on incidence of atopy in infants.
Development of atopic disease in susceptible children is influenced by 
many environmental factors (Cogswell et al 1987). Family history of atopy 
is the most significant factor in the prediction of atopic disease in 
infants (Vandenplas & Sacre 1986, Savilahti et al 1987a). Poysa et al 
(1989) observed 23% of infants with a positive family history of atopy 
had developed atopic disease by 1 year of age, compared with 14% of 
infants with a negative family history. Atopic eczema was found more 
commonly in infants with a positive family history, and where atopy was 
present in a family, the child usually exhibited the same manifestation. 
Cow's milk given to newborn infants of non-atopic mothers does not appear 
to increase the risk of IgE-mediated diseases (0stergaard 1985), 
indicating the importance of family history in the development of such 
conditions. Research is now being directed at identifying factors which 
play a role in reducing the risk of atopy in susceptible infants and the 
development of strategies to achieve this.
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7.2 Aims of study.
The major aims of this prospective study are two fold. First to investigate 
the transfer of food antibodies and antigens from mother to infant in the 
last few days of fetal life and in the early stages of neonatal life. The 
influence of the transfer of maternal antibodies on the development of the 
infant's immune system and the development of atopy in infants will be 
investigated. The second aim of this study is to investigate the long term 
consequences of feeding either human or modified cow's milk in infants 
with atopic and non-atopic mothers, with respect to the production of food 
antibodies and the development of atopy in the infant.
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7.3 Methods.
7.3.1 Subjects
Women at 32 -34 weeks gestation were recruited from antenatal clinics held 
at St.Luke's Hospital, Guildford and Louise Margaret Maternity Wing, 
Cambridge Military Hospital, Aldershot. A full explanation of the study 
was given to each mother before consent was obtained. Permission from the 
Consultant Obstetricians at both hospitals for the inclusion of women 
under their care had been obtained and ethical approval for the study was 
received from the Ethical Committee of the South West Thames Regional 
Health Authority. The women were given a questionnaire to complete, 
giving details of personal and family history of allergy.
From January 1988 to July 1989, 26 women were recruited into the study, 13 
were atopic and 13 non-atopic. 8 women in each group breast-fed their 
infants, 5 infants were fed modified cow's milk formula from birth (Figure 
7.1). The women were allocated to the atopic group following the same 
criteria as employed in the adult study (Chapter 4).
7.3.2 Collection of samples
a) Maternal samples.
At 35 - 36 weeks gestation, the mothers completed a 7 day weighed food
record, and were asked to make particular note of foods containing egg,
wheat or milk. At the beginning of the 7-day period, a venous blood sample 
and an unstimulated saliva sample were obtained from each mother. At 
delivery a cord serum sample was collected into plain, sterile glass blood
tubes by the midwives at the two hospitals involved. The venous and cord
serum samples were allowed to clot at room temperature and the serum 
collected, aliquoted and frozen at -20®C until required. The saliva 
samples were centrifuged at 2000g for lOmins to remove any particulate 
matter and then aliqoted and frozen at -20®C.
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Figure 7.1. Division of mothers recruited into four study groups.
Mothers recruited 
(26)
Atopic
(13)
Non-atopic
(13)
Breast
(8)
Bottle
(5)
Breast
(8)
Bottle
(5)
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Breast milk samples were collected from each mother for the first 10 days 
postpartum and then at days 14, 21 and 28. The mothers were asked to
collect the samples at approximately the same time each day and before 
feeding the baby. Samples were frozen at -20*C in glass tubes immediately 
after collection and stored until required.
b) Infant samples.
Infants saliva samples were collected using preweighed pairs of sterile 
cotton buds. Samples were collected every week for one month post 
delivery, then at monthly intervals, timed from the date of birth, until 6 
months of age, then at 6 monthly intervals until 18 months of age. The 
mothers were asked to ensure the sample collection was made before the 
child was fed to prevent contamination with milk or food. The saliva and 
cotton buds were then weighed and frozen at -20*C until required for 
analysis.
Heel prick blood samples were obtained from the infants at 1 week, 3 
months, 6 months and 12 months of age. Samples were obtained using an
Autolet lancet and the blood collected via a pipette into microcentrifuge
6
tubes. This was kept cool on ice until centrifugation in an Ependorph 
microcentrifuge for 5 mins. The serum was collected and aliquoted before 
freezing at -20°C until required.
The mothers were asked to keep a record of the age at which new foods 
were introduced to the infants. Particular attention was given to the 
introduction of modified cow's milk formula to breast-fed infants.
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c) Assessment of incidence of atopy.
Every child was assessed for atopic disease by an Pediatrician (Senior 
Registrar, St.Luke's Hospital, Guildford) who did not know the children 
and was given no information regarding the child's feeding history or 
family history of atopy. A standard form was completed for each child, and 
if atopy was present, the condition was scored according to severity.
7.3.3 Preparation of samples.
The preparation of the breast milk and infant saliva samples was carried 
out as in section 6.3.3 before analysis.
7.3.4 Analysis of samples.
a) Analysis of questionnaire.
Personal details, such as age and occupation, were obtained from the 
questionnaire and collated. Socioeconomic class was determined by the 
mother's occupation if she worked, otherwise it was based on her husband's 
occupation. The incidence of allergy in the mothers, their children and in 
first degree relatives was noted and a score of 1 was given for each 
family member suffering from atopic disease.
b) Analysis of food intake data.
The 7-day weighed food records were analysed using the COMPEAT dietary 
analysis package (Lifeline Nutritional Services Ltd, London). An estimate 
of the intake of wheat, egg and milk protein was made from the protein 
source breakdown produced.
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c) Analysis of samples,
IgG antibodies to ovalbumin, gliadin and B-lactoglobulin were determined 
by ELISA (see chapter 2) in the maternal serum and cord serum samples. 
Ovalbumin and gliadin were measured by ELISA (see chapter 3) in these 
samples. SIgA antibodies to ovalbumin and gliadin were determined in the 
maternal and infant saliva samples (see chapter 6 for details). SIgA 
antibodies to all three proteins were measured in the breast milk samples 
obtained.
7.3.5 Statistical analysis.
Multivariant and univariant analysis was carried out using SSPX program 
on the University of Surrey Prime network. Paired Student's T-test and 
Spearman's correlation were carried out on a Apple Macintosh, using the 
Statworks program.
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7.4 Results.
7.4.1 Questionnaire Results.
26 women were involved in the study, with a mean age of 3 0 + 4  years 
(range 23 - 34). The mean age of the atopic mothers (29 years) was 
slightly lower than that of the non-atopic women (31 years). No 
differences were seen in the ages of the mothers when divided into the 
four study groups. The women, excluding the child involved in this study, 
had an average of 1.75 children, with no differences seen between the 
parity of the study groups. 54% (14/26) of the women were primiparous, 27% 
(7/26) had 1 child and 19% (5/26) had more than 1 child. 38% (10/26) of 
the women were classified as being in socioeconomic class I, 31% (8/26) in 
class II, 22% (6/26) in class III and 9% (2/26) in class IV. No
differences were seen in the socioeconomic class distribution between the 
four study groups.
Of the 13 atopic women in the study, 2 reported suffering from food 
allergies, 4 hayfever, 3 eczema and 2 asthma alone. The remaining two 
reported suffering from asthma and hayfever, and eczema and hayfever. No 
allergies were reported in the non-atopic group. The mean score of first 
degree relatives, excluding the mother, with atopic disease in the whole 
group was 0.3 + 0.1 and no differences were seen between the four study 
groups. The mean score of second degree relatives with atopic conditions 
was also similar in the four groups (0.9+0.3).
7.4.2 Food intake analysis.
A summary of the analysis of the 7-day weighed food intakes is shown in 
Table 7.1. The atopic group were consuming significantly more protein (89 
V 72g/day: p<0.05) and milk (26 v 19g/day: p<0.05) than the non-atopic
group. The energy intake of the atopic group was also higher compared to 
the non-atopic group, but this did not reach significance.
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Table 7.1. Summary of weighed food intakes in atopic and non-atopic 
pregnant women (mean intake per person per day).
p<0.05
Atopic Non-atopic
Mean Range Mean Range
Energy (Kcal) 2287 1511-2850 1995 1412-2825
Protein (g) 89* 68-148 72* 49-86
Egg (g) 3 0—8 2 0-5
Wheat (g) 17 10-29 17 7-28
Milk (g) 26+ 13-44 19+ 9-33
Table 7.2. Specific IgG antibody content of maternal serum and cord 
serum in atopic and non-atopic women.
Antigen
Serum
(ug/ml)
Atopic Non-atopic
Cord serum 
(ug/ml)
Atopic Non-atopic
Ovalbumin - Mean 
SEM 
Range
256*+
17
20-769
145 251** 281
17 27 35
6-858 10-921 6-1320
Gliadin — Mean 
SEM 
Range
86*
5
15-234
63
4
14-162
67
7
ÜD-206
47
11
2-114
B-lacto­
globulin
- Mean 
SEM 
Range
57+
5
3-245
39
5
ÜD-178
26*’
2
4-76
44
5
1-181
ÜD = undetectable
p<0.02
+ ** p<0.01
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7.4.3 Antibodies and antigens in maternal serum, saliva and cord serum.
The concentrations of specific IgG antibodies to ovalbumin, gliadin and B- 
lactoglobulin in maternal serum and cord serum are shown in Table 7.2. In 
the atopic group, anti-ovalbumin IgG concentrations in serum were 
significantly higher (256 + 17ug/ml) than levels of anti-gliadin IgG (86 
+ 5ug/ml: p<0.02) and significantly higher in both maternal serum and cord 
serum (251 + 27ug/ml) than anti-B-lactoglobulin IgG (serum: 57 + 5ug/ml, 
p<0.01, cord serum:26 + 2ug/ml, p<0.01). The concentrations of IgG 
antibodies to ovalbumin, gliadin and B-lactoglobulin were not 
significantly different in the non-atopic group. Anti-ovalbumin IgG levels 
were higher in the serum of the atopic group (256ug/ml) compared to the 
non-atopic mother (145 + 17ug/ml), but this difference was not present in 
the cord serum. Serum levels of anti-gliadin and anti-B-lactoglobulin IgG 
were higher in the atopic mother compared to the non-atopic group, but 
did not reach significance.
Anti-ovalbumin IgG concentrations in maternal serum (145 + 17ug/ml) were 
lower than those in cord serum (281 + 35ug/ml) in the non-atopic group, 
and the levels in these samples were highly correlated (r = 0.8,
p<0.005). In the atopic group, the mean anti-ovalbumin IgG concentrations 
in maternal serum and cord serum were very similar (256 v 251ug/ml) but 
did not correlate. Overall the non-atopic group showed a mean gain of 
+93ug/ml anti-ovalbumin IgG from maternal serum to cord serum, whereas the 
mean gain of the atopic group was significantly lower (p<0.05) at - 
27ug/ml.
192
Anti-gliadin IgG concentrations were lower in the cord serum of both 
atopic and non-atopic subjects compared to the maternal serum, with the 
mean loss of antibody from maternal serum to cord serum in the atopic 
group of -27ug/ml and in the non-atopic group of -24ug/ml. Concentrations 
of anti-gliadin IgG were higher in maternal serum and cord serum in the
atopic group compared to the non-atopic group, but this was not
significant. The maternal and cord serum anti-gliadin IgG concentrations 
were not correlated.
Anti-B-lactoglobulin concentrations increased from maternal serum to cord 
serum in the non-atopic group, with a mean gain of +2ug/ml. In the atopic 
group however, a decrease in antibody concentration from serum to cord
serum occurred, with a mean loss of -39ug/ml. Maternal serum and cord
serum concentrations of anti-B-lactoglobulin IgG were correlated in the
non-atopic group (r=0.9, p<0.001), but not in the atopic group.
Ovalbumin and gliadin concentrations in maternal serum and cord serum are
illustrated in Figure 7.2. Concentrations of ovalbumin were similar in 
serum (atopic; 3.5ng/ml, non-atopic: 5.2ng/ml) and cord serum (atopic:
4.0ng/ml, non-atopic: 6.9ng/ml), and no differences were seen between the 
atopic and non-atopic women. Gliadin concentrations were higher in both
maternal serum (13.8ng/ml) and cord serum (12.0ng/ml) in the atopic group
than in the non-atopic group (serum: 9.5ng/ml, cord serum: 3.7ng/ml), and
concentrations of gliadin in cord serum were significantly (p<0.05) higher 
than ovalbumin. Decreases in gliadin concentrations from maternal serum to 
cord blood occurred in both groups, with a mean loss of -3.0 + 1.3ng/ml 
in the non-atopic group and of -3.4 + 1.4ng/ml in the atopic group. 
Concentrations of ovalbumin and gliadin in cord serum were correlated with 
specific antibody levels ( ovalbumin: r= -0.6, p<0.05, gliadin: r=+0.9,
p<0.01) in the non-atopic group, no correlations were seen in the atopies.
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Figure 7.2. Food antigen concentrations in maternal serum and cord serum 
of atopic and non-atopic mother.
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Figure 7.3. Maternal specific salivary slgA concentrations.
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Maternal salivary concentrations of anti-ovalbumin and anti-gliadin sIgA 
in the atopic and non-atopic groups are shown in Figure 7.3. No 
differences were found between the concentrations of these antibodies in 
the two groups, and no correlations were found between specific salivary 
sIgA and specific serum IgG concentrations.
7.4.4 Breast milk sIgA concentrations.
The mean anti-ovalbumin, anti-gliadin and anti-B-lactoglobulin sIgA 
concentrations in breast milk of atopic and non-atopic women are 
illustrated in Figures 7.4, 7.5 and 7.6 respectively. A very steep decline 
in antibody concentrations occurred in the first week postpartum, with the 
concentrations levelling out after this time. No differences were apparent 
in specific sIgA antibodies in breast milk of atopic and non-atopic women.
7.4.5. Salivary and heel prick antibody concentrations in infants.
The 26 infants (10 male, 16 female) were all born normally at term, with 
no complications requiring special care. One infant was born by Caesarian 
section. The infants were all healthy and suffered no more than normal 
childhood illnesses during the period of study.
Salivary concentrations of anti-ovalbumin and anti-gliadin sIgA in bottle- 
and breast-fed infants with atopic and non-atopic mothers are shown in 
Figures 7.7 and 7.8 respectively. Anti-ovalbumin sIgA in saliva was 
detectable in 46% (12/26) of the infants at Iwk, in 77% (20/26) by 4wks 
and in 81% (21/26) at 1 year of age. At 1 year, 5 infants had no
detectable salivary anti-ovalbumin sIgA, in 4 of these children anti­
ovalbumin sIgA had been detected at an earlier age.
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Figure 7.4 Anti-ovalbumin sIgA concentrations in the breast milk of atopic 
and non-atopic women.
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Figure 7.5 Anti-gliadin sIgA concentrations in the breast milk of atopic 
and non-atopic women.
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Figure 7.6 Anti-fî-lactoglobulin sIgA concentrations in the breast milk of 
atopic and non-atopic women.
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Figure 7.7 Salivary anti-ovalbumin sIgA levels in breast- and bottle-fed 
infants with atopic and non-atopic mothers.
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Figure 7.8 Salivary anti-gliadin sIgA levels in breast- and bottle-fed 
infants with atopic and non-atopic mothers.
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Concentrations of anti-ovalbumin sIgA rose steeply in infants with non- 
atopic mothers from 4 weeks of age (bottle: 11 + 6%, breast: 8 + 2%) to
a peak at 2 months in breast-fed infants (25 + 12%) and at 3 months of age
in bottle-fed infants (66 + 36%), then declined, beginning to increase
again by 18 months of age. Infants with atopic mothers showed an increase 
in anti-ovalbumin sIgA from birth (bottle: 5 + 3%, breast: 5 + 2%) to 4
weeks of age (bottle: 15 + 2%, breast: 14 + 3%), then a slow decline
until 18 months of age (bottle: 3 + 1%, breast: 6 + 2%). A significant
effect of maternal atopy on anti-ovalbumin sIgA antibody levels in the 
saliva of infants was seen at 4 weeks of age (p<0.05) with higher anti­
ovalbumin sIgA concentrations in infants with atopic mothers (15%) 
compared to infants with non-atopic mothers (9%).
Anti-gliadin sIgA was detectable in 50% (13/26) of infants in the first 
week of life and in 69% (18/26) at 4 weeks of age. By 1 year of age, it 
was detectable in 85% (22/26) of infants and undetectable in only 4 
infants. In three of these infants, no or very low levels of antibody had 
been detected at an early age. The levels of anti-gliadin sIgA rose in the 
saliva of all infants over the first month of life, with the mean 
concentration in all the infants studied 3 + 3% at 1 week of age and 16 +
17% by one month. Concentrations then declined slightly, before reaching a 
constant level at 4 months of age (10 + 3%) until 18 months of age (13 +
3%). No significant differences were seen in anti-gliadin sIgA 
concentrations between the four study groups.
In heel prick samples from the infants, anti-ovalbumin IgG concentrations 
fell in the first 3 months of life in all infants and began to increase 
again from 3 months in breast-fed infants of atopic mothers (Figure 7.9). 
In the remaining three groups of infants, an increase in anti-ovalbumin 
IgG concentrations was not seen until 6 months of age.
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Figure 7.9 Anti-ovalbumin IgG levels in breast- and bottle-fed infants 
with atopic and non-atopic mothers.
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Figure 7.10 Anti-gliadin IgG levels in breast- and bottle-fed infants with 
atopic and non-atopic mothers.
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Using multivariant analysis, the combination of mode of feeding and 
maternal atopy caused significant differences in anti-ovalbumin IgG 
concentrations at 1 week of age (p<0.02) and 12 months of age (p<0.05). 
Presence of maternal atopy had a significant influence on anti-ovalbumin 
IgG levels during the first 6months of life (p<0.05) and from Smonths to 
12months of age (p<0.03). By univariant analysis, infants with atopic 
mothers had significantly higher anti-ovalbumin IgG concentrations at Iwk 
of age (p<0.05) than those with non-atopic mothers. Mode of feeding had a 
significant influence on the infant's anti-ovalbumin IgG levels over the 1 
wk to 6 month period (p<0.03) and from 3months to 12months (p<0.02) by 
multivariant analysis, with higher concentrations of specific antibody 
seen in breast-fed infants than in bottle-fed infants. Significant 
differences in anti-ovalbumin IgG concentrations were seen at 12 months of 
age in bottle and breast-fed infants (p<0.001) with higher concentrations 
seen in the bottle-fed infants (137 + 40ug/ml) than in the breast-fed 
infants (69 + 23ug/ml).
Anti-gliadin IgG concentrations in the infants serum fell in the first 3 
months of life, before increasing upto 12 months of age in all but the 
bottle-fed infants of atopic mothers (Figure 7.10). In this group, the 
specific IgG concentrations continued falling until 6 months of life. 
Using multivariant analysis, mode of feeding and maternal atopy combined 
had a significant effect on anti-gliadin IgG levels over the first 6 
months of life (p<0.01). These two factor individually were found to have 
significant influence on concentrations over this period (p<0.02, p<0.005 
respectively), with the most significant influence of specific antibodies 
within one subject being time (p<0.001).
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Anti-J3-lactoglobulin IgG concentrations increased from Iwk of age in all 
but breast-fed infants with non-atopic mothers (Figure 7.11). After 
6months of age, bottle-fed infants with non-atopic mothers showed a 
decline in antibody concentrations, with increases seen in the other 
groups upto 1 year of age. Using univariant analysis, maternal allergy had 
a significant influence on concentrations of anti-B-lactoglobulin IgG at 
Iwk of age (p<0.01), with anti-B-lactoglobulin IgG higher in infants with 
atopic mothers (122 + 37ug/ml) than infants with non-atopic mothers (48 + 
15ug/ml).
Mode of feeding showed a significant effect at 3 months of age (p<0.01) 
with concentrations higher in bottle-fed infants (159 + 64 ug/ml) than in 
breast-fed infants (80 + 41ug/ml). Mode of feeding and maternal atopy 
produced significant "between subject' effects (feed: p<0.02, atopy: 
p<0.02), with combination of mode of feeding and time producing 
significant 'within subject' effects (p<0.1).
Maternal serum and cord serum concentrations of anti-ovalbumin IgG were 
correlated with the concentrations seen in the infants at 1 week 
(serum:r=0.6, p<0.02, cord serum: r=0.6, p= ns) and at 3 months of age
(serum: r=0.8, p<0.001, cord serum: r=0.9, p<0.001). Correlations were
also seen between maternal serum and cord serum concentrations of anti- 
gliadin IgG and the titres observed in the infants at 3 months of age 
(serum: r=0.7, p<0.05, cord serum: r=0.6, p<0.05). Cord serum titres of
anti-gliadin IgG were also correlated with infant concentrations at 1 week 
of age (r=0.7, p<0.05).
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Figure 7.11 Anti-fî-lactoglobulin IgG levels in breast- and bottle-fed 
infants with atopic and non-atopic mothers.
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7.4.6 Incidence of atopy and introduction of new foods.
By 12 months of age, 27% of children from all four groups had developed 
signs of atopic disease. A total of 7 infants showed signs of atopy,
with 5 developing eczema and 2 asthma. Cow's milk allergy was identified
as the cause of eczema in one infant who had been bottle-fed and egg 
allergy in another who had been breast-fed. Food allergy had not been 
identified as a problem in the other 5 children. 60% (3/5) of bottle-fed 
infants with atopic mothers developed atopy, compared to 20% (1/5) of
bottle-fed infants with non-atopic mothers, 25% (2/8) of breast-fed
infants with atopic mothers and 12% (1/5) of breast-fed infants with non-
atopic mothers. Dividing the infants by family history of atopy, 39%
(5/13) with a positive history developed atopy compared to 15% (2/13) with 
a negative history.
The antibody concentrations in maternal serum, cord serum and heel prick 
samples at 12 months are illustrated in Table 7.3. No significant 
differences were found between the maternal serum and cord serum
concentrations of anti-ovalbumin and anti-gliadin IgG in the infants
developing atopy compared to those that did not. Maternal serum
concentrations of anti-B-lactoglobulin IgG in the infants developing atopy
were approximately double those seen in the maternal serum of infants not 
developing atopy, but this difference was not significant.
Anti-B-lactoglobulin concentrations in cord serum were significantly 
higher in the infants developing atopy (mean: 105ug/ml) compared to those 
that did not (mean: 23ug/ml, p<0.005). Specific antibody concentrations to 
ovalbumin, gliadin and B-lactoglobulin in heel prick samples at 12 months 
of age were higher in the group of infants developing atopy compared to 
those that did not, these differences, however, were not significant.
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The mean age at which foods were introduced to the infants are summarized 
in Table 7.5. Apart from the differences in the age of introduction of 
cow's milk formula in the two feeding groups, breast fe^d infants received 
egg for the first time much later than the bottle-fed infants. Fruit juice 
was also introduced earlier in the bottle-fed group. In the breast-fed 
group, the non-atopic mothers ceased breast feeding after an average of 9 
months (range 4-12 months). Three mothers still breast-fed their infant at 
least once a day at the age of 1 year. The atopic mothers fed their 
infants for an average of 6 months (range 3-8 months) and none were still 
breast feeding at 1 year of age.
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Table 7.3 Specific antibody titres in the seven infants developing atopy 
(mean + SEM).
Ovalbumin
Antigen
Gliadin B-lactoglobulin
(ug/ml) (ug/ml) (ug/ml)
Serum 290 + 97 66 + 21 76 + 23
Cord blood 303 + 92 92 + 36 105 +37
Heel prick at 131 + 46 210 + 67 499 + 137
12 months
Table 7.4 Age of introduction of foods to bottle and breast-fed infants.
Bottle--fed Breast--fed
Food Atopic Non-atopic Atopic Non-atopic
CM formula Birth Birth 6mon 8mon
(3-8) (4-10)
Egg 5mon 6mon 8mon lOmon
(3-9) (4-10) (4-12) (6-13)
Fruit juices 3mon 3mon 6mon 5mon
(3-4) (3-4) (3-9) (2-11)
Citrus fruit 7mon 7mon 8mon 8mon
(4-12) (3-11) (7-10) (6-10)
Wheat products 4mon 6mon 5mon 4mon
(3-6) (3-7) (2-8) (3-6)
[mean ( range of times of introduction)]
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7.5 Discussion.
7.5.1 Subjects.
The mothers recruited were similar in age, parity, social class and living 
environment, and, overall, were a well educated, well motivated group of 
individuals. No social class bias was observed in the bottle feeding 
groups compared to the breast feeding groups, even though the incidence of 
bottle feeding is greater in social classes IV and V (Martin & White 
1985). The mothers in the study were volunteers which may be the reason 
for the predominance of upper social class women and the degree of 
motivation shown. Only 18% of women in Great Britain have reported still 
breast feeding their infants at 1 year of age (Martin & White 1985), which 
is comparable with the findings of this study (19%). The age of 
introduction of solid foods was much later in this study than average for 
Great Britain as a whole. Only 20% of infants had received solid food at 
the age of 3 months compared to 55% in London and the South East and 62% 
in the nation as a whole (Martin & White 1985).
No differences in family history of atopy were seen between the atopic and 
non-atopic groups, when the mothers were excluded. Thus any differences 
between the groups related to atopy may be considered a result of the 
presence or absence of atopy in the mothers rather than a result of family 
history.
7.5.2 Maternal food intake.
The higher protein and energy intakes which were observed in the atopic 
mothers compared to the non-atopic mothers are of interest. Atopic mothers 
could be considered to be better motivated than the non-atopic women as 
the study was involved in factors contributing to the occurrence of atopy.
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The atopic women may therefore produce a more complete and accurate record 
of food intake than the non-atopic women. Under-reporting of food intake 
may occur in the non-atopic women due to the proposed motivational 
differences between the groups, and these factors combine to produce the 
observed differences in energy and protein intake.
7.5.3 Maternal serum and cord serum concentrations of specific antibodies 
and antigens.
Maternal serum concentrations of anti-ovalbumin, anti-gliadin and anti-B- 
lactoglobulin IgG were higher in the atopic group compared to the non- 
atopic group, but these differences were not significant. The reasons for 
differences in specific antibody concentrations between atopic and non- 
atopic subjects have been fully discussed in Chapter 4.
Transfer of food specific antibodies from mother to fetus via the placenta 
did not occur to the same extent in atopic compared to non-atopic women. 
A high degree of correlation was seen between maternal serum and cord 
serum concentrations of anti-ovalbumin and anti-B-lactoglobulin IgG in the 
non-atopic group, with the concentrations of both these antibodies higher 
in cord serum than maternal serum. The results indicate active 
transplacental transfer of these antibodies is occurring, favouring fetal 
accumulation, as has been proposed by Brambell (1966).
No correlations were found between maternal serum and cord serum 
concentrations of these two antibodies in the atopic women. In addition, 
the concentrations of anti-ovalbumin and anti-B-lactoglobulin IgG in cord 
serum were lower than those seen in the maternal serum. It is possible 
that the transfer of antibodies from mother to fetus in atopic women is 
defective and the active transport mechanism is not functioning to the 
same degree as seen in the non-atopic women, resulting in a disrupted, 
more random transfer of immunoglobulin to the fetus.
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These findings are not in agreement with other studies (Danneaus et al 
1978, Renz et al 1991a), where comparable levels of food specific 
antibodies were seen in the maternal serum and cord serum of both atopic 
and non-atopic women.
The net gain of anti-ovalbumin IgG in the fetal circulation was 
significantly lower in the atopic group compared to the non-atopic group, 
indicating that the transfer of this antibody had been greatly limited in 
the atopic women, with transfer favoured in the non-atopic women. The 
result of these differences was that in the cord serum, comparable 
concentrations of anti-ovalbumin IgG were seen in the atopic and non- 
atopic groups despite very different concentrations in maternal serum. The 
same differential between transplacental transfer in atopic and non-atopic 
women was seen for anti-B-lactoglobulin IgG. The transfer of anti-gliadin 
IgG occurred to similar degree in both atopic and non-atopic women, with 
no apparent restriction in transfer occurring. It would appear,therefore, 
that each specific antibody is handled in a different manner by the 
placenta, but the factors determining these differences in handling are 
unclear.
It has been proposed that transport of antibodies via the placenta may be 
regulated by the best interests of the fetus (Falth-Magusson et al 1988), 
with the presence of regulating mechanisms in the distribution of IgG 
between mother and fetus in favour of the later (Lilja et al 1988). In 
atopic mothers, it is possible that the regulatory mechanism is not 
functioning correctly, so limiting the transfer of specific antibodies. 
Alternatively, high levels of certain specific antibodies may have a 
detrimental effect on the fetus, thus the placenta is restricting transfer 
to achieve 'optimum' concentrations of specific antibodies in fetal 
circulation.
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Similar concentrations of antigenically intact ovalbumin and gliadin 
were observed in maternal serum and cord serum of the atopic and non- 
atopic groups. In the non-atopic group, concentrations of ovalbumin and 
gliadin in the cord serum correlated well with the respective specific 
IgG concentrations. It is possible that the antigens are transferred 
across the placenta complexed to their specific antibody, producing in the 
observed relationship seen in cord serum.
However, the Fc receptors on the placenta, thought to be involved in the 
transplacental transfer of IgG molecules, do not recognise complexed 
antibodies (Lin 1980, Wood et al 1982). If an antigen-antibody complex is 
transferred, another mechanism has to be present as it does not appear 
possible for such complexes to utilize the transport mechanism identified 
to date. The similarity between maternal serum and cord serum 
concentrations of ovalbumin and gliadin does not exclude the possibility 
of diffusion of these molecules through the placenta. This is very 
unlikely and it has been suggested that an as yet unelucidated mechanism 
is responsible for transfer of antigens across the placenta (Cant et al 
1985).
The lack of correlation between cord serum concentrations of ovalbumin and 
gliadin and the concentrations of the respective specific IgG antibodies 
in the atopic group may be considered to be further indication of the 
disruption in transplacental transfer in these individuals compared to 
the non-atopic women.
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7.5.4 Breast milk specific antibody content.
No differences were found in the anti-ovalbumin, -gliadin and -J3- 
lactoglobulin sIgA concentrations in the breast milk of atopic and non- 
atopic women. This is in agreement with the findings of a number of other 
studies (Machtinger & Moss 1986, Falth-Magnusson 1989), but not with Renz 
et al (1991b), who observed anti-B-lactoglobulin sIgA concentrations to be 
lower in atopic compared to non-atopic women. They stated however that the 
genetic predisposition of an infant was likely to be as important in the
development of atopy as the lower quality of breast milk produced by
atopic mothers.
In contrast, Machtinger & Moss (1986) felt that parental history was less 
important than maternal breast milk sIgA antibody levels, and inadequate 
maternal passive antibody protection has a role in the development of 
infantile atopy. In this study, the number of breast-fed infants 
developing atopy was low, therefore an investigation of the role of 
maternal breast milk specific sIgA concentrations on development of atopy 
was not possible.
Secretory IgA concentrations in breast milk may play a role in the 
differences seen in atopy development between bottle (40%) and breast-fed 
(19%) infants, but as no differences in sIgA levels were noted between the 
atopic and non-atopic women, overall, it is unlikely that breast milk 
antibody concentrations are influencing atopy development in relation to 
family history of atopy in this study. The determination of food protein
concentrations in breast milk of atopic and non-atopic women may be
important in the role of breast milk in atopy development in infants, with 
antigenically intact food proteins reported to be present more frequently 
in the milk of atopic women compared to non-atopic women (Jakobsson et al 
1985, Axelsson et al 1986).
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7.5.5 Salivary and heel prick specific antibody concentrations in infants.
The development of salivary concentrations of anti-ovalbumin and anti- 
gliadin sIgA over time in the infants studied has been discussed fully in 
chapter 6. From 1 month of age, anti-ovalbumin sIgA concentrations rose 
steeply in the infants with non-atopic mothers, peaking at 2 months of 
age, with no such increase observed in the infants with atopic mothers. 
The differences in salivary anti-ovalbumin sIgA concentrations between 
infants with atopic and non-atopic mothers were no longer apparent after 4 
months of age.
The transient IgA deficiency, said to occur in atopic infants, has been 
reported to occur at about 3 months of age (Taylor et al 1973, Soothill 
et al 1979). The results of this study would indicate that a relative 
specific IgA deficiency appears to be present in infants with a positive 
family history of atopy at about this age, although it is not seen at 
an earlier age. It would appear that the mechanisms of secretory IgA 
production are not functioning to the same degree in infants with atopic 
mothers after the first month of life compared to those with non-atopic 
mothers, and it is possible that this is an element in the predisposition 
to atopy as suggested by Jarrett (1977). The frequency of atopic disease 
during the first year of life has been correlated with the concentration 
of salivary anti-alpha casein sIgA at birth, with elevated anti-B- 
lactoglobulin sIgA also a means of identifying 'at risk' infants (Rieger 
et al 1990, Renz et al 1991b). Determination of total secretory IgA in 
saliva revealed no differences between atopic and non-atopic children, 
from 1 month to 6 years of age (Solé et al 1988).
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An early transient rise in total salivary sIgA at 2 months of age has been 
reported, similar to the rise seen at this time in anti-ovalbumin sIgA 
concentrations in the saliva of infants with non-atopic mothers. This 
rapid, short lived increase in salivary IgA has been assumed to be 
stimulated by the pulse of food and microbial antigens presented to the 
gut mucosa following birth (Gleeson et al 1982), resulting in a polyclonal 
expansion of mucosal B-cells in response to polyclonal activators. The 
rapid fall may be caused by a negative feedback mechanism, possibly 
involving mucosal T-cell populations which would limit lymphocyte 
proliferation. The higher response seen in the bottle-fed infants in this 
study, compared to the breast-fed infants, may be the result of increased 
stimulation of mucosal B-cells, due to the greater antigenic load exerted 
by feeding cow's milk protein from an early age. The concentrations of 
anti-gliadin sIgA in saliva do not support this hypothesis as only breast 
fed infants of non-atopic mothers showed an increase in concentrations at 
2 months of age.
It is possible that the infants received egg at a very early age and this 
was not reported by the mothers. If this were the case, the smaller rise 
in specific anti-ovalbumin sIgA seen in the breast-fed infants can be 
explained by the presence of specific sIgA antibodies in breast milk 
reducing the absorption of intact egg proteins in these infants. The 
increase in anti-gliadin sIgA in breast-fed infants may be due to the 
occurrence of intact gliadin in the breast milk, leading to stimulation of 
the mucosal immune system and production of specific antibodies. This 
could be confirmed by the determination of gliadin concentrations in 
breast milk. The relative lack of response seen to these two antigens in 
the infants with atopic mothers may be a indication of the differences in 
immune responsiveness that predispose to the development of atopy.
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This study has found no significant differences between the production of 
specific salivary antibodies in bottle and breast-fed infants. This is in 
contrast to a large number of other studies where formula fed infants have 
been observed to have higher concentrations of food specific sIgA 
antibodies, in particular cow's milk protein specific antibodies 
(Mellander et al 1984, 0stergarrd 1985, Gleeson et al 1986, Frick & Rieger 
1987, Renz et al 1991a). The lower concentrations of specific salivary 
antibodies seen in breast-fed infants are possibly due to an active 
principle in the breast milk, which may be functioning macrophages or 
proteins, which seem to stimulate the production immune factors (Renz et 
al 1991a). In addition breast milk contains epidermal growth factors which 
promote the development of intestinal mucosal cells, thus preventing the 
penetration of foreign proteins. The slight, continuous rises in antibody 
titre seen in breast-fed infants results from low level antigenic 
stimulation and the maternal supply of protecting sIgA antibodies 
(0stergaard 1985).
The decline in anti-ovalbumin and anti-gliadin IgG concentrations in heel 
prick blood samples over the first three months of life was due to the 
rate of immunoglobulin catabolism outstriping production by the infant. 
From 3 months of age, the rate of production was sufficiently great to 
bring about increases in antibody titre. This decline was not seen in the 
concentrations of anti-B-lactoglobulin IgG, as the presence of cow's milk 
protein in the diet in the bottle-fed infants causes the production of 
milk specific antibodies to be greater than their catabolism from birth. 
The rapid increase in antibody concentrations in the first few months of 
life results from higher permeability of the intestine combined with an 
immature secretory immune system (Tainio et al 1988), leading to the 
uptake of large amounts of intact protein.
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Breast fed infants showed no decline in anti-B-lactoglobulin IgG 
concentrations, possibly due to the use of supplementary cow's milk feeds 
which were not reported by the mother. Alternatively, cow's milk proteins 
may be present in the breast milk of the women, however it would be 
expected that egg and wheat proteins would also be present in equally
quantities making this explanation of the rise in anti-B-lactoglobulin 
IgG concentrations from birth unlikely. The effect of contact with 
occasional, small amounts of cow's milk would be minimized by the
presence of specific sIgA antibodies in the breast milk, complexing with 
milk proteins and so reducing their absorption through the gut mucosa,
leading to the small increases in antibody concentration seen.
Specific antibody concentrations reach a peak in all infants, but the age 
at which this occurs and the height are dependent on the age of
introduction of cow's milk (Tainio et al 1988), with the highest and 
earliest peak produced when formulas are given before 30 days of age. The 
decrease in mean titres is a result of factors including changes in gut 
permeability, reduction in the consumption of milk, and the development of 
a state of immunological unresponsiveness (Kletter et al 1971). In infants 
of atopic mothers, it would appear that tolerance was not achieved or was 
only partially achieved, as no decline, as seen in the infants with non- 
atopic mothers, in antibody titres occurred in these infants. It is 
possible that in infants with a family history of atopy, the 'switch' for 
development of tolerance is set at a higher level than in infants with no 
family history of atopy, causing the elevation in specific antibody titres 
seen in this study and in adults.
215
Results obtained for anti-B-lactoglobulin IgG concentrations indicate the 
infant's immume system is able to produce appreciable levels of specific 
antibodies, given sufficient stimulation, very soon after birth. Infant 
below 35 weeks gestation are unable to produce antibodies against ingested 
proteins, with the ability to produce detectable antibody after antigen 
challenge reached in the last part of gestation (Rieger et al 1975).
Both maternal atopy and mode of feeding had a significant influence on 
anti-ovalbumin IgG concentrations in infants over the first year of life, 
but the influence of these two factors on anti-gliadin IgG only extended 
to 6 months. The mean age at which wheat was first given in each group was 
lower than that for egg, with wheat introduced before 6 months of age and 
egg after. The introduction of new antigens into the diet brings about an 
increase in production of specific antibodies, with a massive antigenic 
load on the GALT favouring the rapid development of IgG, IgM and IgA 
antibodies (Dannaeus et al 1978, Gerrard 1979). The introduction of wheat 
to the infants became the predominant factor influencing specific antibody 
production, swamping any effects exerted by maternal atopy and previous 
feeding history. This effect was not observed during the study period for 
anti-ovalbumin IgG.
The amounts of ovalbumin and gliadin received by the infants are likely to 
be very different, with consumption of wheat usually significantly higher 
than that of egg. Consumption of ovalbumin was insufficient to produce the 
very rapid increases in specific IgG concentrations seen with anti-gliadin 
IgG production, thus the influence of maternal atopy and feeding history 
was still apparent at 12 months of age. Differences in amounts consumed 
are also reflected in the mean antibody concentrations reached at 12 
months of age, with anti-gliadin IgG concentrations in the range of 120 - 
380ug/ml compared to anti-ovalbumin concentrations of 50 - lOOug/ml.
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Anti-gliadin and anti-ovalbumin concentrations in maternal serum and cord 
blood correlated with those observed in the infant to 3 months of age, but 
not at 6 months of age due to the influence exerted by introduction of 
antigen. Lilja et al (1990) reported no correlation between particular IgG 
subclass levels in cord serum and serum by 6 months. No correlations were 
seen between anti-B-lactoglobulin concentrations, in the group as a whole 
and maternal serum and cord serum concentrations at any age. The lack of 
correlation is due to the immediate effect of cow' milk formula on anti-B- 
lactoglobulin IgG production in the bottle-fed group. Correlations may be 
present in the breast-fed group.
Breast fed infants appear to have an enhanced production of anti-ovalbumin 
and anti-gliadin IgG compared to bottle-fed infants in agreement with the 
findings of Falth-Magnusson et al (1988). Breast milk contains small 
amounts of antigens, reflecting the diet of the mother. The breast-fed 
infants were being stimulated by these antigens from an early age, 
resulting in higher antibody titres compared to the bottle-fed infants who 
had received only cow's milk antigens. The breast milk may also contain 
anti-idiotypic antibodies, which stimulate the production of the 
corresponding specific antibody (Mellander et al 1986).
7.5.6 Incidence of atopy and specific antibody concentrations.
Anti-B-lactoglobulin IgG concentrations were significantly higher in the 
cord serum of infants developing atopy compared to those that did not. The 
concentrations of all three food specific antibodies were also higher in 
the atopic infants at 12 months of age compared to the non-atopic infants. 
A tendency for higher food specific IgG levels including those against 
gliadin, ovalbumin, alpha-lactalbumin and B-lactoglobulin in infants with 
atopic disease has been noted previously (de Martino et al 1988, Falth- 
Magnusson et al 1988).
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The detection of lower concentrations of specific food antibodies in the 
cord serum of infants developing atopy has been interpreted as indicating 
a protective function of the transferred antibodies (Dannaeus et al 1977, 
Casimir et al 1989). The results of this study do not agree with this 
hypothesis, with indications that high levels of specific antibodies may 
be detrimental to the infant. The mechanism by which this is functioning 
is unclear, but may involve the suppression of immune responses in the 
infant at an early age by the large amounts of circulating specific IgG. 
The higher concentrations of specific antibodies seen at 1 year of age, 
indicate that the elevated antibody levels seen in atopic adults are 
present throughout life and are an marker of their atopic constitution.
In summary, the presence of maternal atopy and feeding practise are both 
influencing the production of food specific antibodies in infants. The 
atopic mothers are passing on a tendency to produce large amounts of food 
specific antibodies to their infants, but it is not clear whether this 
tendency is genetic or due to the antibodies transferred to the infant. 
Further studies are required to investigate the influence of maternal 
atopy beyond 1 year of age, and to investigate more fully the role the 
antibodies transferred to the infant play.
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Chapter 8 
Final Discussion.
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8.1 Final Discussion.
The studies carried out as part of this thesis have found that the
occurrence of specific antibodies to ovalbumin, gliadin and B-
lactoglobulin in the serum of adults and infants, when studied to the age 
of 18 months, is common place, with IgG antibodies to these three food 
proteins detected in more than 90% of the subjects studied. The presence 
of anti-ovalbumin and anti-gliadin IgA in the saliva of adults and infants 
from the first week of life is also a widespread occurrence, although 
the specific secretory antibodies to these antigens were not detected at 
as high a frequency as the corresponding specific antibodies in serum.
Concentrations of specific antibodies to ovalbumin, gliadin and B- 
lactogobulin in serum show a great deal of variation, both between
individuals and within one individual, with respect to the immune response
to different antigens. However in adults, the immune response to ovalbumin 
is greater than that seen to gliadin or B-lactoglobulin. The reasons for 
this differential response to food proteins has been discussed in Chapter 
4, and included the relative antigenicity of different food proteins and 
resistance to intestinal proteolytic enzymes.
i) Food antibodies in adults.
The concentrations of specific antibodies to food protein in adults are 
not related to short term oral intake (Chapter 4). The influence of longer 
term intake was not investigated in this study, however other 
investigators have found it to be very difficult to change specific 
antibody levels in serum by altering food intake for between 4- Gmonths 
(Gallagher et al 1983). These findings indicate - that specific food 
antibody titres are not under the direct influence of food intake in adult 
life as would be expected since the the half life of IgG antibodies is 
approximately 90 days.
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In adults, the habitual intake of egg protein is ; low, compared to the
high consumption of milk protein, with anti-ovalbumin IgG antibody levels
the highest of the specific antibodies studied and anti-B-lactoglobulin
IgG concentrations the lowest. No correlations between food protein intake
and specific antibody concentrations in adults were found. In contrast, in
infants, when studied to the age of 1Smonths, the intake of milk is
considerably greater than intakes of wheat and egg, and the relative
specific antibody concentrations reflect these differences in intake. The
and
question arises from this data in infants and adults as to when why a move 
from the 'infant-type' relationship between intake and antibody production 
to the inverse adult relationship occurs.
The shift, briefly described above, may involve the development of 
tolerance to the antigens in question. The consistent high intakes of milk 
protein as seen in infants may produce a high degree of tolerance in the 
antibody producing lymphocyte clones, sensitized in the first year of 
life. The low, intermittent intakes of egg protein may only be sufficient 
to produce tolerance in a small percentage of antibody producing clones, 
resulting in a larger number of B-lymphocytes remaining able to respond to 
contact with ovalbumin with the production of specific antibodies. The net 
result is the higher concentrations of anti-ovalbumin IgG compared to 
anti-B-lactoglobulin IgG as seen in adults. The intake of wheat in infants 
can be placed between the intake of egg and milk, thus the antibody 
response seen will be between these two outer markers, as in fact is the 
case. This interpretation of the results would imply that the levels of 
specific food antibodies are set early in life and are influenced by the 
amounts of specific proteins consumed at that time.
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Antigen uptake from the gut is a prerequisite for the stimulation of 
antibody production, and uptake varies greatly between normal individuals. 
Determination of uptake of one protein does not enable predictions to be 
made regarding the uptake of other proteins, because, as with the specific 
antibody concentrations, each protein appears to be dealt with in a 
different manner. Proteins appear to compete for uptake across the gut 
mucosa, but it is not conclusively known whether the reduction in antigen 
uptake, when more than one protein is present in the gut, is a result of 
increased volume within the gut or competition for transfer. Studies using 
isovolumetric amounts of single and mixed proteins and isolated gut sacs 
with pure protein are required to determine the relative importance of 
these two factors. Despite the questions arising from the antigen uptake 
studies carried out for this thesis, they have shown that measurement of 
antigen transfer across the gut under controlled conditions does not give 
a true representation of the uptake that occur in the normal dietary 
situation.
A consistent finding through out this project has been that the presence 
of atopy is accompanied by elevations in specific IgG antibody levels in 
serum but not in the production of specific salivary IgA. A cause and 
effect relationship between atopy and specific antibody elevations has 
not been identified in these studies.
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ii) Specific food antibodies in atopic adults.
Higher specific antibody titres are seen in atopic individuals from a very 
early age (see Chapters 4 & 8), however they may appear after development 
of atopy, and can not be used as definitive predictors of atopy.
The reasons for the increased specific antibody levels seen in atopic 
individuals are two fold. Firstly, increased uptake of antigens from the 
gut is said to occur (Jackson et al 1984, Schrander et al 1990), possibly 
due to inflammatory responses in the gut (Bloch & Walker 1981) as a 
result of antigen contact with sensitized lymphocytes. Secondly, atopic
individuals appear to be hyper-responsive to any antigens encountered. 
This is seen particularly with the IgE response to antigens, where the 
regulatory system seems not to function as efficiently (Jarrett 1977).
Possibly these individuals have a higher threshold for the development of 
tolerance determined by their genetic make-up, or atopic individuals may be 
continually reinitiating the immune response to antigens due to inadequate 
or defective tolerance induction (Barrick & Farr 1965).
Production of larger amounts of antibodies may lead to the formation of 
abnormal immune complexes (Pagenelli et al 1984), and thus act as a 
trigger for the development of atopy. There appears to be a continuum on 
which an individuals response to any one antigen can be placed, from very 
low production to very high. It has been proposed that threshold levels 
exist, setting the limits between normal and abnormal production (May et
al 1977), however these levels have not been defined and neither is it
known whether they are the same for the whole population, or whether 
varying groups can be identified within the population in whom different 
levels of antibodies can be reached before an abnormal and detrimental 
state is triggered.
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It would appear from the results obtained in the adult study (Chapter 4), 
that elevated specific IgG antibodies are not related to clinical symptoms 
in the majority atopic individuals. Only when gross elevations occur do 
problems start arising, as seen with the very high anti-ovalbumin IgG 
concentrations in the egg allergic adult studied.
IgG4 antibodies have been reported to be involved in atopic conditions, 
however the results from the studies on atopic adults (Chapter 4) would 
implicate specific IgG3 antibodies as having a possible role in atopic 
conditions. The high levels of specific IgG4 antibodies observed in the 
atopic population have been one of the main reasons for the proposed 
linked between IgG4 and atopy. Elevated specific IgG antibodies are 
commonly seen in the atopic population, and with the majority of food
specific IgG antibodies found as IgG4, the association between the two is
not surprising. The presence of high levels of specific IgG4 antibodies 
may account for the lack of clinical effects attributable to the high 
specific antibody titres observed in the majority of atopic subjects.
Recent studies have shown that IgG4 antibodies may act as blocking agents 
of IgE activity by binding to mast cells and basophils, so preventing IgE 
antibodies binding (Hagan et al 1991). Although these reports were in 
relation to helminth infestation, the only condition other than atopy were 
elevated specific IgE concentrations are seen, they have implications in 
the field of allergy. The exaggerated IgG response to commonly encountered 
antigens within the atopic population may be a means of blocking the
action of the higher levels of IgE antibodies produced. The damaging
effects of IgE can therefore be negated or at least reduced. This 
hypothesis can account for the observed association between IgE and IgG4 
antibodies reported by several investigators (Merrett et al 1984, Lilja et 
al 1990).
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To confirm this hypothesis, a study of concentrations of IgE and IgG4 
antibodies to a range of food antigens in atopic individuals is required. 
Individuals with high specific IgE and IgG4 antibodies, and those either 
just high specific IgE or IgG4 antibodies could then be identified. The 
relationship between levels of the two immunoglobulin and severity of 
symptoms could then be investigated. Further work is also required to 
clarify the role of IgG3 antibodies in atopy. The possibility that an IgG 
subclass other than IgG4 may be important in atopy has been largely 
ignored in the search for a role for IgG4. The ability of IgG3 to activate 
complement would enable it to act directly in response to antigen contact, 
in contrast to the indirect effect of IgG4 proposed by Shakib (1986b) 
involving auto-antibodies to IgG4-antigen complexes.
Hi) Food specific antibodies in infants.
An aims of this project was to determine the role of maternal antibodies, 
transferred across the placenta, in determining antibody production in 
infants. Differences were found in the extent to which antibodies to 
specific antigens were transferred via the placenta and in the transfer of 
specific antibodies via the placenta in atopic women compared to non- 
atopic women (see Chapter 6 & 7).
Disrupted transfer of specific antibodies across the placenta appears to
ed
occur in atopic women. Studies are need to investigate whether this is 
general phenomena of transport mechanisms of the placenta of atopic women, 
or whether it is limited to specific antibodies to commonly encountered
food antigens. Measurement of total cord serum IgG may assist in answering
this question. Additionally, the reason why the transfer of specific 
antibodies is disrupted in this group of women needs to be elucidated,
whether due to defects in the placental receptors for immunoglobulins, or
to the antibody reaching the placenta in the form of complexes.
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The observed disrupted transfer of specific antibodies in atopic women may 
reflect each individual's attempt to produce optimum antibody
concentrations in the fetus (Falth-Magnusson 1988, Lilja et al 1988). The 
extent to which this is achieved may differ between individuals, leading 
to the apparent disruption in IgG transfer seen in the group as a whole. 
Transfer of antibodies in women with exceptionally high specific antibody 
titres would clarify whether maximum levels of transfer are present.
Some explanations have been gained from the studies in adults regarding 
factors influencing specific antibody levels in adults. However the
earliest influences may come from the mother, and the antibodies she
transfers to the fetus in utero, with it suggested that adult antibody
production is strongly influenced by such early signals (Wikler et al
1980). The prospective study in infants has found that maternal specific 
antibody levels are influencing antibody production in the infants, with 
correlations existing to 6 -12 months depending on the antibody studied. 
Maternal idiotypic and anti-idiotypic antibodies may be involved in
determining the levels of specific antibody production in the infant
(Nagal et al 1989).
iv) The influence of maternal antibodies in the infant.
Idiotypic maternal antibodies are thought to be able to presensitize the 
infant to antigens to which the mother is exposed (Eloi-Santos et al
1989), and anti-idiotypic antibodies can substitute for the original
antigen in the induction of specific IgG and IgE antibody responses
(Nagpal et al 1989). High levels of specific maternal antibodies may
stimulate the infant's immune system from two fronts. Firstly in the
amounts of idiotypic antibodies present presensitizing the infant, and 
secondly through the higher levels of anti-idiotypic antibodies that are 
likely to accompany the high concentrations of specific antibodies.
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The presence of maternal atopy has a very strong influence on the 
production of specific antibodies, and if the above hypothesis is true, 
this influence is working through the elevated specific antibody titres 
seen in the atopic women, as well as genetic factors determining the 
likelihood of atopy development. It is of note that the incidence of 
paternal atopy was identical in the atopic and non-atopic groups, 
indicating that the effects, seen in relation to atopy, are of maternal 
origin. The influence that maternal atopy exerts on specific antibody 
production in the infant may therefore be more than simply a genetic 
predetermination of antibody production levels.
High maternal levels of anti-B-lactoglobulin antibodies, and to a lesser 
extent anti-ovalbumin and anti-gliadin, appear to be exerting a 
detrimental effect on the infant in terms of atopy development. The 
transfer of high amounts of these maternal antibodies to the infant may 
produce a higher degree of sensitization within the T- and B-lymphocyte 
populations prior to antigen contact than is seen in infants receiving 
lower concentrations of maternal antibodies. On contact with the antigen, 
a greater antibody response, than would be anticipated, occurs and this 
may lead to the development of atopy.
The exact mechanism by which atopy develops is unclear but may depend on 
the prominence of IgG and IgE in the response which may in turn be 
determined by inherited genetic factors. The heightened response to food 
antigens results in the production of larger amounts of specific 
antibodies, beginning the cycle which leads to differences in specific 
antibody titres encountered in atopic and non-atopic adults.
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Further work is required in this area, with larger numbers of mothers and 
infants needed to confirm these findings and to confirm that the levels of 
specific IgG antibodies in cord blood can be used in the prediction of 
atopy in infants. Groups of infants need to be defined according to the 
amounts of maternal antibodies present in the cord blood, and predictions 
of the incidence of atopy in each group tested. Measurement of the 
specific antibody titres in the serum of the infant over time are also 
required, to map the proposed differences in antibody response in those 
infants developing atopy and those who do not.
The response of the infant's immune system to the maternal antibodies may 
be modified by the type of milk that the infant first encounters. The 
consumption of breast milk will expose the infants to very small amounts 
of food antigens, and it has been proposed that this is of importance in 
the development of tolerance (Kilshaw & Cant 1984), although an increased 
production of specific antibodies over that seen in bottle fed infants is 
observed until weaning occurs. Thus the small amounts of antigens the 
infants are receiving may induce tolerance within the presensitized 
cells and the infants developing atopy are those in whom development of 
tolerance is inadequately maintained or insufficient to bring them below 
a threshold level.
When infants are fed cow's milk formula from birth, the antibody response 
to the large antigen load is greater, and a higher proportion of infants 
may have been recruited into the atopic group, as no time has been allowed 
for tolerance to develop with the presensitized lymphocyte clones. Infants 
may be defined as either definitively atopic, and in these infants the 
chances of preventing atopy are low, borderline atopic, in whom atopy may 
be prevented or delayed by careful feeding practises in the first few 
years of life, or those in whom atopy is not very likely to develop.
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Maternal serum antibodies appear to be of prime importance in the
influence of antibody titres in the infant, although there is a complex
interplay between this and a number of other factors, including whether
the infant is breast or formula fed and the genetic make-up of the infant. 
The influence of maternal antibodies can only be seen directly in the
first few months of life. After this time, it is swamped by the effect of 
weaning and the consequence of introducing large amounts of antigen to 
the infant's immune system. The early signals given by maternal 
immunoglobulins have, by this stage, predetermined the way in which the 
infant's immune system will react to dietary antigens when they are first 
encountered. The levels of food specific antibodies seen in adults are to 
a very large extent preset in the first few months of life.
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8.2 Clinical Implications.
This study has found that one of the major determinants of levels of 
specific antibodies in any one individual is the amount of specific 
antibodies obtained from the mother before birth, and that high 
concentrations of these specific antibodies are detrimental to the infant 
in terms of atopy development. These finding suggest that it may be 
possible to predict which infants are 'at risk' of atopy development early 
in uterine life, by determination of the maternal serum antibody titres to 
milk, egg, and wheat and possibly common inhalant allergens such as house 
dust mite and grass pollens. If this were possible, the mothers at most 
risk of having atopic children could be targeted and advice given on 
reducing the chance of the infant becoming atopic. The promotion of breast 
feeding needs to be continued as it is one of the most effective methods
found to date of reducing allergy risk. The model for atopy development
proposed in this study shows breast feeding is beneficial in the 
prevention of 'borderline atopic' infants becoming atopic.
The determination of cord blood antibodies could be used as a second 
screening of the 'at risk' group as the placenta in some atopic and normal 
women appears able to restrict the transfer of certain specific 
antibodies, particularly when high concentrations are present. The infants 
can therefore be divided into those in whom the placental transfer of
specific antibodies falls in the 'optimum range' and those in whom the 
transfer is outside this range. According to the findings of this study, 
the latter group are those at most risk of atopy development. In these 
infants, advice may be given about the delayed introduction in the case of 
food antigens or minimization of exposure in the case of inhalant
antigens, depending on the specific antibody titres in cord blood. Where 
the titre is high, the chance of presensitization is greatest.
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An alternative approach is to actively reduce the risk of sensitizing the
unborn infant by reducing the maternal levels of specific antibodies
before the third trimester of pregnancy. The majority of immunoglobulin
transfer occur in the last 3 months of gestation, hence the importance to
alter antibody titres before this time. Studies on the use of exclusion
diets during pregnancy have found that significant decreases in specific
IgG antibodies to ovalbumin, gliadin and B-lactogobulin (Falth-Magnusson
et al 1988, Lilja et al 1988) and to alpha-casein and B-lactoglobulin
(Lovegrove et al 1991). No significant difference in the amount of
specific antibodies in cord blood from women following an exclusion diet,
and those who were not, was found. None of these studies provided
information on the occurrence of atopy in the infants within the dietary
exclusion group compared to the group with an unrestricted intake. It is 
a .
fesible to reduce specific antibody titres by elimination of the specific 
food item from the diet from early in pregnancy. Advances in the 
prevention of atopy may be made by tailoring advice to the individual. The 
studies mentioned above enforced the same dietary restriction on all 
mothers, however the maximum benefit could be gained from tailoring the 
dietary restrictions to each individual, dependent on the concentrations 
of specific antibodies present.
In summary, the clinical implications of the findings of this study are 
that it may be possible to determine those infants at highest risk of 
developing atopy, before they are born, by measurement of specific 
antibody titres in the mother. An individual strategy can then be devised, 
including the exclusion of food items from the diet with the aim of 
reducing the specific titres against them. The effectiveness of these 
measured can be determined by the levels of specific antibodies in the 
cord blood and the strategy reassessed at birth.
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À small number of infants will inevitably develop atopy despite all 
attempts to prevent this happening, in these children, the genetic 
propensity to develop atopy is so great that little can be done to 
prevent it. However, all attempts should be made to reduce the incidence 
of atopy where possible, and this study has provided some information as 
to how that may be achieved.
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